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Abstract
Two DNA sequences, termed CRE1 and CRE2, located upstream of the Major 
Histocompatibility Complex (MHC) class I gene have been shown to play an important 
role in controlling transcription of this gene. MHC class I expression is down- 
regulated in cells expressing Adenovirus (Ad) 12 E1A compared to cells expressing 
El A from Ad2 or Ad5. The possible involvement of these sequences and the factors 
that bind to them in this down-regulation was investigated using transient expression 
assays and in the case of CRE1, also by gel retardation and Western blotting. The 
transient expression assays did not demonstrate a functional role for these sequences in 
transcriptional down-regulation. The implications of this result in relation to the 
experimental design are discussed. Gel retardation assays showed that the levels of 
CREl-binding factors detected were dependent on the technique employed to prepare 
the nuclear extracts. Preparation of nuclear extracts by a technique in which the 
potential for cytoplasmic contamination and proteolytic degradation was minimized 
showed that the level of CRE1 factors, likely to represent NF-kB (p50/p65 
heterodimers) and H2TF1 (p50 homodimers), was higher in cells expressing Ad2 or 
Ad5 E1A than those expressing Adl2 E1A. Western blotting using an antibody 
prepared to the p50 subunit of NF-kB did not show a difference in levels of this subunit 
between different Ad-transformed cell lines. These results suggest therefore that the 
levels of p50 are similar in these cell lines but that the levels of p50 bound to either p65 
or another p50 subunit, and capable of binding DNA, are higher in those transformed 
by Ad2 or Ad5 E1A.
The binding site of CRE2-binding proteins was investigated in Ad-transformed cells by 
DNase I footprinting. The factors RXR/3/H-2RIIBP which bind to this sequence are 
members of the ER/TR subfamily of steroid/thyroid hormone receptors. Members of 
this subfamily have the sequence AGGTCA conserved in their binding sites; this 
sequence formed part of the area of protection found on the DNase I footprint.
The mechanism of nuclear induction of NF-kB was investigated in Ad-transformed cells 
by the use of the free radical producer benzoyl peroxide and other inducers such as 
tumour necrosis factor and cycloheximide. Benzoyl peroxide was shown to activate 
transcription and scavengers of free radicals prevented the induction. These results 
were incorporated into a model of NF-kB induction involving hydrogen abstraction.
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1 General Introduction
Major histocompatibility (MHC) class I antigens play a central role in the immune 
system. They are involved in the presentation of antigens including those of viral and 
tumour origin to cytotoxic T-cells (Zinkemagel and Doherty, 1979). There are many 
serotypes of human adenovirus (Ad) and this study was based on work with cells 
transformed by three serotypes, Ad2, Ad5 and Adl2. The transformation of rat 
cells with Adl2 is associated with a reduction in the steady state levels of surface MHC 
class I antigens (Schrier et al., 1983). It has been proposed that this reduction in class I 
expression may enable these cells to evade immune surveillance by cytotoxic T-cells. 
The decrease in MHC class I levels is known to involve a reduction in the rate of 
transcription (Ackrill and Blair, 1988a; Friedman and Ricciardi, 1988; Lassam and 
Jay, 1989). In the following section human adenoviruses will be described in more 
detail. This will be followed by an introduction to the MHC, concentrating on class I: 
its structure, function and regulation by viruses including adenoviruses and other 
agents. The regions of the MHC class I promoter important to transcriptional control 
will be described in detail along with the transcription factors which bind to them. 
Special features of the control of transcription by adenoviruses will be discussed 
separately.
1.1 Adenoviruses
1.1.1 Introduction
Adenoviruses, which form a family Adenoviridae, derive their name from their initial 
discovery in human adenoid tissue (Rowe et al., 1953). They are widespread in 
several mammalian and avian species. Human adenoviruses were the first human 
viruses to be shown to have tumorigenic properties when tumours were induced in 
newborn hamsters after inoculation with Adl2 (Trentin et al., 1962). Adenoviruses 
have been intensely studied and several important discoveries in molecular and cell 
biology were made through the study of these viruses. For example, splicing was 
first encountered in the formation of adenovirus late mRNA (Chow et al., 1977). One 
property of adenoviruses is the ability to transform cells in vitro and this has been a 
useful model for tumorigenesis.
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1.1.2 Classification of human adenoviruses
More than forty serotypes of human adenovirus have been identified and classified into 
subgenera A-F based on their oncogenicity in newborn hamsters, their antigenic 
properties and their DNA homology (Table 1.1). This study used cells transformed 
by Ad2, Ad5 or Adl2. Ad2 and Ad5 are both members of subgenus C; viruses in this 
group are non-oncogenic in newborn rodents, as is the case for subgenera E and F. 
Adl2 is a member of subgenus A; members of this group are highly oncogenic and 
induce tumours at high frequency and with short latency. Subgroup B viruses induce 
tumours at low frequency and with long latency. Although group D viruses are not 
tumorigenic in hamsters, they have been shown to induce mammary tumours in female 
rats of certain strains (Ankerst et al., 1974). DNA and viruses of all serotypes can 
transform rodent cells in vitro (Flint, 1980; van der Eb, 1980; Jochemsen et al., 1980). 
Such transformed cells retain the oncogenicity of the original transforming virus, for 
example, rodent cells transformed by oncogenic Adl2 are tumorigenic when injected 
into newborn rodents, whereas those transformed by non-oncogenic group C viruses are 
themselves non-oncogenic ( van der Eb and Bernards, 1984).
1.1.3 Diseases associated with human adenoviruses
Adenoviruses have a propensity to generate persistent infections in humans (Jefferies 
and Burgert, 1990). The different groups of adenovirus are associated with different 
diseases in humans, common clinical manifestations include conjunctivitis, as well as 
respiratory, gastrointestinal and urinary tract infections (Table 1.1). There is no 
evidence that adenoviruses from any of the subgroups form tumours in humans (Green 
et al., 1980).
1.1.4 The structure of human adenoviruses
Adenoviruses have a linear double stranded DNA genome of approximately 36 kb. 
They are non-enveloped viruses of 65 - 80 nm in diameter (Home et al., 1959). The 
DNA is packaged in a nucleoprotein structure containing at least two basic proteins 
which are virally encoded (Nermut, 1980). Their DNA/nucleoprotein core is 
surrounded by a protein coat (capsid). The capsid is comprised of 252 capsomers or 
protein morphological units arranged to form an icosahedron. There are two types of 
capsomer; hexons and pentons, the capsid consisting of 240 of the former and 12 of 
the latter. Hexons are so called because each of these capsomers is surrounded by six 
neighbouring capsomers. Pentons derive their name by the fact that each is surrounded
3
Table 1.1 Classification, oncogenicity in newborn rodents and clinical manifestations 
in humans of human adenoviruses
This table shows the division of different serotypes of adenovirus into six subgroups: 
A-F, each subgroup being associated with characteristic clinical manifestations in 
humans and a specific level of oncogenicity in newborn rodents. The table is modified 
from Waddell et al. (1977) and Paabo et al. (1989).
4
S ubgroup Serotype O ncogenicity Clinical M anifestations
in new born  in hun ians
roden ts
A 12 ,18 ,31  high enteric infections?
B 3 , 7 , 1 1 , 1 4 ,  low respiratory infections,
16, 21, 34, 35 infections of the urinary
tract
1 , 2 , 5 , 6  nil respiratory infections
D 8 ,9,  10, 13, nil epidemic kerato-
15, 17, 19, 20, conjunctivitis
22-30, 32, 33,
36-39, 42-47
nil conjunctivitis, respiratory
infections
F 40,41 nil acute gastroenteritis
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by five other capsomers; the peripentonal hexons (Ginsberg et al., 1966). The structure 
consists of twelve five-sided vertices, a penton is present at the base of each vertice. 
The capsid, apart from hexons and pentons, contains other hexon associated proteins 
(Flint, 1980). Knob-like structures are present at the end of the fibres that extend from 
the twelve five-sided vertices. These structures are considered to be important in viral 
attachment to cells in order to gain entry (Petersson et al., 1967).
1.1.5 Adenovirus infection of permissive, semi-permissive and non-permissive cells
There are various outcomes of adenovirus infection depending on whether the host cells 
are permissive, semi-permissive or non-permissive. Permissive cells have the 
required cellular proteins to allow lytic infection to occur which culminates in the 
release of virions; human cells are examples of permissive cells. Semi-permissive 
and non-permissive cells do not support virion production to an appreciable extent 
(Huebner et al., 1963; Girardi et al., 1964). Rodent cells are examples of semi- 
permissive hosts. The infection can either be abortive, in which case the virus is 
eventually lost from the cells, or in a small proportion of cases a process occurs called 
transformation when viral DNA is incorporated into cellular DNA.
1.1.5.1 Lytic infection
The lytic infection begins with entry of the virion into the cell by attachment of the 
fiber protein (IV) to specific cell receptor proteins. A part of the virion containing 
both DNA and proteins (at least II, III, V, VII) gains entry into the cell. The viral 
DNA reaches the nucleus within 30 - 60 minutes from absorption into the cell. The 
viral DNA is transcribed by cellular enzymes. Adenovirus genes are denoted 'E' or 
'L' indicating ’early’ or ’late' genes respectively. The expression of early genes 
begins before the onset of viral DNA synthesis, while late genes are expressed 
following viral DNA synthesis. There are three phases during which different genes 
are transcribed and translated ; the early (1-8 hrs), intermediate (8-12 hrs) and late 
phase (12-36 hrs). The first viral protein to be made in the early phase is E l A which 
is required for the transcription of the other early genes (E1B, E2, E3 and E4). The 
transcription of these genes also begins in the early phase. Viral DNA synthesis 
commences in the intermediate phase. In the late phase structural proteins are produced 
and virions are formed. Eventually virions accumulate to such an extent that the cells 
lyse (reviewed by Darnell et al., 1986; Sharp, 1984). Not all infected permissive
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cells undergo lysis; for example, adenoviruses can produce persistent infections in 
humans (Jefferies and Burgert, 1990).
1.1.5.2 Cell transformation
Transformation is the name given to a process which brings about many changes in cell 
properties. Before describing the way by which adenoviruses cause transformation, 
the term itself, along with the term 'cell line', will be defined. When cells are taken 
from an embryo or an adult animal, most of the adherent cells will proliferate for only 
a limited number of divisions before senescing. However some cells in some species 
undergo a change which allows them to grow indefinitely. A culture of cells with an 
indefinite life span is considered immortal and such a culture is called a cell line. 
In human cells, only tumour cells grow indefinitely. With rodent cells however, 
cultures of adherent cells from embryos frequently give rise to cell lines.
Several different treatments, such as exposure to some viruses, certain chemicals or 
irradiation can dramatically change the growth properties of adherent cells in culture. 
In addition these treatments can sometimes cause the cells to form tumours when 
injected into animals. Such changes in growth properties and tumour-forming capacity 
(when present) are collectively referred to as malignant transformation or 
transformation. The following is a list of some of the major properties associated with 
transformed cells (as reviewed by Darnell et al., 1986). However, just as not all 
transformed cells have tumour-forming capacity, not all transformed cells have all the 
characteristics listed below :-
1. Increased saturation density ; they continue to grow when normal cells cease 
growing.
2. Decreased growth factor requirements.
3. Loss of capacity for growth arrest.
4. Transformed cells can generally grow without attachment to substratum.
5. Transformed cells appear more rounded with fewer processes.
6. Loss of contact inhibition of movement.
7. Proteins on the cell surface are more mobile in transformed cells ; possibly due to 
the loss of cytoskeletal elements.
8. Altered gene transcription.
All transforming agents are thought to cause changes to host DNA. In the case of 
viruses, segments of the viral DNA become stably integrated into the cellular DNA, as
has been shown for adenoviruses (Bellett, 1975). Ad2-transformed cell lines have been 
shown to contain viral DNA sequences from the left 14% of the viral genome 
(Gallimore, 1974; Flint et al., 1976; Johansson et.al., 1977, 1978). This part of the 
genome contains the El A and E1B genes. These two genes can stably transform 
primary rodent cells in culture (White and Cipriani, 1990). The various properties of 
these genes including their ability to cause transformation will be covered in more detail 
in the following section.
1.1.6 The genome of human adenoviruses
The genome of human adenoviruses has been conventionally divided into 100 map 
units. The early genes consist of El A, E1B (together called El), E2A, E2B (forming 
region E2), E3 and E4. The late genes are called L1-L5 (Fig 1.1). As E1A and E1B 
will be discussed in most detail the other gene products will be described first.
1.1.6.1 E2
E2A region encodes a protein called DNA-binding protein which activates several 
promoters (Chang and Shenk, 1990) and aids viral DNA replication (Stuiver and van 
der Vliet, 1990). Two other proteins encoded by E2B gene are the terminal protein 
(Smart and Stillman, 1982) and a DNA polymerase (Stillman et al., 1982).
1.1.6.2 E3
This region contains multiple open reading frames. One protein, of 19 kDa, encoded 
by this region has been reported to be involved in down-regulation of surface MHC 
class I antigens during adenovirus infection as will be described in more detail later 
(Jefferies and Burgert, 1990). Another protein encoded by this region of 14.7 kDa 
prevents Tumour Necrosis Factor (TNF)a-mediated cytolysis of adenovirus infected 
cells (Gooding et al. , 1990).
1.1.6.3 E4
Two proteins encoded by this region called 294R and 116R (because they consist of 294 
and 116 amino acid residues respectively) are involved in permitting the nuclear 
accumulation of viral RNA (Bridge and Ketner, 1990). 294R is also involved in
stimulating transcription from the E2 promoter (Nevins, 1991).
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Fig 1.1 Schematic representation of the Ad2 genome showing cytoplasmic RNA 
transcripts
The 36,500 bp genome of Ad2 is represented by two parellel lines divided into 100 map 
units. The early transcripts are shown schematically as thin arrows, whereas the late 
transcripts are shown as thick arrows. The direction of transcription being along either 
the r or the 1 strand. The promoters are present at the 5’ end of each of the transcripts 
and are indicated by vertical brackets. The E2 transcription unit is transcribed during 
the early phase from a promoter located at 75 map units and also during the late phase 
from a promoter located at 72 map units. Late r-strand mRNAs (from genes L1-L5) 
are transcribed from a single major late promoter (MLP). Proteins derived from the 
transcripts are shown at the top of the figure and are designated by K (1000 mol wt) 
or by Roman numerals. Modified from Fraenkel-Conrat et al. (1988).
9
05
r*- rr
* -  CM
in
<uJ2 ~ 3tt"N ~ *42 i^n
co*u’>coc
*nn
*
CMC*
,111111,
coX0)JZ
c o «-* , c <u Q.
>a.
>OL
*
CMininin
1
, t t t
cn
CM
X * in in r- in
CO >5 COcm in mi iCM CO •«r mt
m
LU
rA*
LU V
*44..I I,
n  o
-Srrrrrn
oCT3
"'CO
O
oto
oin
on
oCN
1 a
I • T 2i
t t t
- o
(N 1 . . . .  
LU M
in
I
10
1.1.6.4 Late genes
These genes encode structural proteins. They are all under the control of the same 
promoter, the major late promoter (as reviewed by Paabo et al., 1989).
1.1.6.5 E1A
a. Physical properties of the E1A gene and its products
El A extends from 1.3-4.5 map units (Berk and Sharp, 1977). El A proteins are 
translated from three major mRNAs sedimenting at 13S, 12S and 9S. Two additional 
niRNAs of 11S and 10S have also been detected (Stephens and Harlow, 1987; 
Ulfendahl et al., 1987) (Fig 1.2a). All the niRNAs are transcribed throughout infection 
apart from 9S which is restricted to the late phase. 9S mRNA encodes a structural 
protein, polypeptide IX, which is part of the viral capsid. The two most abundant 
niRNAs of 12S and 13S encode proteins of 243 and 289 residues in group C viruses, 
and these proteins will be referred to as 243R and 289R (as reviewed by Boulanger and 
Blair, 1991). In the case of group A virus, Adl2, the 12S and 13S mRNAs encode 
proteins of 235 and 266 residues respectively, and so will be referred to as 235R and 
266R (Lamberti and Williams, 1990).
All the E1A proteins except polypeptide IX have the same N- and C- termini and are 
translated in the same reading frame. Both 243R and 289R appear as a multitude of 
discrete bands on SDS gels, the different bands representing various phosphorylated 
forms of these proteins (as reviewed by Boulanger and Blair, 1991).
There are three regions of E1A which have a high degree of homology between 
different serotypes. These conserved regions are called CR1, CR2 and CR3. In Ad2 
CR1 is located between residues 40-80, CR2 between 120-139 and CR3 between 139- 
186 (Kimelman et al., 1985). Because of differential splicing CR3 is contained within 
the 46 amino acids unique to the 289R species.
b. Functional properties of the El A proteins 
Transcriptional transactivation
E1A activates transcription from all the other early gene promoters, that is, E1B, E2, 
E3 and E4 (Osborne et al., 1984; Jones and Shenk, 1979). E l A can promote the 
transcription of genes transcribed by RNA polymerase II and III (Spangler et al., 1987; 
Datta et al., 1991). E1A activates transcription from several other viruses including
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Fig 1.2 Splicing events and gene products of Ad2 El A and E1B regions
A. The solid line at the top of the figure is the left-hand end of the adenovirus linear 
genome from 500 to 1600. The Ad2 El A mRNAs are shown as solid lines and the 
protein coding sequences as coloured boxes, representing the three alternative reading 
frames.
B. The E1B promoter controls a rightward transcript that starts at nucleotide 1699 
(+1) in the Ad2 genome. The coloured boxes represent the three alternative reading 
frames. Synthesis of the virion structural polypeptide IX begins at the intermediate 
stage of infection, from the E1B 9S mRNA.
Figs A and B from Boulanger and Blair (1991).
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HTLV-1 (Nicholas and Nevin, 1991). E l A can activate cellular genes including p53 
(Braithwaite et al., 1990) and c-fos (Simon et al., 1990).
The sequence of 46 amino acids unique to 289R which contains CR3 is able to induce 
transcription from the E2 promoter and has therefore been described as an autonomous 
transcriptional activation domain (Lillie et al., 1987). Experiments with a 49 amino 
acid peptide, suggested that the CR3 region facilitates promoter complex formation 
(Loewenstein and Green, 1989). However, Braithwaite et al. (1991) have claimed that 
it is not just CR3 which is involved in transactivation and have proposed that both 289R 
and 243R are involved. Fahnestock and Lewis (1989) found evidence for sequences 
outside CR3 being involved in the positive regulation of transcription.
E1A can activate transcription from several unrelated genes that do not share common 
promoter elements (reviewed by Boulanger and Blair, 1991). It has been proposed 
therefore that the transcriptional activation of E1A is indirect, mediated by cellular 
proteins (Nevins, 1991). There is evidence for indirect involvement in several 
situations, for example, Datta et al. (1991) found in the case of a gene transcribed by 
RNA polymerase III that E1A mediated its effect through altering the DNA-binding 
properties of TFIIC. Nevins (1991) suggested that E1A transactivates the E2 promoter 
in two ways, both involving transcription factor E2F. E1A can dissociate E2F from 
cellular proteins (Raychaudhuri et al., 1991). El A also causes E2F to be in an active 
phosphorylated state. While there is no evidence that El A acts as a kinase itself, 
Nevins (1991) has suggested that E1A may either activate a kinase or inhibit a 
phosphatase. In the case of c-fos, ElA-dependent activation appeared to be mediated 
through a TATA-specific DNA-binding protein (Simon et al., 1990). Horikoshi et al., 
(1991) demonstrated that E1A can directly interact with the TATA box transcription 
factor TFIID.
Transcriptional repression
E1A proteins can repress transcription of certain viral and cellular genes such as the 
SV40 and polyoma early genes (Borrelli et al., 1984; Lebkowski et al., 1985; Lewis 
and Manley, 1985), the rat insulin gene (Stein and Ziff, 1987) and rodent muscle 
specific genes (Webster et al., 1988). Transformation of primary cells by Adl2 is 
associated with reduced expression of MHC class I, transformation by Ad5 leads to 
maintained or increased levels of class I (Schrier et al., 1983). Sawada et al. (1985)
14
used two recombinant viruses containing either El A of Adl2 and E1B of Ad5 or E l A 
of Ad5 and E1B of Adl2 in transformation. Oncogenicity of the transformed cells was 
dependent on the presence of the Adl2 E1A gene. This would be consistent with the 
Adl2 E1A gene and not the Adl2 E1B gene being responsible for the down-regulation 
of MHC class I.
The expression of Adl2 El A proteins reduced steady state levels of MHC class I heavy 
chain mRNA in transformed cells of rat (Schrier et al., 1983), mouse (Eager et al.,
1985), hamster (Ackrill and Blair, 1988b) and human origin (Vaessen et al., 1987). 
Both 289R and 243R have been reported capable of mediating repression of certain 
genes. In the case of Ad5 E1A and SV40 early transcription, Jelmsa et al. (1989), 
using deletion mutants, found that residues 4-25 and 36-60 were important in 
repression. These residues include part of CR1 (40-80).
Svensson et al (1991) showed that El A bound to the cellular protein p300 and that CR1 
is required for this binding. Using various mutants they found that transcriptional 
repression correlated with p300 binding. Other groups have found that CR1 and CR2 
are both required for repression (Lillie et al., 1987; Schneider et al., 1987). It is 
possible that the precise amino acid sequences involved in repression depend on the 
promoter. The repression of class I gene expression mediated by Adl2 E1A could be 
unusual as it appears to be caused by the 13S and not the 12S product (Bernards et al., 
1983), which suggests that CR3, the region unique to 13S, might be involved in causing 
the repression.
Stimulation of host cell proliferation and cellular DNA synthesis 
Cells expressing E1A have been shown to have increased rates of cellular DNA 
synthesis and cell proliferation (Kaczmarek et al., 1986; Quinlan et al., 1987; Stabel 
et al., 1985). Smith and Ziff (1988) have localised these properties to the CR1 domain 
and its flanking N-terminal region . Quinlan et al. (1987) propose that the phenomena 
of induction of cellular DNA synthesis and cell proliferation by E1A might, at least in 
part, be due to the secretion of growth factors by infected cells. There is a 
transcriptional activation of p53 in quiescent normal rat kidney cells when infected with 
Ad5 (Braithwaite et al., 1990). This effect has been shown to be due to the 289R 
product of E1A. Since there is evidence that p53 regulates normal diploid cell
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proliferation, at least some of the effects on cell proliferation of El A in Ad5 infected 
cells could be due to the effect of El A on p53.
Immortalization and malignant transformation
The E1A region alone is able to immortalize non-permissive rodent primary embryo 
cells, and in conjunction with E1B or other oncogenes such as activated H-ras, it can 
induce morphological transformation of these cells (Houweling et al., 1980; White and 
Cipriani, 1990). In Adl2 the product of the 13S mRNA, 266R, can transform alone, 
whereas the product of 12S mRNA, 235R, cannot (Lamberti and Williams, 1990). 
With other serotypes both the 12S and the 13S products are required for stable and 
complete transformation (Houweling et al., 1980). The transforming properties of El A 
have been mapped to CR1 and CR2 (40-80,120-139) (Velcich and Ziff, 1988). Similar 
sequences were found to be important by Jelmsa et al. (1989), namely 4-25, 36-60 and 
111-138. The 243R product appears to be able to drive Go arrested cells into S phase 
(Montell et al., 1982) and may thus be important in adenovirus-induced cell 
immortalization (Spindler et al., 1985). It has been suggested that E l A causes 
transformation through association with cellular proteins. El A has been shown to be 
associated with several cellular proteins. These included p300, pl05 and pl07 
(Svensson et al., 1991). Mutations that abolished the ability of El A to bind p300 or 
p i05 and p i07 reduced its capacity to transform primary rodent cells in association with 
H-ras. Mutations that abolished both p300 and pl05/pl07 binding abolished the 
transforming activity of E1A, suggesting that two additive mechanisms were involved 
(Svensson et al., 1991). pl05 is the product of the retinoblastoma tumour suppressor 
gene (RB gene) (Whyte et al., 1988). It has been suggested that it is the binding of 
E1A to the products of tumour suppressor genes may somehow lead to their 
inactivation, which in turn could cause transformation.
Tumour suppressor effect of adenovirus E1A in human tumour cells
Frisch (1991) found that stable expression of Ad5 E1A reduced anchorage-independent 
growth and tumorigenic potential, caused cytoskeletal reorganization, induced flat 
morphology and restored contact inhibition in three human tumour cell lines. E l A 
in this situation seemed to behave like as a tumour suppressor gene. E1A appears to 
be capable of acting as a transforming agent or a tumour suppressor depending on 
context.
16
Degradation of host and viral DNA and cytopathic effect
E1A has been shown to cause cytopathic effect and degradation of host and cellular 
DNA. These effects have been shown to be mediated by the region of E1A at the 
amino terminus between amino acids 22 and 8 6  (White et al., 1991)
Apoptosis
El A is thought to induce apoptosis in certain circumstances (White et al., 1991). 
Mapping studies have shown that induction of apoptosis is a function of the N-terminus 
of E l A that encompasses CR1 (White et al., 1991). Debbas and White (1993) found 
wildtype p53 was required for the induction of apoptosis by E1A. Lowe and Ruley 
(1993) found El A caused the stabilization of nuclear wildtype p53.
1.1.6.6 E1B
a. Physical properties of the gene and its products
The E1B gene is located between 4.6 and 11.2 map units (Berk and Sharp., 1977). 
The E1B region encodes three major mRNA species of 22S, 13S and 9S as well as two 
minor species of 14S and 14.5S. The 22S and 13S mRNAs are derived from a 
common mRNA precursor by alternative RNA splicing (Pettersson et al., 1983). The 
22S mRNA encodes two unrelated proteins, pl9 and p55 (or 19K and 55K), which are 
translated in different reading frames. The pl9 protein is also translated from a 13S 
mRNA. Another protein, p8  or 8 K, can be encoded from the 13S mRNA (Fig 1.2b). 
p8  is related to the N-terminal region of p55, although this truncated species has not 
been detected in infected cells. Both p55 and pl9 proteins are post-translationally 
modified. The p55 protein is phosphorylated on serine and threonine residues (Russell 
and Blair, 1979) and is also a substrate for poly ADP ribosylation in vitro (Goding et 
al., 1983). A protein kinase activity has also been reported to be associated with p55 
(Branton et al., 1985). pl9 protein has been found to be covalently linked to lipid 
(McGlade et al., 1987).
b. Functional properties of the E1B proteins 
Viral DNA replication
p55 has been shown to be necessary for viral DNA replication (Mak and Mak 1990; 
Stillman, 1986). Mak and Mak (1990) found residues between 114 and 155 to be 
essential for this function.
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Accumulation and transport of late mRNAs
p55 is important in the intranuclear maturation of late mRNAs and appears to facilitate 
the transport of these RNAs to the cytoplasm (Leppard and Shenk, 1989).
Overcoming E1A induced cytotoxic effects
El A in infection causes the degradation of host and viral DNA and disrupts cytoplasmic 
architecture. The presence of E1B pl9 is sufficient to overcome these effects (White 
et al., 1991). pl9 was found to increase expression from several viral promoters and 
the cellular promoter hsp70 (Hermann and Mathews, 1989). pl9 was found to activate 
transcription indirectly by stabilizing DNA.
Transformation and tumorigenicity
E1B gene products are required with El A to produce full morphological transformation 
of primary rodent cells (Houweling et al., 1980; White et al., 1991). However, high 
level expression of Ad2 E1A can enable full morphological transformation of 
established cells to occur in the absence of E1B (Senear and Lewis, 1986). During 
infection pl9 prevents E lA ’s disruption of cytoplasmic architecture, whereas in the 
process of transformation pl9 itself causes the disruption of the intermediate filaments 
in the cytoplasm (White and Cipriani, 1990). The morphological differences between 
primary cells and transformed cells are greater than those between cell lines and 
transformed cells, and this perhaps explains the need for E1B in the transformation of 
primary cells and not cell lines. Transformation by p55 and E1A does not cause a 
gross disruption of intermediate filaments. pl9 also confers resistance to TNFa 
mediated cytotoxic effects, which could be important in allowing tumours to survive 
in hosts. Deletions of amino acid residues 1-24, 80-96 and 114-155 of p55 in Adl2 
greatly reduced the transforming ability of both viruses and plasmids containing any 
one of these deletions (Mak and Mak, 1990). Cells transformed by plasmids with 
deletions to residues 80-96 were non-tumorigenic. In Ad5-transformed cells both pl9 
and p55 appear to contribute to transformation. McLorie et al. (1991) found either 
pl9 or p55 in cooperation with E1A could transform primary baby rat kidney cells, 
albeit with an efficiency greatly reduced to that observed when both E1B proteins were 
present. They suggest this indicates that the two processes of transformation by these 
E1B proteins are additive. However Adl2 mutants where only the p55 and not pl9 
were produced were found to transform primary BRK cells in association with E1A at 
efficiencies similar to those of wild-type Adl2 (Edbaeur et al., 1988).
18
Tumour suppressor properties of p55
Van den Heuwel et al. (1990) found that Ad5 El-transformed 3Y1 rat cells which 
express low levels of p55 do not contain a p53/p55 complex. These cells which have 
nuclearly located p53 are highly oncogenic in nude mice. In 3Y1 cells expressing p55 
at higher levels, p53 is complexed to p55 in the cytoplasm. These cells only form 
tumours after a very long latency period, the tumours appear in cells where selection 
has occurred to lose this complex. Comparable results were obtained when 
Adl2-transformed cells which do not normally have the p55/p53 complex were 
supertransfected with the Ad5 E1B region. Van den Heuwel et al. (1990) suggested 
that nuclear p53 with a wild-type conformation contributes to the oncogenicity of 
Ad-transformed cells. Therefore p55, in as much as it retains p53 in the cytoplasm, 
could be acting as an tumour suppressor gene product.
Suppression of apoptosis
The 19 kDa and the 55 kDa products of E1B are both capable of suppressing E1A 
induced p53 dependent apoptosis (Lowe and Ruley, 1993; Debbas and White, 1993).
1.2 Major Histocompatibility Complex (MHC)
1.2.1 The major subdivisions of the MHC region
The genes responsible for the rejection of transplanted tissues and thus the ability to 
distinguish 'self' from 'non-self' have been mapped to a region which has become 
known as the Major Histocompatibility Complex (MHC). All vertebrate species studied 
so far have been found to have a MHC region (Male et al., 1991). The mouse and 
human systems are by far the most intensely studied.
MHC is a multigene family approximately 3000 kb in size, located on chromosome 17 
in the mouse and chromosome 6  in humans (Male et al., 1991). Both mouse and 
human MHC regions have been divided into three major classes I, II and III. The 
class I region can be divided into the classical genes, responsible for transplantation 
rejection, and the non-classical genes. In the mouse the classical genes map to two 
regions called K and L; the genes themselves include H-2K, H-2D and H-2L (not all 
strains carry the L gene) (Fig. 1.3). The non-classical class I genes in the mouse map 
to a region known as Qa/Tla. In mice the number of class I genes in the haploid 
genome is around thirty but this number varies amongst different inbred strains (Singer 
and Maguire., 1990). Most of the class I genes map to the Qa/Tla region and are of
19
Fig 1.3 Organization of murine and human MHC
The location and major loci of class I, class II and class III regions are shown for the 
murine and human MHC. Reproduced from Male et al. (1991).
20
M ouse
_________
H -2  c o m p le x Q a/T la c o m p le x
l-E
J L
C4 S ip  8 f C2 T N F .T N F ,
_ _______ ___Human
HLA c o m p le x
DQDP DR C la ss  III
DPj, DPa DO* D Q , DRf, D R. C4B C4A Bf C2 TNFa TNF(1 B
21
^
unknown significance. Extensive polymorphism in regions K and D has created a 
large number of possible combinations of alleles. Each combination of alleles is termed 
a haplotype, examples of mice haplotypes include b, k and bml. The gene products for 
a particular haplotype are denoted by the name of the gene followed by the haplotype 
in superscript, for example H-2Kb. The number of genes in a particular region varies 
between haplotypes. For example, five genes map to the D region for H-2? mice, 
whereas for H-2b mice only one gene maps to region D (Male et al., 1991).
The number of genes in the human class I region has been estimated to be between 15 
and 25 (Singer and Maguire, 1990). The class I region includes A, B and C, these 
regions contain the major transplantation antigens, 'Human Leucocyte Antigens' 
HLA-A, -B, and -C which are analogous to H-2K, D and L in the mouse (Fig 1.3). 
These regions also contain several other genes including HLA-E, -F and -G whose 
functional significance is unknown. A cluster of class I -like genes is located telomeric 
to HLA-A; however it is uncertain whether any of these genes represent the human 
equivalent of the murine Qa/Tla genes (Male et al., 1991).
The class II genes are encoded by regions I-A and I-E in the mouse and by region D 
in humans. Most class I and class II molecules (with the exception of Qa/Tla antigens) 
are highly polymorphic structures.
The class III region, although originally defined as encoding four of the components of 
the complement system, is now known to contain several diverse genes including TNFa 
and TNF/3 (Male et al., 1991).
The structural similarities between class I and class II gene products show that they may 
have evolved from a common origin. There is no evidence for functional or structural 
similarities between the gene products of class I and class II with those of class III 
(Male et al., 1991).
1.2.2 The structure of MHC class I
MHC class I molecules are present on the cell surface. These molecules consist of a 
glycosylated polypeptide chain, the heavy chain, of 42-45 kDa, associated non- 
covalently with /52 microglobulin, a 12 kDa polypeptide (Singer and Maguire, 1990).
22
The heavy chain consists of three extracellular regions a2 and a3, a transmembrane 
region and a cytoplasmic domain.
02 microglobulin is a non-polymorphic protein in humans, dimorphic in mice. It has a 
high degree of sequence homology between species, implying evolutionary 
conservation. 02 microglobulin is thought to stabilize the heavy chain (van Bleek and 
Nathenson, 1992).
There is crystallographic evidence that a large groove between and a2 constitutes the 
binding site for antigen in the form of peptides (Bjorkman et al., 1987; Garrett et al., 
1989).
H-2K/H-2D and HLA-A/HLA-B are highly polymorphic, whereas H-2L and HLA-C 
molecules appear less so. There are three main hypervariable regions in cq and a2, 
whereas a 3 appears to be much more conserved. Most of the hypervariable regions are 
in positions in which the side chains point towards the antigen-binding groove (van 
Bleek and Nathenson, 1992).
1,2.3 The function of MHC class I gene products
MHC class I is involved in presenting antigenic peptides to cytotoxic T-cells. These 
T-cells have the cell surface marker CD8 + (Monaco, 1992). They cannot recognise 
the antigenic peptides alone, their T-cell receptors (TcR) recognise the conformation of 
antigenic peptide in association with a MHC class I molecule (Zinkemagel and Doherty,
1979). This phenomenon is called MHC class I restriction. The MHC genes are co- 
dominantly expressed, so any one individual has between three and six different types 
of class I molecules available to present antigenic peptide to cytotoxic T-cells (Male et 
al.,1991). Since the variety of class I molecules is so limited, it is not surprising that 
each class I molecule is capable of binding to several different types of peptide 
(Jorgensen et al.,1992).
The antigenic peptides presented by class I molecules are generally proteolytically 
processed from endogenously synthesized proteins, whereas class II molecules bind 
peptides derived from membrane glycoproteins and serum proteins that have entered the 
cell by endocytosis (Germain, 1991). Peptides which bind to class I have an optimal 
length of eight or nine amino acids depending on the class I molecule (van Bleek and
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Nathenson, 1992). Little is known about the proteases involved in generating these 
peptides, however several genes recently found in the MHC region encode proteins 
which appear to be involved in the supply of peptides to class I molecules (De Mars and 
Spies, 1992). The peptides include those of viral or tumour origin. Since different 
class I molecules vary in their ability to present a particular antigenic peptide to T-cells, 
depending on the haplotype of an individual, particular peptides will be presented to 
T-cells with varying degrees of success (Jorgensen et al., 1992).
Once the TcR has bound to a particular peptide/MHC class I configuration, the 
cytotoxic T-cell is stimulated to proliferate and also to release chemicals such as 
perforins which cause the killing of cells presenting that particular antigen. By this 
means MHC class I is central to the destruction of tumour cells and virally infected 
cells by cytotoxic T-cells (Male et al., 1991).
1.2.4 Patterns of classical MHC class I gene expression
Nearly all tissues express class I antigens, however their levels of expression vary. 
Cells can be divided into those which show high, weak or no detectable expression of 
classical class I antigens. The highest level of class I has been found on splenocytes. 
Keratinocytes also display very high levels of class I. Intermediate levels of class I 
expression occur in the thymus, lymph node, kidney and lung with lower levels in the 
heart and adrenal glands. Low levels of class I expression are found on skeletal 
muscle, in the pancreas, thyroid and the small intestine. Class I antigens expression 
is low on erythrocytes, reticulocytes and endocrine cells (apart from adrenal cells). 
Class I antigens are not detectable at all in the brain, on corneal endothelium, acinar 
cells of the parotid gland, the exocrine region of the pancreas, on ova and on mature 
sperm (Singer and Maguire, 1990; Male et al., 1991).
1.2.5. Patterns of expression of non-classical MHC class I genes 
Since this study is concerned with classical MHC class I, little will be said about the 
expression of non-classical genes. However it is interesting to note that certain non- 
classical gene products are expressed in just one organ, for example the liver. 
Although the brain has generally been considered a class I deficient organ, expression 
of non-classical genes may occur in the brain (Singer and Maguire, 1990).
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1.2.6, Regulation of MHC class I expression
1.2.6.1 Regulation of MHC class I expression during development
The expression of MHC class I antigens is developmentally regulated. No cell surface 
expression of class I is detectable on either ova or mature sperm (Ostrand-Rosenberg,
1980). Class I mRNA has been detected in 8.5 day embryos. Even at the earliest 
stages at which expression is detected, both classical and non-classical genes are 
found, and their tissue distribution varies already (Fahmer et al, 1987). Cell surface 
expression of class I is detectable only after the mid-somite stage of development (Ozato 
et al., 1985). Since there is a limited availability of embryonic tissue, most research 
on developmental regulation of class I genes has been done on embryonic carcinoma 
cells (EC). EC cells such as F9 can be maintained in culture as undifferentiated 
pluripotent cells. In this state, such cells express no detectable cell-surface class I 
antigen and barely detectable levels of mRNA (Rosenthal et al 1984; Morello et al., 
1982). EC cells can be induced to differentiate and express both class I mRNA and 
cell surface antigen by treatment with retinoic acid, alone or in combination with 
cAMP (Rosenthal et al., 1984; Croce et al., 1981; Morello et al., 1982; Daniel- 
Vedele et al., 1985). Treatment of F9 cells with either a/(3 or y  interferon similarly 
induces high levels of class I expression (Wan et al., 1987) but does not cause 
differentiation. This shows the mechanisms controlling class I expression are separable 
from those controlling differentiation.
I.2.6.2. Regulation of MHC class I expression by interferons
Interferons (IFNs) were originally identified by their ability to prevent viral replication 
(Isaacs and Lindenmann, 1957). a , /? and y  interferons are all capable of inducing 
increased cell surface MHC class I (Burrone and Milstein, 1982; Branca and Baglioni,
1981). IFN treatment results in increased rates of transcription of MHC class I 
(Friedman and Stark, 1985; Blanar et al., 1988), but post-translational control is also 
important (Revel and Chebath, 1986). IFNs have to react with a specific cell surface 
receptor to induce an immune response. IFNs a, (3 share a common receptor; type I, 
while IFN7  has a separate receptor; type II. Type I IFNs (IFNa and IFN/3) are 
produced following viral infection of leucocytes and fibroblasts respectively. Type II 
or IFN7  is produced by antigen or mitogen activated T-cells (Male et al., 1991). In 
vitro treatment of cells with IFNs induces MHC class I expression in a wide variety of 
cells of haemopoietic, lymphoid, epithelial, fibroblastic and neuronal origin (Halloran 
et al., 1986; Wong et al., 1984). The relative effects of type I and type II IFNs
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depend on the target cell type, for example, in mouse fibroblast lines they are equally 
effective (Korber et al., 1988), whereas in mouse thymocytes type II IFN elicits a 
greater induction of class I (Sonnenfield et al., 1981). When IFNs are used to treat 
tumour cells which express low levels of class I, there is a concomitant decrease in 
tumorigenicity (Tanaka et al., 1985).
I.2.6.3. Regulation of MHC class I expression by TNF
TNF, also known as TNFa, is a protein of 17-18 kDa in size depending upon the 
species. O’Malley et al. (1962) first reported a tumour necrotizing factor in serum. 
Although it was first discovered because of its ability to kill tumour cells, TNF is now 
known to have pleotropic effects. TNF selectively lyses certain transformed cells 
(Bonavida, 1991) and kills some virally infected cells (Rook et al., 1991). It mediates 
severe inflammatory reactions, stimulates collagenase and prostaglandin, stimulates 
fibroblast and endothelial cells, regulates T- and B-cells causing the killing of virally 
infected cells and stimulates several cytokines from different cell lines. TNF is itself 
induced by the gram-negative lipopolysaccharide and by lipoteichoic acid of gram- 
positive cocci. It is possible that all micro-organisms trigger the release of TNF. 
TNF is produced by macrophages and CD4+ lymphocytes (reviewed by Gifford and 
Duckworth, 1991).
TNF causes an increase in the cell surface expression of MHC class I (Collins et al., 
1986). TNF also causes translocation of the transcription factor NF-kB from the 
cytoplasm to the nucleus (Duh et al., 1989). It is possible that many of the actions of 
TNF including i ts  effect on class I are due to it’s action on NF-kB, as will be 
described in more detail later.
1.2.6.4 Regulation of MHC class I expression in human adenovirus infected cells
The E3 19 kDa protein from adenovirus subgroups B-E but not subgroup A has been 
shown to bind to MHC class I antigens during adenovirus infection (Wold and Gooding, 
1989; Flomenberg et al., 1987; Paabo et al., 1986). The association of E3 19 kDa 
protein with nascent class I heavy chains within the endoplasmic reticulum prevents 
terminal glycosylation of the class I molecules, inhibiting their transport beyond the cis 
Golgi to the cell surface (Severinsson et al., 1986; Kampe et al., 1983). In contrast 
to the above results, Rosenthal et al. (1985) found that in infected mouse cells, either 
Adl2 or Ad5 increased the level of class I mRNA.
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1.2.6.5 Regulation of MHC class I expression in human adenovirus-transformed 
cells
Primary cells transformed by oncogenic Adl2 show decreased steady state levels of 
class I mRNA, whereas non-oncogenic Ad2 and Ad5 either stimulate or do not alter the 
steady-state levels of cytoplasmic class I transcripts (Schrier et al., 1983; Eager et al., 
1985; Vasavada et al., 1986). This has led to a view by several workers that it is the 
lower level of class I expression in Adl2-transformed cells which allows such cells to 
escape T-cell-mediated immune surveillance and so cause the increased oncogenicity of 
Adl2 (Schrier et al., 1983; Eager et al., 1985; Tanaka et al., 1985).
The suppression of class I appears to be due to a reduced level of transcription initiation 
(Friedman and Ricciardi, 1988; Ackrill and Blair, 1988a; Lassam and Jay, 1989). 
Shemesh et al. (1991) investigated several Adl2-transformed cell lines, in some the 
reduced class I appeared to be due to lowered levels of transcription, whereas in other 
cell lines it seemed to be due to interference with processing of the post-transcriptional 
product.
Introduction, by transfection, of functional class I genes under the control of a SV40 
promoter into Adl2-transformed cells has been shown to abolish their tumorigenicity 
(Tanaka et al., 1985). This provides evidence for the proposition that it is the lowered 
levels of class I in Adl2-transformed cells which is in some way responsible for their 
tumorigenicity. However differences in levels of class I and corresponding variations 
in susceptibility to cytotoxic T-cells may not be the only factors relevant to the range 
of tumorigenicity found among the different adenovirus serotypes. Natural killer (NK) 
cells do not have receptors which bind to MHC class I. Adl2-transformed cells have 
been shown to be resistent to lysis by NK cells (Sawada et al., 1985). Haddada et al. 
(1986) have shown that transformation with Ad2 and Ad5 E1A genes can increase 
susceptibility to natural killer cells and activated macrophages with concomitant reduced 
tumorigenicity.
1.2.6.6 Regulation of MHC class I expression by infection with other tumour 
viruses
Viral infections in general cause the release of cytokines such as TNF and interferons 
which instigate an increase in the transcription of MHC class I antigens. Despite this 
the overall effect of infection by certain viruses on the levels of MHC class I can be a
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reduction. For example, infection by human cytomegalovirus can down-regulate 
class I expression. A CMV encoded homologue of the class I heavy chain, the UL18 
gene product (Berk and Bareli, 1988), has been shown to sequester host 
02microglobulin and so disrupt the assembly of the class I heterodimer (Browne et al., 
1990, 1992). Infection with HSV-1 and HSV-2 has been shown to reduce the 
expression of class I antigens although the mechanism by which this process occurs has 
not been elucidated. HIV-1 infection has also been associated with the down-regulation 
of class I in certain cells. (Scheppler et al., 1989).
1.2.6.7 Regulation of MHC class I expression by transformation with other 
tumour viruses.
Several viruses which are capable of transforming cells in vitro have a concomitant 
effect on the levels of MHC class I; for example, Rous sarcoma virus transformed 
human fibroblasts have down-regulated class I expression (Gogusev et al., 1988) due, 
at least in part, to a reduction in steady state levels of class I mRNA. Levels of class I 
mRNA were also reduced in cells transformed by Radiation leukaemia virus (RadLV), 
this reduction was associated with methylation and rearrangement of MHC DNA 
(Meruelo et al., 1986). SV40 transformation of cells is associated with an up- 
regulation of class I (Brickell et al., 1985).
1.2.6.8 Regulation of MHC class I expression by virally-induced tumours
Tumours can be induced in animals by treating them with certain viruses. Many of 
the virally induced tumours show a lack of both H-2K and H-2D antigens. For 
example, there is a lack of class I antigen expression with a SV40-induced 
fibrosarcoma, a RadLV-induced Lymphoma, a Gross MuLV-induced lymphoma and 
several Moloney virus-induced lymphomas (reviewed by Elliot et al., 1989). Human 
papillomaviruses (HPV)16 and 18 are strongly associated with cervical carcinoma and 
greater than 30% of such tumours show a complete or partial loss of MHC class I 
expression (Conner and Stem, 1990).
1.2.6.9 Regulation of MHC class I expression in non-virally induced tumours
Tumours can occur spontaneously and be of unknown aetiology or they can be induced 
by viruses or by several non-viral inducing agents which include chemical carcinogens, 
ultraviolet light and y  irradiation.
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a. Regulation of MHC class I expression in human tumours
Certain human tumours seem to be strongly associated with a down-regulation of MHC 
class I; for instance, McDougall et al. (1990) found dramatically reduced levels of 
MHC class I in colon cancer as compared to normal colonic mucosa samples taken 
5-10 cm away from each tumour. HLA class I expression was undetectable in 28% 
of the specimens, diminished in 6 8 % (as compared to normal control tissue) and normal 
in only 4% of the samples. Some other tumours are associated with little or no class I, 
for example, neuroblastomas (Lampson et al., 1983), however since the normal neural 
tissue from which these tumours originate is also class I negative, the levels of MHC 
class I probably is not of relevance to the development of tumours in these tissues. 
Other tumours seem to be associated with down-regulation of MHC class I, but the 
relationship is less strong, for example, Garrido and Ruiz-Cabello (1991) found 10% 
of melanomas and 27% of breast carcinomas to be HLA class I negative. Further 
evidence that reduced MHC class I can be important for immune evasion comes from 
results with human tumours, where it has been shown over a wide range of tumours 
including melanomas (Ruiter et al., 1984) and breast cancer (Natali et al., 1983) that 
tumours with lower class I expression have greater metastatic potential. Additional 
support for a role of class I in the development of at least some tumours comes from 
studies of the human malignant leukemia line K562; introduction of specific MHC 
genes into this cell line, with resulting cell surface class I expression, restores the 
susceptibility of these cells to antigen-specific cytolysis by cytotoxic T-cells (Maziarz 
et al., 1990).
Some tumours do not appear to be associated with changes in HLA expression, for 
example, colorectal adenomas and nonmucinous colorectal carcinomas (Elliot et al., 
1989). Certain tumours are even associated with increased class I expression (Smith,
1991). It has been demonstrated that some human tumours selectively lose HLA-A or 
HLA-B locus products (Lopez Nevot et al., 1989).
Overall, the results with human tumours sugggest reduction in the levels of MHC 
class I does seem to be of importance in the development of certain tumours. It is not 
known what causes MHC class I levels to be suppressed in some tumours and not in 
others.
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b. Regulation of MHC class I expression in non-virally induced tumours in animals
Some carcinogen-induced and spontaneous tumours in animals still express all class I 
antigens, for example, the methylcholanthrene-induced mastocytoma P815, whereas in 
others there is noncoordinate loss of H-2K, -D antigens as in the spontaneous mammary 
carcinoma TA3 which is Kk\  Dk+. In other tumours the situation is that commonly 
found in virally induced tumours, in that there is loss of expression of H-2K and H-2D 
antigens, as for instance in the spontaneous mammary carcinoma SPI (reviewed by 
Elliot et al., 1989).
Transfections of class I genes into animal tumour cells have provided further support 
for the view that expression of MHC class I can, at least in certain circumstances, make 
tumours susceptible to attack by the immune system. Such experiments have been 
performed by several workers with a variety of tumours. Wallich et al.(1985) found 
a highly metastic methylcholanthrene-induced sarcoma lost its metastic properties after 
expression of new H-2 gene products on its surface. A spontaneous murine melanoma 
line was rendered non-tumorigenic in syngeneic mice by the expression of the 
transfected class I gene (Tanaka et al., 1988).
1.2.6.10 Regulation of MHC class I expression by oncogenes
Certain oncogenes have been shown to have an effect on MHC class I expression, for 
instance, induction of class I by 12-0-tetradecanoyl phorbol-13-acetate or dimethyl 
sulfoxide was preceded by a transient burst of c-fos (Barzilay et al., 1987). A positive 
correlation between MHC class I and c-fos expression has been found in other tumours 
such as PCI2 phaeochromocytoma and Lewis Lung carcinoma (Kushtai et al., 1988). 
In the latter system low-metastic clones express c-fos and high levels of class I 
antigens, whereas highly metastic clones are deficient in class I and do not express 
c-fos. Transfection of c-fos or v-fos into class I negative cells resulted in increased 
levels of class I proteins and gave such clones a low-metastic phenotype. Bernards 
et al. (1986) have shown that class I expression in neuroblastoma cells correlates 
inversely with N-myc expression. Transfection of rat neuroblastoma cells with N-myc 
resulted in down-regulation of class I expression. Versteeg et al. (1988) demonstrated 
that transfection of c-myc into two human melanoma cell lines resulted in a reduction 
of class I expression, whilst IFNy treatment both restored class I expression and 
suppressed c-myc mRNA levels. Alon et al. (1987) have shown that k-ras mRNA
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levels were elevated in low MHC-expressing variants of T10 sarcoma which have high(drmetastjc ability.
In summary, there is strong evidence that certain oncogenes can influence levels of
MHC class I in certain tumour systems. However, because these oncogenes haveatpleiotropic effects it is difficult to know whether the tumorigenic/metasjjc properties of 
these proteins are directly related to their effects on expression of class I antigens.
1.2.6.11 Regulatory sequences within the class I promoter and the transcription 
factors that bind to them
As described in the previous sections, the MHC class I genes are of great importance 
to the immune system; because of this the control of transcription of these genes has 
been the subject of intensive investigation.
Several sequences within the promoter region have been shown to control the 
transcription of class I genes, some sequences appear to play different roles in different 
circumstances such as at certain developmental stages. The interspecies similarity of 
regulatory sequences within the promoters of MHC class I genes suggests that similar 
mechanisms of regulation of class I exist in different species.
The following section will describe these sequences and what is known about the factors 
which bind to them (Fig 1.4), starting with sequences actually in introns, then 
considering sequences progressively further upstream from the transcription start site.
a. Intron enhancer-like sequences
In the human MHC class I gene HLA-B7, enhancer-like sequences have been identified 
in introns 3 and 5 (Ganguly et al., 1989).
b. TATA box
The first important regulatory sequence upstream from the transcription start site is the 
TATA box, a TA-rich region. This highly conserved sequence is required for the 
correct positioning of RNA polymerase II. Its exact position varies between different 
class I genes in different species, but it occurs around -30 to -25, where +1 represents 
the transcription initiation site (David-Watine et al., 1990).
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Fig 1.4 Regulatory sequences within the MHC class I promoter and the transcription 
factors which bind to these sites
The major sites that have been shown to been shown to be important in the control of 
transcription of MHC class I genes are represented schematically in this figure. The 
transcription factors that bind to these sequences are also shown.
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c. CCAAT boxes
Many eukaryotic genes possess one or more transcriptional regulatory element(s) that 
contain the pentanucleotide sequence CCAAT between -80 and -60, MHC class I are 
examples of genes with such sequences. In the mouse H-2Kb gene, one CCAAT 
element is present at -51 and a second at -72, the two CCAAT elements motifs being 
AACCAAT and ACCCAAT respectively. The CCAAT element at -51 is on the 
coding strand, whereas the one at -72 is on the non-coding strand (David-Watine et 
al.,1990).
A DNA-binding protein called CPI binds with high affinity to the CCAAT element at 
-51. CPI binds with high affinity to several CCAAT elements including the adenovirus 
major late promoter and the human a  globin gene. A second DNA-binding protein 
called CP2 binds to both CCAAT elements in the H-2Kb upstream region with high 
affinity. CP2 also binds to the rat y  fibrinogen promoter with high affinity (Chodosh 
et al., 1988). CCAAT sequences are thought to be involved in regulating the frequency 
of transcription initiation (David-Watine et al., 1990)
d. Enhancer B
This enhancer region, like enhancer A, is conserved within the upstream region of 
several genes coding for classical transplantation antigens but not in the promoter of 
Qa-TIa region genes. Enhancer B was first described by Kimura et al. (1986) and 
spans from -121 to -61 in the H-2Kb promoter. The -72 CP2 site lies within 
enhancer B. Between this site, and the -51 CP1/CP2 binding site, has been found the 
binding site for another member of the CCAAT family of DNA-binding proteins called 
Nuclear factor 1 (NF-1). The NF-1 site also lies within enhancer B (Driggers et al., 
1992). This is a cellular DNA-binding protein that binds to the adenovirus origin of 
replication and is required for the initiation of adenoviral replication (Chodosh et al., 
1988).
The region between -121 and -107 of enhancer B has been called site a  (Dey et al., 
1992). In this study two MHC class I genes, the transgene HLA-B7 and the 
endogenous H-2Kb gene, are occupied in a tissue-specific fashion that correlates with 
the expression of these genes. In vivo protection was not present in the brain where 
class I expression was virtually absent, whereas protection of certain sequences 
occurred in spleen tissue which expresses class I. The strongest in vivo protection was
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seen at site a. Dey et al. (1992) performed chloramphenicol acetyl transferase (CAT) 
assays to investigate the functional role of this sequence. They used a CAT construct 
linked to -260 to +1 of the H-2Kb promoter and one with a deletion in site a. The 
latter gave 50% lower CAT activity in Namalwa B lymphocytes, but the deletion had 
no effect on CAT activity in LTK' DAP fibroblasts. This demonstrates that site a 
enhances class I transcription in a cell type-specific fashion. Using a DNA- 
immunoprecipitation assay, it was shown in the same paper that RXR/3, expressed in 
baculovirus infected insect cells, bound to site a. RXR/3 is the human homologue of 
the mouse protein H-2RIIBP. The same group originally isolated a cDNA clone for 
this factor (Hamada et al., 1989). The latter binds to a GGTCA motif present in the 
MHC class I promoter in a sequence called region II, which will be described in more 
detail later. The same GGTCA motif is present in site a. This site has also been 
shown to bind purified AP-1 (Israel et al., 1989; Korber et al., 1988).
e. Interferon responsive sequences
MHC class I is one of several interferon-responsive genes. Friedman and Stark (1985) 
identified a 28bp consensus sequence located 5’ of the transcription start site in several 
IFN inducible genes, including two class I genes. Further investigation by several 
groups has led to the identification of a consensus sequence present in several IFN 
inducible genes:
A/GGGAAA/G (N)XGAAACT 
Where N = A, C, T or G and x is a positive integer.
This sequence has been termed the IFN-stimulated response element (ISRE). The 
mouse H-2Kb gene between -153 and -141 has all but the first two bases of this 
sequence. It has been proposed that IFNs mediate their effects through their binding 
to their cell surface receptors. This, after several intermediate steps, is thought to lead 
to ISRE binding factor(s) binding to particular ISREs and so activating transcription. 
Various ISREs have been found to bind at least three distinct factors called IFN 
stimulated gene factors, ISGFs (Levy et al., 1988). ISGF1 binds constitutively to 
ISRE and its function is unknown. The other two factors are inducible. ISGF2 
appears to be identical at the DNA level to independently identified factors IRF-1 (Pine 
et al., 1990) and IBP-1 (Blanar et al., 1989). IRF-1 was identified as an IFNa//? 
responsive factor and IBP-1 as a IFN7  responsive factor. However this factor might
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be post-translationally modified in various forms. Ali Imam et al. (1990) suggested 
that different forms may be involved in IFNa//3 and IFNy induction of IFN-responsive 
genes. IRF-1 has been cloned (Harada et al., 1989, 1990). Expression of IRF-1 
cDNA constructs in IRF-1 negative EC cells resulted in the activation of endogenous 
IFNa genes and co-transfected promoters of IFNa , IFN/3 and MHC class I; 
ISGF2/IRF-1 could therefore be important in mediating the increase in MHC class I 
induced by IFNs a//3. A second cDNA clone was isolated for a factor which also 
binds ISRE referred to as IRF-2. Activation of all the above genes was strongly 
repressed by co-transfection with IRF-2 cDNA constructs (Harada et al., 1990). These 
workers suggested IRF-2 acts to switch off IRF-1 induced responses.
The third ISGF, ISGF3 has been shown to be a major factor mediating IFNa induction 
of several IFN responsive genes. However, Yusof (1993) found that ISGF3 did not 
bind to the class I promoter ISRE, therefore ISGF3 is unlikely to be important in 
IFN-mediated class I induction.
In different genes containing ISRE sequences, the flanking sequences also seem to play 
a role in mediating the IFN response. In the case of class I a sequence from -165 
to -137 called the IFN consensus sequence (ICS) or IFN response sequence (IRS) has 
been shown to play a role (Israel et al., 1986). The IRS was found to be active with 
both types of IFNs only in conjunction with the adjacent sequence, enhancer A. 
However, others have observed that the IRS alone could confer responsiveness to IFNs 
a/(3 or y  in certain cell types (Korber et al., 1987; Sugita et al., 1987). Nielsch et 
al. (1991) found that IFN/3 caused the nuclear translocation of NF-kB. It is possible 
that NF-kB is involved in causing the increase in class I transcription in response to 
IFN, maybe in cooperation with other IFN-inducible factors.
Another cDNA clone has been isolated which encodes a protein called ICSBP which 
binds to the ICS of MHC class I genes (Driggers et al., 1990). A negative regulatory 
element (NRE) has been identified within the ICS and is located 5’ of the ISRE. It 
binds a factor present in undifferentiated but not differentiated F9 EC cells and it has 
therefore been proposed that this binding activity could play a role in negative 
regulation during development (Flanagan et al., 1991).
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f. Enhancer A
Results from CAT assays have shown a sequence between approximately -200 and -160 
which acts as an enhancer in many cells (Kimura et al., 1986; Katoh et al., 1990; 
Israel et al., 1989; Baldwin and Sharp, 1987). This region has been called enhancer 
A (Kimura et al., 1986) or a very similar region has been described as CRE (class I 
regulatory element) (Miyazaki et al., 1986). Enhancer A/CRE can act as a negative 
transcription element in undifferentiated F9 EC cells (Miyazaki et al., 1986).
Shirayoshi et al. (1987) used a variety of probes from segments of enhancer A in gel 
retardation analysis to distinguish regions bound by separate DNA-binding proteins. 
These regions were called I, II and III and are positioned between -173 to -161, -203 
to -185 and -189 to -161, respectively, in the H-2Kd promoter and found between -171 
to -159, -201 to -183 and -187 to -159 in the H-2Kb promoter.
Region I
This region has been shown to act as an enhancer region in CAT assays with certain 
cell lines, for example, Mauxion and Sen (1989) cloned a dimer of -175 to -156 into 
a CAT plasmid and found CAT activity was double that of the plasmid alone in a 
murine plasma cell line. However the dimer was ineffective in a murine T-cell line 
and in Hela cells. Baldwin and Sharp (1987) used a CAT plasmid containing the 
sequence from -190 to +1 and in vivo competition with a trimer of region I or a 
mutated version of region I (mutated at G residues found to be important for protein 
binding). The trimer of region I but not the mutated version reduced CAT activity. 
Burke et al. (1989) used mouse cells and a plasmid containing 1.4 kb of the 5’ flanking 
region of H-2Ld gene and an identical plasmid apart from mutations to the first two 
G’s of region I, they found the latter had 50% lower CAT activity.
Binding to region I correlates with the cell surface expression of MHC class I in a 
variety of adult and developing tissues (Burke et al., 1989). Dey et al. (1992) showed 
that there was in vivo protection of region I in cells expressing class I genes but not 
in cells where class I expression was absent.
Region I has been found to bind a wide variety of DNA-binding factors, some of which 
have been well characterised, others less so. The precise role played by all of these 
proteins in the enhancer activity displayed by region I is not known, however, in cases
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where the protein has been cloned and expressed, its transcriptional regulatory 
properties are better understood. The following section will describe DNA-binding 
proteins that have been found to bind to region I and what precise role such proteins 
have on transcription in general and in particular that of class I genes, if known. The 
proteins which bind to region I can be divided into two major groups: one group, 
which includes NF-kB, is called the rel-related protein group and the other which 
includes larger proteins such as PRD-BF1 have zinc fingers and the latter shall be 
described as the PRD-BF1-related protein family.
The family of rel-related proteins
NF-kB is a transcription factor found to be very important in the control of MHC 
class I genes and several other important genes, as will be described in more detail in 
the following section. NF-/cB has been shown to consist of two subunits, a p50 and 
a p65 (Kawakami et al., 1988; Nolan et al., 1991). Sequence analysis of human and 
murine cDNAs encoding p50 (Kieran et al., 1990; Ghosh et al., 1990) and p65 (Nolan 
et al., 1991; Ruben et al., 1991) have shown that in these two proteins there is a 
sequence at the N-terminal which shows extensive homology. This region of homology 
has been found to be present in several other proteins, including one very similar to 
p50 called p49, for which the cDNA has been isolated from a human cDNA library 
(Schmid et al., 1991). The region of homology is also present in plOO, the precursor 
of p49. p50 has its own precursor, pl05, which not surprisingly contains the region 
of homology. This region is also present in v-rel and c-rel (Gilmore, 1991; Hannink 
and Temin 1991) and in the maternal effect gene dorsal in Drosophila (Govind and 
Steward 1991) and RelB (Blank et al., 1992).
The region of homology has been described by Blank et al. (1992) as the rel/dorsal 
homology region. p50 has been shown to be able to dimerize in vitro with p65 (Nolan 
et al., 1991), v-rel (Kieran et al., 1990), c-rel (Logeat et al., 1991) or RelB (Blank et 
al., 1992) and in vivo with p65 (Schmitz et al., 1991) or c-rel (Ballard et al., 1992). 
p65 can probably form heterodimers with c-rel in vivo (Hansen et al., 1992). All these 
interactions demonstrate the control of transcription by rel-related DNA-binding proteins 
is very complicated .
The family of rel-related proteins will be described in more detail in the following 
section.
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NF-kB (p 5 0 /p 6 5 )
The term N F - kB  was originally given by Sen and Baltimore (1986) to a DNA-binding 
protein that binds specifically to the sequence GGGGACTTTCC present in the 
immunoglobulin k light chain enhancer. This sequence is similar to the sequence 
TGGGGATTCCCCA known as region I. It was found that N F - kB  also binds to 
region I (Israel et al., 1989). Several other genes have been found to have sequences 
similar to those found in region I and the k light chain enhancer. These sequences 
can all bind N F - kB  and are known as NF-/cB-like DNA-binding motifs. These motifs 
are found in the promoter regions of several genes important to the immune system 
such as IFN/3, TNFa, lymphotoxin and T-cell receptor /3. Such motifs are also 
present in several viruses such as HIV-1, cytomegalovirus and SV40. As detailed 
above N F - kB  has been cloned and found to consist of a p50 and a p65 subunit. This 
heterodimer is normally only constitutively present in the nucleus of a small subset of 
cells which includes T-cells, B-cells and monocytes (Blank et al., 1992) and some 
virally infected cells such as those transformed by certain serotypes of adenovirus 
(Nielsch et al., 1991). In all other cells N F - kB  is retained in the cytoplasm by its 
attachment through its p65 subunit to one of a family of proteins called NURP s 
(nuclear-uptake regulatory proteins) (Schmitz et al., 1991). NURPS which include 
I - kB «  and I - kB/3 are proteins which inhibit the DNA-binding ability and nuclear uptake 
of N F - kB  and related proteins. I-KBce and I - kB/3 have been isolated from the cytosol of 
human placenta (Zabel and Baeuerle, 1990) and are acidic proteins of 37 and 43 kDa 
respectively. I - kB/3 inhibited the stimulation of transcription mediated by N F - kB  in 
an in vitro transcription system (Kretzschmar et al., 1992). It is yet to be clarified 
whether I - kB/3 enters the nucleus and has a similar function in vivo. Another inhibitory 
protein of N F - kB  has recently been cloned called I-rel (Ruben et al., 1992). It differs 
from I - kB q: and I - kB/3 in that it binds to p50 not p65. It is a 6 6  kDa rel-related 
protein that attenuates the DNA-binding activity of p50 and the transcriptional induction 
of N F - kB . I-KB7  (the C-terminal half of the pl05 N F - kB  precursor) appears to be 
another new member of the I - kB  family (Inoue et al., 1992). Inhibitory proteins of 
N F - kB  can play three roles: retaining N F - kB  in the cytosol so it is unable to act as 
a transcription factor, allowing induction to occur through N F - kB  release and entry 
to the nucleus where it acts as a transcription factor, or binding to N F - kB  once again 
and so attenuating its action. Although evidence for the latter role has still to be 
established, the first two steps do seem to occur, at least in the case of I - kB «  and
I - kB/3 (Baeuerle 1991).
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NF-kB is not constitutively present in the nucleus in most cell types, therefore basal 
levels of expression of MHC class I are probably not due to this factor. A variety of 
agents including TNFa (Duh et al., 1989) and lipopolysaccharide (Sen and Baltimore,
1986) induce the release of the inhibitory proteins from NF-kB. Dissociating agents 
such as formamide or sodium deoxycholate can have the same effect (Baeuerle and 
Baltimore 1988).
The induction of NF-kB by several agents such as TNFa, phorbol ester and 
interleukin- 1 can be inhibited by free radical scavengers such as pyrrolidine derivative 
of dithiocarbamate (PDTC) and N-acetyl cysteine (NAC) (Schreck et al., 1991, 1992).
These results imply that induction by all these agents leads to the release of reactive 
oxygen intermediates (ROI), which by some as yet unknown mechanism, cause NF-kB 
to dissociate from I-kB, and enter the nucleus. Other workers have suggested 
phosphorylation of I-kB causes it be be released from NF-kB (reviewed by Baeuerle,
1991). The importance of NF-kB to class I transcription is indicated by the positive 
correlation between levels of class I expression and the amount of NF-kB binding 
activity detected in various cell lines and tissues (Burke et al., 1989; Blanchet et al.,
1992). Although transient expression assays have shown region I to act as an enhancer 
sequence, in certain circumstances, such experiments do not reveal which transcription 
factor is responsible for the enhanced transcription. Region I has been shown to act 
as a particularly strong enhancer when cells are treated with TPA or TNFa, two agents 
which both cause the nuclear localization of NF-kB (Israel et al., 1989). This suggests 
that NF-kB could be responsible for this enhancer activity. Cotransfection of p65 and 
p50 with a CAT plasmid linked either to the k enhancer or HIV NF-KB-motif caused 
an induction of CAT activity (Ballard et al., 1992). Further evidence for the 
involvement of NF-kB in transcriptional activation comes from the use of in vitro 
transcription systems, where a single protein can be investigated without contaminating 
proteins giving misleading results. Under these conditions NF-kB purified from Hela 
cytosol stimulated transcription from the HIV-1 promoter (Kretzschmar et al., 1992). 
NF-kB purified from Jurkat cells stimulated transcription from a PRDII NF-KB-like 
DNA-binding motif using an in vitro transcription assay (Cohen and Hiscott, 1992) 
Overall, the available evidence suggests that NF-kB plays an important role in 
enhancing transcription from MHC class I genes especially in situations where 
transcription has been induced by factors such as TNFqj, LPS etc.
40
p50 homodimers
A protein was purified by Kawakami et al. (1988) from human Burkitt Lymphoma cells 
by affinity chromatography using k enhancer DNA-binding motif. The protein was 
estimated to be 51 kDa, and was considered to be NF-kB. KBF1 (kappa-enhancer 
binding protein 1) was the name given by Yano et al. (1987) to a protein isolated from 
a mouse T-cell line by its affinity to region I. It became clear when both subunits of 
NF-kB were cloned and sequenced (Ghosh et al.,1990; Ruben et al.,1991) that 
Kawakami et al. (1988) had in fact only purified the p50 subunit of NF-kB and not the 
whole protein. When KBF1 was cloned and sequenced it was found to be identical to 
the p50 subunit of NF-kB (Kieran et al., 1990).
Purified p50 and p65 have been denatured and renatured as p50 homodimers and as 
p50/p65 heterodimers (Cohen and Hiscott, 1992). The two proteins can be 
distinguished as the homodimers have faster gel mobility. NF-kB binds with twice the 
affinity of p50 dimers for the k enhancer DNA-binding motif, whereas region I is 
recognised equally well by both (Baeuerle, 1991). p50 dimers appear to be
constitutively present in most cell types (Baeuerle, 1991), however Blanchet et al. 
(1992) found some human tumour cell lines which did not appear to have p50 
dimer/KBFl binding activity. They found that cell lines which retained NF-kB binding 
but had lost KBF1 binding still retained normal levels of MHC class I expression, 
suggesting KBF1 is not essential for class I gene transcription. In vitro transcription 
assays have given different results as to the role of p50 dimers as activators of 
transcription. Kretzschmar et al. (1992) found p50 dimers to be strong transcriptional 
enhancers when using the HIV NF-kB DNA-binding motif, whilst Cohen and Hiscott 
(1992) found p50 to be ineffective in stimulating transcription from a PRDII NF-kB 
DNA-binding motif. Kretzchmar et al. (1992) suggest the specific NF-kB motif used 
could be critical as to whether p50 dimers act as transcriptional enhancers or not. The 
importance of the particular NF-kB motif is further shown by the cotransfection 
experiments of Schmitz and Baeuerle, 1991. In these experiments p50 and p65 
expression plasmids were transfected separately or together with a CAT plasmid 
controlled by the k enhancer. Here p50 alone did not induce transcription and in fact 
reduced the transcriptional activation by p65. Since the role of p50 dimers appears to 
vary between different NF-kB motifs, their role in the transcriptional regulation of 
class I genes requires experiments using region I before it can be determined.
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p65 homodimers
p65 dimers have not been detected when probes of NF-KB-like DNA-binding motifs 
were used with cellular extracts in gel retardations, and it is not known if such dimers 
occur in vivo (Schmitz and Baeuerle, 1991). However gel purified and renatured p65, 
although binding with a lower affinity than p50 dimers or NF-kB, has been shown to 
produce dimers in gel retardations (Baeuerle, 1991; Urban et al., 1991; Cohen and 
Hiscott, 1992). When eukaryotic expression vectors of p65 were cotransfected with 
a CAT reporter gene linked to multiple copies of the k  enhancer, CAT activity was 
significantly enhanced (Schmid et al., 1991; Perkins et al., 1992; Schmitz and 
Baeuerle, 1991). However similar experiments using region I linked to CAT did not 
show induction by p65 (Perkins et al., 1992) suggesting p65 may not be an important 
activator of class I transcription.
p49
p49 was isolated from a Xgtll library prepared from a human B-lymphoid leukemia 
(Schmid et al., 1991). The library was screened at low stringency for hybridization to 
a human c-rel probe. p49 is derived from a large protein plOO which was also cloned 
by the same workers (Schmid et al., 1991). p49/pl00 are members of the rel-related 
family most closely related to p i05 (60% identity). Schmid et al. (1991) investigated 
the functional role of this protein, alone and dimerized to p65, by use of expression 
plasmids cotransfected into Jurkat cells with CAT reporter genes linked either to the 
HIV or k  enhancer NF-kB DNA-binding motifs. p49 alone slightly increased CAT 
activity, however, when contransfected with p65, it significantly enhanced CAT 
activity (more so than p50/p65). In fact p50/p65 were only effective in stimulating the 
k enhancer, not the HIV enhancer. p49 did not stimulate the region I enhancer either 
alone or with p65, despite the ability of p49 to bind to this sequence (Perkins et al.,
1992).
H2TF1
Baldwin and Sharp (1987) described a factor, termed H2TF1 (H-2 transcription 
factor 1) which binds to region I. They found this binding activity to be present in 
many different cell types. Baldwin et al. (1990) estimated H2TF1 to have a molecular 
weight of 110 kDa. Baeuerle (1991) has suggested that H2TF1 represents a p50 dimer.
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KBF2
Another factor which binds specifically to region I, KBF2 (kappa-enhancer binding 
factor 2) was purified from differentiated mouse cells. This factor was estimated to 
have a molecular weight of 58 kDa. Whether KBF2 is a post-translationally modified 
form of p50 remains to be determined.
CRE1
This is a binding activity described by Ackrill and Blair (1989) which binds specifically 
to a probe which includes region I. It is possible that this binding activity represents 
p50 homodimers.
EBP1
A protein called EBP1 (enhancer-binding protein 1) of molecular weight 57 kDa, has 
been isolated from Hela cells (Clark et al., 1989). EBP1 binds to the core region of 
the SV40 enhancer (an NF-/cB-like motif) and to region I. Biochemical analysis of 
EBP1 suggests EBP1 is a p50 dimer (Clark et al., 1990).
TC-IIA and TC-IIB
Macchi et al. (1989) describe two DNA-binding proteins, TC-IIA and TC-IIB, which 
bind to the SV40 NF-/cB-like motif (present in the TC-II enhancer) and to region I. 
TC-IIB has a higher affinity for region I. Macchi et al. (1989) suggest TC-IIB is a 
H2TFl/KBFl-like protein and TC-IIA is a NF-/cB-like protein.
v-rel
The avian reticuloendotheliosis virus, REV-T, was isolated from a turkey tumour by 
Theilen et al. in 1958. The virus transforms immature lymphoid cells in vitro and 
produces fatal lymphomas (Theilen et al., 1966; Beug et al., 1981; Hoelzer et al., 
1980). The REV-T genome includes the gene rel which is known as v-rel, for viral 
rel. This gene is expressed as a phosphoprotein of 59 kDa. Twelve in-frame residues 
at the N-terminus and 19 amino acids at the C-terminus are derived from the viral env 
gene, v-rel differs from cellular rel (c-rel) in terms of size and composition, v-rel is 
smaller than c-rel, it also has 2 1  base changes and three small in-frame deletions 
(Stephens et al., 1983; Wilhemsen et al., 1984; Sylla and Temin, 1986; Rice et al., 
1986). v-rel is highly transforming for avian spleen cells (Kamens et al., 1990).
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v-rel has been shown to bind to NF-/cB-like DNA-binding motifs (Kochel and Rice, 
1992; Kabrun et al; 1991). v-rel has been found to suppress transcription from 
NF-kB sites (Inoue et al., 1991; Ballard et al., 1990). However, since v-rel is not 
generally present in cells, it is not relevent to the normal transcriptional control of 
MHC class I genes.
c-rel
The protein c-rel is of cellular origin. The v-rel oncogene is a truncated and mutated 
form of the avian c-rel protein, c-rel has two N-terminal and 118 C-terminal amino 
acids that are not present in v-rel. There are also several internal differences between 
c-rel and v-rel. Chicken c-rel, a 6 8  kDa protein, is weakly transforming at best 
(Kamens et al., (1990). The protein c-rel has been shown to bind to NF-kB motifs 
including region I (Inoue et al., 1991; Kochel and Rice, 1992). There is evidence that 
c-rel can associate with p50 (Logeat et al., 1991) and p65 (Hansen et al., 1992). In 
cotransfection experiments c-rel has activated transcription from CAT genes linked to 
NF-kB sites including region I (Inoue et al., 1991).
Richardson and Gilmore (1991) found that full length chicken c-rel and mouse c-rel 
only weakly activated transcription. They found that c-rel proteins consist of an N- 
terminal inhibitory domain and a C-terminal activation domain. The activation domain 
is absent in v-rel. The transient expression results obtained by Inoue et al. (1991) 
were with plasmids only containing the activation domain. In conclusion c-rel may 
be a transcriptional activator in vivo, including in the regulation of class I genes, but 
only if mechanisms exist to overcome the inhibitory effect of the N-terminal domain, 
c-rel also contains a cytoplasmic retention sequence (Hannink and Temin, 1989) which 
may interfere with its ability to transactivate in the nucleus.
Other rel-related proteins
When proteins have been purified through their affinity for NF-KB-like DNA-binding 
motifs, several proteins have been isolated apart from p50 and p65. For example 
Cohen and Hiscott (1992) also isolated a p72 protein which could heterodimize with 
p50, a p47 and a p56. Moliter et al.(1990) have also isolated several rel-related NF-kB 
specific proteins. They isolated a p75 and cloned p75 cDNAs based on peptide 
sequence information derived from affinity-purified protein and have demonstrated the 
complete identity of p75 and NF-kB p65 at the protein level (Ballard et al., 1992).
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This suggests that post-translational modifications could be responsible for the 
difference in molecular weight. This group also found a p55 which was identical to p50 
at the protein level, again suggesting post-translational modification (Moliter et al., 
1990). A p42 proteolytic break-down product of p50 has been described which retains 
DNA-binding capabilities (Baeuerle, 1991). The functional role of the proteins 
described in this section is yet to be determined.
PRDII-BFl-related DNA-binding proteins
Several cDNA clones have recently been isolated from mouse, rat and human cDNA 
libraries. The proteins encoded by these cDNAs all have in common the property that 
they bind to region I and the proteins are large.
PRDII-BF1 (Fan and Maniatis, 1990), HIV-EP1 (Maekawa et al., 1989) and MBP-1 
(Baldwin et al., 1990) are all clones from human cDNA libraries. All three clones are 
thought to cover different amounts of sequence from the same protein (Baeuerle, 1991; 
Michelmore et al., 1990). A full length cDNA was isolated from screening a Xgtll 
cDNA expression library prepared from MG63 cell mRNA (Fan and Maniatis, 1990). 
The library was screened with a probe containing multiple copies of PRDII which is 
one of the two positive regulatory domains of the IFN/3 gene promoter. The cDNA has 
a single open reading frame of 8151 nucleotides and is estimated to encode a protein 
of 298 kDa called PRDII-BF1 (positive regulatory domain II binding factor 1). The 
protein contains two sets of two zinc fingers. Either set of zinc fingers can bind both 
PRDII or region I NF-/cB-like DNA-binding motifs with approximately fivefold higher 
affinity for the latter. Little is known about the functional role of this protein. Fan 
and Maniatis (1990) found that the steady state level of HLA class I mRNA increased 
upon serum induction. Treatment with serum also caused an increase in PRDII-BF1, 
which occurred more rapidly than the increase in HLA class I mRNA.
Several overlapping cDNA clones were isolated from a B-cell library screened with 
probes to region I. 6.5 kb of sequence was obtained (Baldwin et al., 1990). The 
cDNAs were found to encode a protein they called MBP-1 (MHC enhancer binding 
protein 1).
Maekawa et al. (1989) used a Southwestern method to isolate a cDNA encoding a 
protein that binds to the HIV NF-zcB-like DNA-binding motif. The cDNA was obtained
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from a human B-cell Xgtll library. The protein was called HIV-1 enhancer binding 
protein 1 (HIV-EP1). The insert consisted of 1035 bp and included two zinc finger 
domains.
Nakamura et al. (1990) screened a Xgtll expression library of mouse transformed lens 
cells for proteins that bind to a section of the aA-crystallin gene promoter which 
contains a NF-fcB-like DNA-binding motif. They isolated a 2.5 kb cDNA which 
encoded a protein, called aA-CRYBPl (oA-crystallin binding protein 1) which also 
binds to region I. This cDNA hybridized to a 10 kb mRNA . They suggest 
aA-CRYBPl is either homologous or extremely similar to human MBP-1/PRDII-BF1 
and HIV-EP1.
Michelmore et al. (1990) screened a rat liver cDNA library in Xgtll for proteins that 
bind to the B domain of the c^-antitrypsin promoter, an element which is important for 
the liver-specific expression of ojj antitrypsin. Two partial cDNAs coding for DNA- 
binding proteins (AT-BP1 and AT-BP2; a r antitrypsin binding proteins) have been 
isolated. Both proteins contain two zinc fingers and both bind to the NF-/cB-like DNA- 
binding motif in region I with higher affinity than to the one in the 
immunoglobulin k  light chain gene enhancer or to the B domain of c^-antitrypsin gene 
promoter.
Northern blot analyses with probes derived from AT-BP1 and AT-BP2 identified 
mRNA species of 9.5 and 9.0 kb. Fan and Maniatis (1990) detected a 9.5 kb mRNA 
for 298 kDa PRDII-BFI protein. Although the predicted amino acid sequence of the 
complete AT-BP1 and AT-BP2 proteins are not yet known, the sizes of their RNAs 
suggests that they too are unusually large for transcription factors.
Ron et al. (1991) screened a rat liver cDNA expression library for proteins that bind 
to the acute-phase response element (APRE) in the promoter of the angiotensinogen 
gene. APRE binds a factor indistinguishable from NF-kB. They isolated a single 
clone that encodes a protein which they called angiotensinogen gene-inducible enhancer- 
binding protein 1 (AGIE-BPl). It contains a zinc finger motif virtually 
indistinguishable from those of MBP-1/PRDII-BFI or aA-CRYBPl. Outside this 
domain the sequences diverge considerably. On Western blotting, antiserum to AGIE- 
BPl detects a protein larger than 250 kDa and Northern blotting detected a mRNA
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greater than 10 kb in a variety of tissues. Because the mRNA is larger than those of 
AT-BP1 and AT-BP2 it may encode a different protein.
In summary, PRDII-BFI, MBP-1 and HIV-EP1 may correspond to the same human 
protein. However, several related proteins might be present in human cell lines; Fan 
and Maniatis (1990) detected two to three high molecular mass proteins (250-290 kDa) 
by Western blotting using anti-PRDII-BFl antiserum. AGIE-BPl, AT-BP1 and AT- 
BP2 probably represent the rat and aA-CRYBPl the mouse form(s) of these high 
molecular weight proteins that bind to NF-*B-like DNA-binding motifs. Little is 
known about their function but their zinc fingers suggest that they may act as 
transcription factors. Their mRNAs have been found in many different tissues 
(Maekawa et al., 1989; Baldwin et al., 1990; Fan and Maniatis, 1990; Michelmore 
et al., 1990; Nakamura et al., 1990; Ron et al., 1991). Since they bind to region I, 
it is possible that they play a role in the control of MHC class I transcription and their 
widespread distribution suggests that they may be active in many different cell types.
Region II
Shirayoshi et al. (1987) found a factor in mouse L cells and LH8  T lymphocytes which 
bound to a H-2Ld sequence; using synthetic oligonucleotides, they found that the 
sequence required for binding was GGTGAGGTCAGGGGTGGGG which extended 
from -203 to -185 and they called this region II. Hamada et al. (1989) screened a 
mouse liver cDNA expression library with a radiolabelled region II binding site and 
isolated a cDNA clone which encoded a protein (termed H-2RIIBP) which bound to 
region II. This protein belongs to the steroid/thyroid hormone receptor superfamily 
and it recognises the estrogen response element as well as region II (Hamada et al., 
1989).
Following binding of the appropriate ligand, members of the steroid/thyroid receptor 
superfamily translocate to the nucleus where they act as transcription factors and bind 
to specific sequences called hormone response elements (HREs). The DNA-binding 
domain of the receptors mediates specific recognition of the HREs and includes two 
zinc finger structures (Seveme et al., 1988). Three amino acids in the stem of the first 
finger, the P box, are critical to specify the half-site sequence (Danielsen et al., 1989; 
Mader et al., 1989; Umesono and Evans, 1989). The receptors in this superfamily 
have been divided into two subfamilies based on their P box sequence (Danielsen et al.,
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1989; Mader et al., 1989; Umesono and Evans, 1989). The subfamilies have been 
called the GR (glucocorticoid receptor) and the ER/TR (estrogen receptor/thyroid 
hormone receptor) subfamilies. The GR subfamily includes glucocorticoid, 
mineralcorticoid, androgen and progesterone receptors. These recognise common 
HREs consisting of an inverted repeat of TGTTCT half-sites. All the other receptors, 
including ER, two isoforms of TRs, retinoic-acid receptors (RARs) a , /?, and 7 , 
retinoid X receptors (RXRs) a, /3, and 7  and human vitamin D3 receptors belong to the 
ER/TR subfamily. Members of the ER/TR class display cross-recognition of the 
palindromic HREs consisting of a half-site AGGTCA or a closely related sequence 
(reviewed by Umesono et al., 1991; Leid et al., 1992). RARs bind retinoic acid then 
bind to retinoic acid response elements (RAREs) in retinoic acid-responsive promoters 
in response to nanomolar concentrations of retinoic acid. RXRs activate different 
target genes to RARs and bind to different response elements in response to higher 
concentrations of retinoic acid (reviewed by Yu et al., 1991) some receptors such as ER 
are known to bind as homodimers (Gordon and Notides, 1986), others such as RAR, 
TR and vitamin D3 receptors have been thought to bind as heterodimers with a 
coregulator which enhances binding and transcriptional activation. The identity of any 
coregulator was unknown until recently when a cDNA was isolated that encodes a 
protein that binds to RARE and to RAR. The protein was found to be a member of 
the RXR subgroup of receptors and was called RXR/3 (Yu et al., 1992). RXR/3 forms 
heterodimers with RAR, TR amd vitamin D3 receptors, and enhances binding and 
activates transcription from each receptor’s specific response element (Hallenbeck et al., 
1992; Yu et al., 1992). RXR/3 isolated from a human cDNA library was found to 
be equivalent to H-2RIIBP, a clone isolated from a mouse cDNA library. In fact the 
term RXR/3 has been used interchangeably with H-2RIIBP (Dey et al., 1992).
Ackrill and Blair (1989) described a binding activity termed CRE2 in Adl2 -transformed 
cells which interacted with a probe which includes region II. It is possible that CRE2 
can be distinguished from H-2RIIBP (Griffiths, 1992).
The functional role of region II and RXR/3/ H-2RIIBP in class I is not well understood. 
Burke et al. (1989) performed CAT assays with plasmids containing the 1.4 kb 
sequence 5’ of the H-2Ld gene and with identical constructs apart from mutations to G 
residues within region II which had been shown to interfere with binding when 
methylated (Shirayoshi et al., 1987). The mutated form had 30% lower CAT activity,
48
indicating weak enhancer activity of this sequence. The distribution of region II 
binding activity, if anything, suggests a negative effect on transcription; Burke et al. 
(1989) found region II binding in the brain and early in gestation, when both region I 
binding and MHC class I antigens are undetectable. Region II has been shown to act 
as a repressor of the transcriptional activation caused by region I in Adl2 but not in 
Ad5 cells (Kralli et al., 1992; Ge et al., 1992). Retinoic acid is known to play a 
critical role in vertebrate development (Spom and Roberts, 1983). However there is 
evidence that the role of RXR/3/H-2RIIBP is not in fact negative and that it plays a 
critical role in the initial activation of MHC class I expression in development. During 
the early stages of embryonic development cells are class I negative (Ozato et al., 
1985). Cell lines have been created from such tissue and are called EC cells. As 
mentioned earlier such cells can be made to differentiate and express class I under the 
influence of retinoic acid (Morello et al., 1982). It seems likely that the effects of 
retinoic acid are mediated by RXR/3/H-2RIIBP. Nagata et al.(1992) found that a 
RXR/3/H-2RIIBP expression plasmid enhanced the CAT activity of a plasmid containing 
the MHC class I promoter linked to a CAT gene when using N-tera, a human EC cell 
line, which is class I negative. The enhancement was retinoic acid-dependent and 
mediated through region II. Both the DNA-binding domain and the ligand-binding 
domain were required for transactivation of the MHC class I promoter. No significant 
transactivation by RXR/3/H-2RIIBP was observed in differentiated class I positive N- 
tera 2 cells or in murine L fibroblasts or monkey COS-7 cells. Kralli et al. (1992) 
found retinoic acid treatment caused region II to no longer act as a repressor. In vivo 
footprinting studies performed by Dey et al (1992) failed to identify any protection of 
region II in the transgene HLA-B7 and the endogenous H-2Kb gene from adult spleen 
or brain tissue. However, if RXR/3/H-2RIIBP plays a role in development one might 
only expect to see region II binding in developmental tissue at stages which respond to 
retinoic acid. Although Dey et al. (1992) presented evidence for the presence of 
RXR/3/H-2RIIBP in brain tissue, the lack of in vivo protection suggests that for some 
reason, possibly unfavourable chromatin structure, RXR/3/H-2RIIBP is prevented from 
binding to region II. The inability of RXR/3/H-2RIIBP to bind to region II could 
contribute to the lack of expression of class I antigens in this tissue.
Region m
Shirayoshi et al (1987) describe a region between -189 and -161 which overlaps region I 
(-173 to -161) but binds distinct factors. Israel et al. (1989) propose that in untreated
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Hela cells KBF1 binds to region I and AP2 binds to the adjoining region which is part 
of region III. In contrast TNFa stimulated cells NF-kB dislodges KBF1 from region I 
and binds itself to this region while also dislodging AP2 from the adjoining region. AP2 
then binds slightly further upstream but still within region III. NF-kB binds to the two 
imperfect direct palindromic repeats, one within region I and one outside it. Israel et 
al. (1989) found that region III activated a heterologous promoter after TNFa or TP A 
induction. Three copies of region III were particularly active following TNFa 
induction. A multimer of either repeat was also responsive to TNFa and TPA 
(particularly the former), whereas a single copy of either repeat was not. These results 
suggest region III is important in enhancing class I transcription under the influence of 
TPA and especially TNFa.
1.2.6.12 Transcription factors and promoter sequences involved in the regulation 
of transcription by adenovirus E1A
As described previously E1A can effect MHC class I transcription in different ways 
depending on the serotype of El A and cells investigated. In primary cells transformed 
by E l, Adl2 El A appears to be involved in a process of down-regulation of MHC 
class I expression, however down-regulation does not always take place when Adl2 
El A is introduced into immortalized rodent cell lines (Vaessen et al., 1986; Nielsch 
et al., 1991). However Katoh et al. (1991) found that class I expression was down- 
regulated in the rat fibroblast cell line 3Y1 following introduction of the Adl2 El A 
gene. Ad5 El A can cause an up-regulation of class I expression in primary cells. This 
means that in different circumstances, differences in the properties ascribed to Adl2 and 
Ad5 E l A could reflect down-regulation by the former or up-regulation by the latter, or 
both processes could account for the different properties of cells transformed or 
transfected with these genes. Both Ad5 El and Adl2 El transformed or transfected 
cells would be expected to have sequences within their class I promoters which act as 
enhancers or repressors. However, for an overall difference in promoter efficiency to 
exist one would expect enhancer sequences to be more efficient under the influence of 
Ad5 El and/or repressor sequences to be more active under the influence of Adl2 E l. 
Kimura et al. (1986) found the H-2Kb and H-2Kd promoter drove approx. ten times 
lower CAT activity in primary mouse cells transformed by the Adl2 El region than in 
those transformed by Ad5 E l. Using a construct containing the region -254 to -61, 
which acts as an enhancer in untransformed fibroblasts, CAT activity in cells 
transformed by Adl2 El was between half and two-thirds of that in cells transformed
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by Ad5 E l. This suggests that although some of the differences in CAT activity 
between cells transformed by Ad5 or Adl2 El is mediated by the sequence -254 to -61, 
sequences outside this region are more important in contributing to these effects.
Katoh et al (1990) used 3Y1 cells, a diploid Fisher rat embryo fibroblast cell line in 
transformation experiments with Adl2 13S or Ad5 13S expression plasmids. In cells 
expressing Adl2 13S there was a greater than twenty fold reduction in CAT activity 
driven by the promoter from -2014 to +12, while the promoter activity was only 
slightly inhibited by expression of Ad5 13S. This difference in the properties of Ad5 
13S and Adl2 13S could not be ascribed to an enhancer activity being stronger in Ad5, 
since a plasmid which contained sequences from -194 to -136 and -61 to +12 linked 
to CAT, enhanced CAT activity more in cells expressing the Adl2 13S product than 
the Ad5 13S product. This result is in conflict with those obtained by Kimura et al. 
(1986) using Ad-transformed primary mouse embryo cells. The reason for the 
variability in results obtained could be related to the different cells used and the 
different enhancer regions used, although both included region I. Also these results 
were with transfected rat cells, whereas those described of Kimura et al. (1986) were 
with transformed mouse cells.
Work by other groups have identified factors which bind to sequences within 
enhancer A could be important in mediating down-regulation by Adl2 E1A. Meijer 
et al. (1992) cotransfected primary BRK with a construct linking region I to CAT and 
either an Adl2 12S or an Adl2 13S expression plasmid. Region I displayed enhancer 
activity in the presence of Adl2 12S but not in the presence of Adl2 13S. They also 
found reduced binding of NF-kB and KBF1 in whole cell extracts from BRK cells 
transformed by Adl2El compared to cells transformed by Ad5El. Nielsch et al. 
(1991) found that nuclear levels of NF-kB, but not KBF1, were lower in Adl2- 
compared to Ad5-transformed cells but their results were obtained by transformation 
of an embryo fibroblast cell line and not BRK cells.
Meijer et al. (1992) also found increased binding of a region II factor in Adl2 
El-transformed cells as compared to Ad5 El-transformed cells, which had been found 
previously by Ackrill and Blair (1989), who suggested this might be relevant to the 
down-regulation of class I in these cells. However Meijer et al. (1992) found no 
evidence that binding to region II mediated a repressor function. The work of Ge et
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al. (1992) and Kralli et al. (1992) did demonstrate a repressor function for region II, 
however, in order to demonstrate this function multiple copies of region II were 
necessary and each copy of region II needed to be linked to a copy of region I. In fact 
it was the repression of the transcriptional activation by region I in Adl2-transformed 
cells but not Ad5-transformed cells which was demonstrated. The differences in 
experimental design could explain the different results obtained by Meijer et al.(1992) 
as compared to Ge et al. (1992) and Kralli et al. (1992).
It has been suggested that the CRE is not the only region of the class I promoter which 
might be of importance to the down-regulation found in Adl2 E1A transformed cells 
(J. Proffitt, E. Sharma & G. E. Blair, unpublished results). BRK cells transfected with 
constructs lacking the CRE were still susceptible to down-regulation by E1A. When 
the region -1490 to -1180 was removed from the 2 kb class I promoter this relieved 
transcriptional repression in Adl2-transformed cells but did not alter promoter activity 
in Ad5-transformed cells. This suggests that the region -1490 to -1180 acts in down- 
regulation in Adl2-transformed cells. Consistent with these results, a construct from - 
1440 to -1070 caused down-regulation of a heterologous (thymidine kinase) promoter in 
Adl2-transformed cells and not in Ad5-transformed cells. Gel retardation experiments 
using approx. 100 bp probes from this region revealed three probes: -1350 to -1230 
as well as 1260 to -1150 and -1180 to -1070 which all formed specific complexes using 
nuclear proteins from Adl2-transformed cells whereas no complexes were formed using 
extracts of Ad5-transformed cells. The probes -1350 to -1230 and -1180 to -1070 
formed faint complexes with proteins from BRK cells suggesting the involvement of 
cellular factors whose binding activity may be modulated by Ad-transformation.
In the study of Katoh et al. (1990), as well as showing in rat embryo fibroblast cells 
that the region -254 to -61 is positively regulated by E1A, they also identified a region 
of negative regulation. They identified a sequence between -1837 and -1521 in the 
H-2Kbml promoter that caused down-regulation of MHC class I transcription in 
Adl2-transformed cells. This sequence was specifically bound by nuclear factors 
derived from Adl2-transformed cells but not from untransformed cells or 
Ad5-transformed cells. However this sequence was only twice as active in cells 
cotransfected by Ad5 13S as compared to those cotransfected by Adl2 13S, which 
shows that it may not be the only sequence involved in causing the twenty fold lower
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CAT activity of the 2 kb promoter when cotransfected with Adl2 13S compared to Ad5 
13S.
The aim of this study was to investigate the possible involvement of the sequences 
CRE1 and CRE2, and the transcription factors that bind to them, in the down-regulation 
of MHC class I transcription in Adl2-transformed cells compared to those transformed 
by Ad2 or Ad5. The transient expression assay, CAT, was used to investigate the 
functional role of these sequences. The nuclear levels of CRE1-specific DNA-binding 
factors was investigated in Ad-transformed cells by gel retardation and Western 
blotting. An antibody was raised to the p50 subunit of the CRE1-specific factor, 
NF-kB; this antibody was used in Western blotting. Other aspects of CRE1- and 
CRE2-binding factors were also investigated in Ad-transformed cells: the binding site 
for CRE2-specific factors was studied by DNase I footprinting along with the 
mechanism of nuclear induction of CREl-binding factors.
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Materials
2.1 Reagents
The following reagents were obtained from Sigma, Dorset, UK: DTT, HEPES,
2-mercaptoethanol, piperidine, PDTC, NAC, Freund’s Incomplete Adjuvant, Rabbit 
ExtrAvidin011 Biotin Staining Kit, goat anti-rabbit alkaline phosphatase, aprotinin, 
leupeptin, BCIP, NBT, Ponceau S, O-phenylendiamine, cycloheximide.
Glycerol, magnesium chloride, chloroform, ammonium persulphate, TEMED and urea 
were purchased from FSA Laboratories, Loughborough, UK. Protein Assay kit and 
broad range molecular weight markers were obtained from Biorad, Munchen, Germany. 
Benzoyl peroxide, triethylsilane and DMS were obtained from Aldrich Chemical 
Company, Dorset, UK.
Brewers yeast tRNA and PMSF were purchased from Boehringer Mannheim 
Biochemica, East Sussex, UK. Bactotryptone, yeast extract and 'Lab M' agar were 
obtained from Amersham International pic, Buckinghamshire, UK. 
Deoxyribonucleoside triphosphates were obtained from BCL, East Sussex, UK. 
Sephadex G-10, G-25 and G-50 (fine), poly(dl-dC) and other polydeoxyribonucleotides 
were purchased from Pharmacia Ltd., Milton Keynes, UK. Glass distilled phenol was 
obtained from Rathbum Chemicals Ltd., Scotland. Ethanol was bought from James 
Burroughs Ltd, Essex, UK. Donor calf serum was obtained from Sera Labs, Sussex, 
UK and cell culture media and constituents were purchased from Gibco, Paisley, 
Scotland. Ellmans reagent and sulpho-SMCC were obtained from Pierce, Illinois, 
USA. Insta-gel liquid scintillation cocktail was purchased from Packard, Groningen, 
Netherlands. Purified protein derivative of tuberculin (PPD) and Bacillus Calmette- 
Guerin (BCG) vaccine were purchased from Statens Seruminstitut, Tuberculin Dept., 
DK2300, Copenhagen, Denmark. Water used was distilled and filtered through a 
Millipore 'Milli Q' system. All other reagents were obtained from BDH. All reagents 
used were Analar grade or equivalent.
2.2 Enzymes
All enzymes were obtained from Boehringer Mannheim Biochemica, East Sussex, UK.
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2.3 Radiochemicals
Deoxyadenosine triphosphate a-thiol [35S] 500 Ci mmol' 1 10 mCi ml' 1 was purchased 
from NEN (Dupont), Hertfordshire, UK.
D-threo (dichloroacetyl -I 14C ) chloramphenicol with a specific activity of 57 mCi 
mmol1(25 mCi ml'1) and [14C] methylated proteins (5 mCi mmol'1) were obtained from 
Amersham International pic, Buckinghamshire, UK. The markers comprised the 
following components: 
myosin 200 kDa
phosphorylase b 92.5 kDa (sometimes an extra band at 100 kDa was also present) 
bovine serum albumin 69 kDa
ovalbumin 46 kDa (sometimes an extra band at 50 kDa was also present) 
carbonic anhydrase 30 kDa 
lysozyme 14.3 kDa
Adenosine 5’ triphosphate (ATP), tetra (triethylammonium) salt [ 7  -32P] > 
4000 Ci mmol'1 10 mCi ml'1 in water and deoxyguanosine 5’-triphosphate (dGTP), 
tetra(triethylammonium) salt [ a-32P] > 3000 Ci mmol'110 mCi ml' 1 in water were 
supplied by ICN Biomedicals Ltd, Buckinghamshire, UK.
2.4 Plasmids
The pBLCAT2 expression vector was used for subcloning, in which the CAT gene is 
under the control of the herpes simplex virus thymidine kinase basal promoter (Luckow 
and Schutz, 1987).
2.5 Antibodies
The rel antibody SB6 6  was kindly donated by Dr P. Enrietto, New York State 
University, Stony Brook. Three antibodies to p50 of NF-kB were kindly donated by 
Dr R. Hay, St Andrews, Scotland. One of these antibodies was raised to the DNA- 
binding domain, amino acids 35-381, from the sequence of Kieran et al. (1990). The 
other two antibodies were raised to the N- and C-terminal peptides, their sequences are, 
C-terminal: CDYGQEGPLEGKI , N-terminal: MAEDDPYLGRPEC
All the antisera were polyclonal and were raised in rabbits.
2 . 6  Oligodeoxvnucleotides
The oligodeoxynucleotides used in gel retardation and/or subcloning are shown in 
table 2.1. kappa, CRE1, mCREl and CRE2 were synthesized in this Division, on a
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Table 2.1 Sequences of the oligonucleotides used in cloning and gel retardation
The sequences are shown of the oligonucleotides used in gel retardations and cloning: 
CRE1, mCREl and CRE2 along with the oligonucleotides used solely in gel 
retardation: kappa and Spl. The residues in bold print differ between CRE1 and 
mCREl. Each oligonucleotide was double stranded, however, for clarity only a single 
strand is shown.
57
cs
58
Gene Assembler (Pharmacia) using phosphoramidite chemistry. The kappa probe 
corresponds to the NF-/dB-like DNA-binding motif present in the immunoglobulin kappa 
light chain enhancer. CRE1 includes region I, the NF-KB-like DNA-binding motif 
present in the H-2Kb gene. The Spl oligonucleotide was a gift from Dr S. P. Jackson, 
Wellcome CRC Institute, Cambridge.
2.7 Cells and cell lines 
Ad2-transformed cells
F19: Ad2-transformed rat embryo brain cells (Harwood and Gallimore, 1975). 
Ad5-transformed cells
BMK 2.4: Ad5 virus-transformed baby mouse kidney cells (Blair-Zajdel and Blair, 
1988).
Ad5Xho: Ad5-transformed baby rat kidney cells. Kindly supplied by K.Raska. 
Adl2-transformed cells
C57AT1: Adl2-transformed mouse embryo kidney cells (Maeta and Hamada, 1979) 
Adl2#l: baby rat kidney cells transformed by Adl2 virus. Kindly supplied by K.Raska 
RFC-1: Adl2-transformed Hooded Lister (LIS) rat kidney cells, transformed by the 
Eco RI-C fragment (containing the El A and E1B genes) of Adl2 (Raska et al., 1980).
Cells transformed by recombinant virus
5A12: Baby rat kidney cells transformed with recombinant Ad5 virus containing the 
Adl2 E1A gene (Sawada et al., 1985).
5B12: Baby rat kidney cells transformed by recombinant Ad5 virus containing the Adl2 
E1B gene (Sawada et al., 1985).
Human cell lines
Hela: Human cell line derived from a cervical epitheloid carcinoma (Scherer et
al.,1953).
2.8 Other materials and reagents
Recombinant TNFa was obtained from Genzyme Corporation. IFN y  was purchased 
from Biotechnology BV, Holland. Dialysis tubing was obtained from Medicell 
International Ltd. Nitrocellulose was obtained from Schleicher and Schuell, Dassel,
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Germany. Microcollodion bags were purchased from Sartorius, Gottingen, Germany.
Glass beads (425-600 microns) were obtained from the Sigma Chemical Company Ltd.
Silica gel TLC plates were purchased from Merck, Darmstadt, Germany. The 96 well
ELISA plates used were obtained from Coming, U.K.
2.9 Buffers and Solutions
2.9.1 Electrophoresis buffers
10 x Tris-acetate EDTA (10 x TAE)
Tris base 48.4 g l'1
glacial acetic acid 11.42 ml I' 1
0.5 M EDTA (pH 8.0) 20.0 ml I 1
10 x Tris/glycine buffer
glycine 139.6 g l"1 
Tris base 30.3 g l*1 
SDS 10 g I 1
5 x Tris borate EDTA (5 x TBE)
Tris base 54 g l"1
boric acid 27.5 g l' 1
0.5 M EDTA (pH 8.0) 20.0 ml I 1
Wet blot transfer buffer
Tris base 9.69 g 
glycine 45.04 g 
methanol 0 . 8  1
made up to four litres with water
2.9.2 Polyacrylamide gel mixtures
6 % retardation gel
57 g acrylamide 
3 g bisacrylamide
made up to 11 in 0.5 x TBE. To 30 mis of gel mixture 225 jil of 10% w/v ammonium
persulphate was added, the mixture was degassed and 30 y\ of TEMED was added.
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15% SDS/polyacrylamide gel 
Separating gel
30% acrylamide 0.8% bisacrylamide, 10.0 mis (30 g acrylamide and 0.8 g 
bisacrylamide made to 1 0 0  mis with water)
1.5M Tris HC1, pH 8 .8 , 6.0 ml 
10% ammonium persulphate 67 p\
10% SDS 200 p\
TEMED 3.8 p\
Stacking gel
30% acrylamide 0.8% bisacrylamide 2.5 ml 
0.5 M Tris HC1, pH 6 .8 , 3.75 ml 
water 8.5 ml
10% ammonium persulphate 0.15 ml 
10% SDS 0.15 ml 
TEMED 20 p\
For both the stacking and the separating gel the mixture was degassed after the addition 
of ammonium persulphate and TEMED was then added.
6 % sequencing gel 
40% acrylamideibis (19:1)
114 g of acrylamide and 6  g of bisacrylamide was made up to 300 mis with water. It 
was stirred gently with 6  g of mixed bed resin, Amberlite MB1. The mixture was 
filtered through sintered glass to remove the resin.
Gel mixture
40% acrylamide:bis (19:1) 150 ml 
10 x TBE 100 ml 
urea 480 g 
made up to 1 1 with deionized water.
1 2 % footprinting gel mixture
40% acrylamide:bis (19:1) 300 ml 
10 x TBE 100 ml 
urea 480 g 
made up to 1 1 with deionized water
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For both the sequencing and footprinting gels, per gel, 60 ml of the gel mix was used 
with 120 [i\ of 25% ammonium persulphate and 70 /zl of TEMED.
2.9.3 Mammalian cell culture media
Dulbecco-modified Eagle medium (DMEM) 1 L 
50 ml 10 x DMEM
5 ml penicillin/streptomycin (10,000 U ml*1)
5 ml 0.1 M sodium pyruvate 
5 ml 0.2 M L-glutamine 
20 ml 7.5% w/v sodium bicarbonate 
415 ml water
RPMI-1640 1 L
50 ml 10 x RPMI-1640 
5 ml penicillin/streptomycin (10,000 U ml*1)
5 ml 0.2 M L- glutamine
13 ml 7.5% w/v sodium bicarbonate
427 ml water
RPMI-1640 medium was made to pH 7.3 before use with sterile HC1
2.9.4 Bacterial growth media
Luria broth (LB)
Bactotryptone 10 g 
NaCl 10 g 
yeast extract 5 g 
made up to 1 1 with water and autoclaved.
LB agar
Bactotryptone 10 g l'1 
NaCl 10 g I*1 
yeast extract 5 g I*1 
agar 15 g l*1
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made up as LB then agar was added just before autoclaving. Plates were poured when 
the LB agar had cooled to approximately 50°C. LB/ampicillin plates were made exactly 
like LB plates accept ampicillin was added at a concentration of 100 /xg/ml just before 
pouring.
2.9.5 Plasmid DNA minipreparation solutions
Solution A
0.05 M glucose 
0.025 M Tris HC1 pH 8.0 
8  mM EDTA
Lyzozyme solution was prepared at a concentration of 12 mg/ml in 50 mM Tris HC1 
pH 8.0
Solution B
0.2 M NaOH 
1% SDS
2.9.6 Nuclear extract preparation buffers
Buffer A
10 mM Hepes
1.5 mM MgCl2 
10 mM KC1 
0.5 mM PMSF 
0.5 mMDTT
Buffer C
20 mM Hepes 
0.42 M NaCl
1.5 mM MgCl2 
0.2 mM EDTA 
0.5 mM DTT
25% v/v glycerol
0.5 >v»M P/V^ p
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Buffer D
20 mM Hepes 
100 mM KC1 
0.2 mM EDTA 
0.5 mM PMSF 
0.5 mM DTT 
2 0 % v/v glycerol
DTT and PMSF were added fresh at time of use. These buffers were sometimes 
prepared with 10 mM NaF as specified in the text. Buffers AM, CM and DM (M for 
modified) were the same as A, C and D except in AMand CM there was 50mM sodium 
fluoride, 0.5 mg/ml leupeptin and 0.24 TIU (trypsin inhibitory units) of aprotinin, 
buffer DM had 50 mM sodium fluoride and 0.5 mg/ml leupeptin.
2.9.7 Western blotting solutions and reagents 
AP buffer
Tris HC1 pH 9.5 100 mM 
NaCl 100 mM 
MgCl2 5 mM
BCIP
0.5 g of BCIP was dissolved in 10 ml of 100% dimethyl formamide.
NBT
0.5 g of NBT was dissolved in 10 ml of 70% dimethyl formamide.
2.9.8 Reagent for ELISA
o-phenylenadiamine was freshly prepared at 1 0  mg/ml in methanol and stored in the 
dark until use.
2.9.9 Colony hybridization buffers
Prehybridization buffer
50% formamide 
6  x SSC 
5 x Denhardt’s 
0.5% SDS
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1 0 0  jug/ml denatured sonicated salmon sperm
Hybridization Buffer
Prepared as prehybridization buffer with the addition of 5 % w/v 
dextran sulphate
Washing Solution
0.5 x SSC 
0.5% SDS
50 x Denhardt’s
Ficoll 5 g
Polyvinylpyrrolidone 5 g 
BSA (pentax fraction V) 5 g 
water to 500 ml
Filtered through disposable Nalgene filter, stored in aliquots at -20°C.
20 x SSC
Dissolved 175.3 g of NaCl and 88.2 g of sodium citrate in 800 mis of water, pH was 
adjusted to 7.0 with concentrated NaOH and the volume was adjusted to 1 L. The 
solution was sterilized by autoclaving.
2.9.10 Other buffers and solutions
Triton X-100 lysis buffer
Triton X-100 20 ml 
1 M Tris pH 8.0 5 ml 
0.5 M EDTA pH 8.0 2 ml 
made up to 1 0 0  ml in distilled water
10 x Kinase buffer
0.5 M Tris HC1 pH 7.6 
0.1 M MgCl2 
50 mM DTT 
1 mM spermidine 
1 mM EDTA pH 8.0
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Tris EDTA (TE)
10 mM Tris HC1 pH 8.0 
1 mM EDTA pH 8.0
PBS
NaCl 8  g 
KC1 0.2 g 
Na2HP04 
KH2P0 4
Made up to 1 L with distilled water
10 x Hepes-buffered saline (HBS)
Hepes 5 g 
NaCl 8  g 
KC1 0.37 g 
Na2HP04 
glucose 1 . 0  g
made up to 100 ml with distilled water then filter sterilized. 0.25 M CaCl2 was
prepared and filter-sterilized.
2.9.11 Sample Buffers
For gel retardations and sequencing gels 
sucrose 2.5 g 
0.25 M EDTA 2 ml 
bromophenol blue 1 0  mg
made up to 5 ml with distilled water
For SDS/polyacrylamide gels 
10% SDS 
urea 4.8 g
1 M Tris HC1 pH 6 . 8  
bromophenol blue 1 0  mg
made up to 1 0  mis with distilled water
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For footprinting
formamide 9.8 ml 
0.5 M EDTA 0.2 ml 
xylene cyanol 1 0  mg 
bromophenol blue 1 0  mg
5 x DNA-binding buffer for CRE1 and Kappa probes 
100 mM Hepes pH7.9 
250 mM KC1 
12.5% glycerol 
1 mM DTT
DNA-binding buffer for the SP1 probe 
20 mM Hepes pH 7.9 
100 mM KC1 
12 mM MgCl2 
0.1 mM EDTA pH 8.0 
17% glycerol 
both buffers were made up with distilled water
2.10 Preparation of materials
All plastics and glassware used for nucleic acid analysis was sterilized by autoclaving. 
Dialysis tubing was prepared by boiling for 15 minutes in 500 ml of 10 mM EDTA 
containing 1 g NaHC03. The tubing was then washed extensively in sterile water and 
stored in 0.05% sodium azide at 4°C.
Methods
2.11 Production of antibody to the C-terminal peptide of NF-kB
The sequence DYGQEGPLEGKI is present at the C-terminus of p50 of NF-kB (Kieran 
et al., 1990). It was decided to synthesize this peptide and its derivative 
CDYGQEGPLEGKI, in which an N-terminal cysteine was added in order to link the 
peptide to a crosslinker and carrier. The peptides were synthesized, purified and 
sequenced by Dr J. Keen and J. Johnson (University of Leeds).
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2.11.1 Peptide synthesis
The peptides were made on a MilliGen/Biosearch 9050 automated solid-phase peptide 
synthesizer, 9-fluoroenylmethoxycarbonyl (Fmoc)-based chemistry with side-chain- 
protected amino acids was used.
2.11.2 Peptide purification
Each peptide was purified by reverse-phase h.p.l.c. on a Pharmacia PepRPCrMHR 5/5 
C2/C18 column. The major peptide peak was collected for subsequent analysis and use. 
An aliquot of peptide was subjected to amino acid sequence analysis to assess quantity 
and purity.
2.11.3 Amino acid sequence analysis
An aliquot of each peptide (1 /xg approximately) was dissolved in water and dried onto 
a glass-fibre disc for sequence analysis on an Applied Biosystems 477A liquid-pulse 
machine. Analysis was performed using standard manufacturers instructions.
2.11.4 Conjugation of the peptide to the carrier protein
a. Reduction of the peptide
12 mg of peptide (of which approximately 50% contained an N-terminal cysteine) was 
resuspended in 500 fil of 0.1 M sodium phosphate buffer pH 6.0 containing 5 mM 
EDTA and 50 mg of DTT and left overnight at 37°C.
b. Desalting of the peptide on a G-10 column
DTT and EDTA were removed from the peptide on a G-10 column. A slurry of G-10 
Sepharose was prepared; 15 g of G-10 Sepharose were suspended in 100 ml of 0.1 M 
sodium phosphate buffer, pH 6.0, containing 5 mM EDTA. The suspension was shaken 
overnight at room temperature. A column was prepared in a 10 ml sterile pipette, 
washed with 3 column volumes of 0.1 M sodium phosphate buffer, pH 6.0, and stored 
in the cold room.
The reduced peptide/DTT mix was added to the column and was eluted with 0.1 M 
sodium phosphate buffer, pH 6.0, at 4°C. Fractions (1 ml) were assayed with the 
Ellman’s reagent. The three fractions containing most of the reduced peptide were 
pooled.
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c. The Ellman’s Assay
Reduced Ellman’s reagent gives a yellow colour, the absorbance of which can be read 
at 412 nm. The free sulphydryl groups of the peptide or DTT reduce the Ellman’s 
reagent. The Ellman’s reagent was prepared by dissolving 4 mg in 1 ml of 0.1 M 
disodium hydrogen orthophosphate, pH 8.0. 20 /d of the reagent was mixed with 20 
lil of each fraction and 1 ml of 0.1 M disodium hydrogen orthophosphate, pH 8.0. The 
absorbance was read at 412 nm.
d. Preparation of activated PPD
7 mg of lyophilized PPD was mixed with 1.4 ml of water and 1.75 mg of sulpho- 
SMCC and placed in an ultrasonic bath for 10 minutes. The pH of the solution was 
adjusted to 7.5 with NaOH. The solution was left at 25°C for 30 minutes with 
occasional gentle mixing.
Activation of PPD results from the n-hydroxysulphosuccinimidyl active ester moiety of 
sulpho-SMCC reacting with the free amino groups of PPD. This reaction occurs at 
pH >7.
e. Separation of activated PPD from unreacted sulpho-SMCC on a G-25 column
11 g of G-25 Sepharose was shaken overnight at room temperature in 100 ml of 50 mM 
sodium phosphate buffer, pH 6.0. A 45 ml column was prepared, washed with three 
column volumes of 50 mM sodium phosphate buffer, pH 6.0, and stored in the cold 
room.
The activated PPD was loaded on the column and eluted with 50 mM sodium 
phosphate buffer, pH 6.0, at 4°C. 1 ml fractions were collected and the absorbance
of each fraction was read at 280 nm. Activated PPD was eluted in the void volume of 
the column and unreacted sulpho-SMCC was present in later fractions. Three 1 ml 
fractions containing most of the activated PPD were pooled.
f. Crosslinking of the reduced peptide to the activated PPD
Reduced peptide was coupled to PPD cross-linked to sulpho-SMCC via the maleimide 
moiety which reacts with the free thiol group of the peptide’s terminal cysteine 
between pH 6 .5-7.5.
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The G-25 and the G-10 columns were run simultaneously so that the 3 x 1 ml fractions 
of reduced peptide could be reacted immediately with the 3 x 1 ml fractions of the 
activated PPD. The pH was adjusted to pH 7.0 with NaOH and the solution was 
gassed with nitrogen and stored at room temperature overnight. The next day distilled 
water was added to give a final volume of 10 mis. The PPD conjugated peptide was 
stored in 1 ml aliquots at -70°C until use.
2.11.5 Preparation of the peptide-PPD conjugate for injection
An emulsion was prepared of the peptide-PPD conjugate (1.0 ml) and Freund’s 
incomplete adjuvant (1.0 ml). The mixture was sonicated until it was of a consistency 
to produce spherical droplets on water.
2.11.6 Antibody Production Protocol
Two New Zealand white rabbits between 2-3 kg were allowed to settle in new 
accomodation for two weeks, then a sample of pre-immune blood was collected from 
each animal. After the collection of blood, the rabbits were injected with 
reconstituted freeze dried BCG vaccine for intradermal use. Each rabbit was given 
2 x 0.1 ml BCG injections in the scruff of the neck. The first injection of the peptide- 
PPD conjugate took place one month later. PPD only elicits its delayed-type 
hypersensitivity reaction in animals that have encountered tubercle bacillus either 
through infection or immunization with BCG. The initial encounter with the PPD- 
peptide conjugate was in the form of 2 x 0.5 ml intramuscular injections in the hind 
legs and 2 x 0.2 ml subcutaneous injections in the scruff of the neck. This was 
followed by three boost injections at three, six and nine weeks after the initial injection. 
The boost consisted of 4 x 0.25 ml injections into the scruff of the neck. The rabbits 
were bled ten days after each of these four injections. Thirteen days after the final 
boost the rabbits were bled out by cardiac puncture.
2.12 ELISA
The peptide was dissolved in 0.06 M NaHC03 buffer (pH 9.6) at a concentration of 
5 ng//d. 200 ijl\ of this solution, the equivalent of 1 fig of peptide, was added to each 
well of the ELISA plates and left overnight at 4°C.
The following day the peptide solution was removed and the wells were blocked with 
0.1% BSA in PBS-Tween (0.05%) for 30 minutes at 37°C. Then the wells were
washed four times with PBS-Tween (0.05 %) using a Wellwash 4 plate-washer (Denley). 
The test sera were diluted in PBS-Tween. Three fold dilutions were made from 1:100 
to 1:218700 for each serum. 200 /d of each dilution was added to two wells (the sera 
were tested in duplicate) and incubated for 30 minutes at 37°C. The wells were then 
washed four times with PBS-Tween (0.05%). When the specificity of binding was 
tested, the serum was preincubated with peptide before use in the ELISA. 1 /xl of a 
1:100 dilution of serum was mixed with 100 fig of peptide in an Eppendorf tube on a 
rotary mixer in a 30°C warm room for 1 hour. Either the peptide to which the antibody 
was raised or an unrelated peptide of the 5/6 loop of the human neurokinin 2 receptor 
was used.
To detect bound antibody the Sigma ExtrAvidin™ Biotin Staining kit was used. The 
biotinylated goat anti-rabbit IgG was diluted 1:1000 in PBS-Tween, 200 /zl of this 
dilution was added to each well and incubated for 30 minutes at 37°C. The solution 
was removed from the wells and the plates were washed four times with PBS-Tween. 
The plates were incubated with ExtrAvidin Peroxidase at 1:500 dilution in PBS-Tween 
for 30 minutes at 37°C, then were washed four times in PBS-Tween. After all liquid 
was carefully removed from the wells, 200 /xl of O-phenylenediamine substrate 
(prepared as described in section 2.9.8) was added to each well and incubated for 30 
minutes in the dark. The reaction was stopped with 25 /xl of 4 M H2S04. The 
absorbance was read at 492 nm on an Anthos plate reader 2001 (Anthos labtec 
instruments).
2.13 Western blotting
30 /xg of MBP3 nuclear extract was boiled in sample buffer and loaded onto a 15% 
SDS/polyacrylamide gel along with molecular weight markers. The gel was run in 1 
x Tris/glycine SDS buffer at 250 V for four hours.
The proteins were transferred to nitrocellulose by a standard wet blotting technique 
(Sambrook et al., 1989) for three hours at 0.3 A using a TE-42 Transphor unit blotting 
apparatus (Hoeffer scientific instruments). When transfer was complete the 
nitrocellulose was stained for protein using 0.1% Ponceau S in 3% TCA. Strips 
corresponding to the sample tracks were cut out and the positions of the molecular 
weight markers indicated. After destaining in water the blots were incubated in 
blocking buffer (PBS containing 2% marvel, 0.1% NP40 and 0.1% sodium azide) for
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1 hour. Antibodies raised in rabbits A and B against the C-terminal peptide of the p50 
subunit of NF-kB were used in Western blotting. Controls with pre-immune sera were 
also included. Antibodies to c-rel (donated by Dr P. Enrietto) and to the DNA-binding 
domain as well as the N- and C-terminal peptides of p50 (donated by Dr R. Hay) were 
also used on Western blots. The specificity of the antibodies to p50 raised in rabbits 
A and B was tested by blocking with either the peptide used for immunization or with 
an unrelated peptide (the 5/6 loop of the human neurokinin 2 receptor). 50 /xg of 
peptide was added to 1 /xl of serum in 500 /xl of PBS containing 0.1% NP40, 0.1% 
NaN3 and left for 1 hour at 30°C on a rotary mixer, then 500 /xl of PBS containing 4% 
marvel, 0.1% NP40 and 0.1% NaN3 was added. The nitrocellulose strips were sealed 
in bags with the appropriate primary antibody diluted in the blocking buffer, and 
incubated overnight at 4°C on a rotary mixer. The following day the blots were 
washed thoroughly in several changes of PBS containing 0.1 % NP40. The blots were 
incubated for two hours in goat anti-rabbit alkaline phosphatase immunoconjugates 
diluted 1:1000 in blocking buffer, washed several times in PBS containing 0.1% NP40 
and rinsed in alkaline phosphatase buffer. The substrate was made up fresh before 
use; 33 /xl of BCIP and 6 6  /xl of NBT in 10 ml of alkaline phosphatase buffer 
(prepared as described in section 2.9.7). Blots were incubated in substrate until blue 
coloured band(s) appeared, then washed in distilled water and dried between filter 
paper.
2.14 Cloning
The vector used was pBLCAT2. Table 2.1 shows the oligonucleotides that were cloned 
into pBLCAT2; these were termed CRE2, CRE1 and mCREl. Each of these 
oligonucleotides was synthesized as complementary strands which were annealed 
together. The annealing conditions used were 3 minutes at 100°C, 15 minutes at 6 8 °C, 
30 minutes at 37°C and 2 hours at RT. The oligonucleotides were constructed with 
Bam HI/Bgl II compatible ends and were cloned into the Bam HI site of pBLCAT2. 
10 /xg of the vector was digested with Bam HI. The digest was treated with 
phenol/chloroform and precipitated with 0.1 volume of 3M sodium acetate and 2.5 
volumes of cold ethanol at -70°C, then spun for 15 minutes at 10,000 rpm. The cut 
vector was treated with alkaline phosphatase. For each of the three ligations, with 
CRE2, CRE1 and mCREl, 0.1 /xg of Bam HI digested vector was used with 6  ng of 
the oligonucleotide to give the latter approximately a 10-fold molar excess. The 
ligations were performed at 15°C overnight, using 1U of T4 DNA ligase.
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2.14.1 Preparation of competent cells
The bacteria used in these experiments was the DH5a strain of E. coli. A single 
colony was taken from an agar plate and grown overnight in 5 ml of LB in a shaking 
incubator at 37°C. 1 ml of this culture was taken and grown in 100 ml of LB, under
the above conditions, until it reached an OD650 of 0.6. The culture was chilled on ice, 
then centrifuged. The cell pellet was resuspended in 50 ml of 0.1 M MgCl2 and spun. 
The pellet was resuspended in 50 ml of 0.1 M CaCl2 left on ice for 30 minutes then 
spun. Each centrifugation was at 3000 rpm for 5 minutes at 4°C in a bench-top 
centrifuge. The final pellet was resuspended in 5 ml of 0.1 M CaCl2 and either stored 
on ice or kept frozen in aliquots at -70°C (with 50% glycerol) until use.
2.14.2 Transformation
Each of the three ligation mixtures was transformed into competent DH5a. pBLCAT2 
cut with Bam HI and treated with alkaline phosphatase then ligase was also transformed 
as a control for religation of the vector. Uncut vector was transformed as a control 
of transformation efficiency. 50 ng of DNA (in 10 /xl) was mixed with 200 /xl of 
bacteria for each transformation and left for 30 minutes on ice. The bacteria were heat 
shocked for 2 minutes at 42°, then 1 ml of Luria broth was added to each tube and 
incubated for 2 hours at 37°C. 50 /xl was plated out onto an agar plate containing
ampicillin ( 1 0 0  /xg/ml).
2.14.3 Colony hybridization
Over one hundred colonies were present on the plate for each ligation. In the case of 
the CRE2 subcloning experiment, a nitrocellulose filter was placed onto the plate in 
order to obtain a mirror image of the colonies on the plate. The filter was treated with 
0.5 M NaOH for 7-8 minutes, followed by 2 minutes treatment in 1.0 M Tris-HCl, pH 
7.4, and 4 minutes in 1.5 M NaCl, 0.5 M Tris-HCl, pH7.4. The filter was dried on 
filter paper, air dried for 2 hours and dried in an oven at 80°C for 2 hours. The filter 
was prehybridized for 2 hours at 42°C. Then hybridized overnight with a CRE2 probe 
end-labelled with [y-32P] ATP (>4000 Ci mmol' 1 10 mCi ml'1) by T4 polynucleotide 
kinase ( prehybridization and hybridization solutions as described in section 2.9.8). The 
filter was given two 2 hour washes at 55°C in 0.5 x SSC/0.5% SDS. The filter was 
washed with gentle agitation. The filter was exposed wet to X-ray film. Many 
colonies gave a strong signal, twenty colonies which gave the strongest signal were 
spotted onto a fresh agar agar plate (containing ampicillin, 1 0 0  /xg/ml) and a second
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nitrocellulose filter. The six colonies which gave the strongest signal where grown up 
in overnight cultures which were used to make minipreparations of DNA. Because a 
high number of positive clones was found for CRE2, it was decided in the case of 
CRE1 and mCREl to omit the colony hybridization step, instead several colonies of 
each transformant were grown overnight and used to make minipreparations of DNA 
for sequencing.
2.15 Mini-preparation of plasmid DNA
A colony was grown overnight in 5 ml of Luria broth containing ampicillin (100 
/xg/ml) in a shaking incubator at 37°C. Three ml of culture was spun in a microfuge 
for 1 minute. The cell pellet was resuspended in 200 /xl of solution A and 6  /xl of 
freshly prepared lysozyme solution (12 mg/ml) was added. After 5 minutes at RT, 400 
/xl of solution B was added, mixed by inversion and left on ice for 5 minutes. Then 
300 /xl of 7.5 M ammonium acetate pH 7.8 was added, mixed gently and left on ice 
for 10 minutes. The precipitate was removed by centrifugation for 15 minutes. 540 
/xl of isopropanol was added to the supernatant, incubated for 1 0  minutes at room 
temperature, and spun for 10 minutes. The pellet was dried and resuspended in TE, 
pH 8.0, then treated with phenol/chloroform and ethanol precipitated as described 
previously. After the final spin (all centrifugations were performed at 10,000 rpm) 
each miniprep was taken up in a final volume of 20 /xl of TE, pH 8.0.
2.16 DNA Sequencing
Sequencing was performed on minipreparations of DNA ( 8  /xl) using a Pharmacia T7 
kit. The reactions were carried out according to the manufacturer’s instructions, except 
that the template DNA was denatured in 0.4 M NaoH for 30 minutes. The universal 
primer provided with the kit was used. The annealing buffer was however replaced 
by the manganese buffer which was included in the Sequenase sequencing kit (USB). 
1 /xl (10 /xCi)[a-35S] dATP (10 mCi/ml) was used in each reaction.
The reaction products were separated by electrophoresis on 6 % polyacrylamide gels. 
The upper tank of the sequencing gel apparatus contained 300-500 ml of 0.5 x TBE and 
the lower tank contained 150 ml of 1 x TBE. The gel was pre-run for 1 hour at 
1500 V. After the pre-run, 75 ml of 3 M sodium acetate was added to the lower 
chamber. The gel was run for 2-3 hours at 1500 V, then the gel was fixed in 10%
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acetic acid for 40 minutes, washed for 5 minutes in water, dried for approximately 
90 minutes at 60° C and exposed to film for at least 24 hours.
2.17 Large scale plasmid preparation
Plasmid DNAs were prepared on a large scale by lysozyme-Triton X-100 lysis followed 
by caesium chloride/ethidium bromide equilibrium gradient centrifugation (Clewell and 
Helinski, 1972). Clones which were found by sequencing to contain the desired insert 
in the required orientation were grown up to make large scale plasmid preparations. 
CRE2, CRE1 and mCREl were used in the forward orientation in CAT assays, CRE2 
was also cloned in the reverse orientation for footprinting. The bacterial culture used 
for the minipreparations was streaked onto agar plates (containing ampicillin, 1 0 0  
/xg/ml), a colony was picked from these plates and grown overnight in 10 ml of Luria 
broth (containing ampicillin, 100 /xg/ml) at 37°C in a shaking incubator. 4 ml of this 
culture was grown in 400 ml of Luria broth (containing ampicillin, 100 /xg/ml) until an 
OD650 of 0.7 was reached. 6  ml of chloramphenicol (lOmg/ml) was added to the 
culture, which was maintained overnight in a shaking incubator at 37°C. The cultures 
were centrifuged in a Sorvall GSA rotor at 5000 rpm for 10 minutes at 4°C, the pellet 
was then resuspended in 3 ml of 25% sucrose in 50 mM Tris HC1 pH 8.0. Lysozyme 
solution was prepared (10 mg/ml) in 50 mM Tris HC1 pH 8.0 and 0.5 ml was added 
to the bacterial suspension which was left on ice for 5 minutes. 1 ml of 0.25M EDTA 
was added and, after a further 5 minutes on ice, 4 ml of Triton X-100 lysis solution 
was added. After a one hour spin at 18,000 rpm at 0°C (Sorvall SS34 rotor), caesium 
chloride was added to the supernatant (clear lysate) at a concentration of 1 g/ml. 
Once the caesium chloride was dissolved, ethidium bromide (10 mg/ml) was added at
23.5 /xl/ml of lysate. The lysate was then divided between two Beckman polyallomer 
quick seal tubes and centrifuged at 65,000 rpm for 3.5 hours at 21°C in a Beckman 
VTi65 rotor. Centrifugation resulted in two UV-fluorescent bands. The lower band 
was removed using a hypodermic needle and the ethidium bromide was extracted six 
times with isopropanol saturated with caesium chloride, then dialysed overnight with 
TE pH 8.0 (three changes of buffer). Then plasmid DNA was ethanol precipitated and 
spun at 0°C in a SS34 rotor at 10,000 rpm for one hour. The pellet was washed in 
70% ethanol, spun for 15 minutes at 10,000rpm, dried and resuspended in 1 ml of TE 
pH 8.0. This was extracted with phenol/chloroform, ethanol precipitated and 
resuspended in 1 ml of TE pH 8.0.
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2.18 Cell culture
Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% (v/v) donor calf serum (DCS) and incubated in a humidified atmosphere 
containing 5% C02. In experiments involving the induction of NF-acB by hydrogen 
peroxide and benzoyl peroxide, the medium was removed one hour before the addition 
of these reagents, the cells were washed in PBS and the iron-free medium, RPMI-1640, 
was added without serum.
2.19 CAT reporter gene transfection assay
2.19.1 Transfections by the calcium phosphate method
Cells were seeded out onto 90 mm plates such that the cells were between 50-75% 
confluent one day after plating. The medium was changed four hours before 
transfection. 15 /xg of DNA (1 mg/ml) was used in the transfections for each 
condition. 2 x HBS was prepared from 10 x HBS stock and made to pH 7.05 before 
use. 2 x HBS was added to the DNA to give a total volume of 250 /xl, to which was 
added dropwise 250 /xl of 0.25 M CaCl2 (stored as 2.5 M). The solution was gently 
mixed and left at room temperature for 2 0  minutes during which time a fine precipitate 
formed. Three ml of fresh medium was added to each plate and the DNA/calcium 
phosphate precipitate was added dropwise to the plates and left at room temperature for 
twenty minutes. Then 7 ml of medium was pipetted onto each plate. Eighteen hours 
later the medium was removed, the cells were washed with PBS and fresh medium 
added.
2.19.2 Preparation of cell lysates
After a further 24 hours the medium was removed and the cells washed with cold PBS, 
fresh PBS was poured on the plates and the cells were scraped with a 'rubber 
policeman'. The cells were spun at 2000 rpm for 5 minutes at 4°C in a MSE coolspin. 
The pellets were resuspended in 1 ml of cold PBS and spun at 10,000 rpm for three 
minutes at 4°C. The PBS was removed and the pellets were resuspended in 100 /xl of 
0.25 M Tris HC1 (pH 7.8). Each sample was sonicated for 30 seconds in a bath-type 
sonicator followed by three cycles of freezing in dry ice and ethanol and thawing in 
a water bath at 37°C. After a fifteen second period of sonication the tubes were spun 
at 10,000 rpm for three minutes at 4°C, and the supernatants (cell lysates) were 
collected.
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2.19.3 Protein estimation of cell lysates
2 /xl of cell lysate was added to 798 /xl of 0.25 M Tris HC1 pH 8.0. Standards 
ranging from 1-25 mg/ml were prepared with bovine serum albumin. 200 /xl of reagent 
from the Biorad Protein Assay Kit was added and left for five minutes at RT. The 
OD595 were read against a blank. A standard curve was plotted and used to calculate 
the protein concentration of the cell lysates.
2.19.4 Analysis of CAT activity
Cell lysates were diluted with 0.25 M Tris HC1 pH 8.0 so that the CAT assay for a 
particular transfection experiment was performed for each condition with an equal 
amount of protein (150- 250 /xg depending on the cell line) in an equal volume (100 /xl). 
The cell lysates were heated at 65°C for 10 minutes. A master mix was prepared to 
ensure that the same batch of frozen acetyl CoA (5 mg/ml) and frozen [14C] 
chloramphenicol (0.025 mCi/ml) would be used for all the samples in any one 
transfection experiment. 8  /xl of [14C] chloramphenicol (25 /xCi ml'1) was used with 
40 /xl of acetyl CoA per assay. The components were mixed and incubated at 37°C for 
three hours or overnight depending on the cell line used. At the end of the incubation 
period 0.5 ml of cold ethyl acetate was added to each tube and after mixing, the tubes 
were spun at 10,000 rpm for three minutes at 4°C. The upper, organic, phase was 
transferred to a new tube and the tubes were spun in a centrifugal evaporator (Univap) 
for 30 minutes at 40°C until all the ethyl acetate was removed. The residue was 
resuspended in 20 /xl of ethyl acetate and spotted on a silica gel TLC plate. The TLC 
plates were subjected to ascending chromatography in chloroform: methanol (95:5), air 
dried and exposed to X-ray film. Spots containing separated chloramphenicol species 
were scraped into scintillation vials, mixed with 2 ml of Instagel and counted in a 
scintillation counter. The counts for the converted and the unconverted forms of 
chloramphenicol were used to calculate the percentage conversion of each sample.
2.20 Footprinting
The DNase I footprinting was performed in collaboration with Mark Griffiths.
2.20.1 Preparation of DNA for labelling
The plasmid pCRE2CAT, containing CRE2 cloned in the reverse orientation was used 
in footprinting. 200 /xg of the plasmid was digested with Eco RI and Hind III in a 
volume of 50 /xl for 90 minutes at 37°C. These enzymes were chosen because they
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gave an 85 bp fragment (a suitable size for footprinting) with different 5’ overhanging 
ends. The coding strand of the vector, containing the non-coding strand of CRE2, had 
a 5’ overhanging end 5’ AGCT- 3’. The non-coding strand of the vector, containing 
the coding strand of CRE2, had a 5’ overhanging 3’-TTAA 5’. Because of the 
different ends, end-labelling with [a-32P] dGTP or dCTP would result in only the non­
coding strand being labelled at the 3’ end. The plasmid pCRE2CATR was used in 
preference to pCRE2CAT, because only the former contains the coding strand of CRE2 
on the non-coding strand of the vector, and it is the non-coding strand of the vector 
which is labelled by the labelling procedure as described above.
The restriction fragments were resolved by electrophoresis on a 1 % (w/v) agarose gel 
in 1 x TAE, the gel was run in 1 x TAE. The fragment of the correct size to represent 
the 85 bp fragment was excised from the gel and diced finely with a razor blade. A 
0.5 ml eppendorf was pierced at the base of the tube and glass wool was placed in the 
bottom of the tube and the agarose pieces were placed on top. The DNA was eluted 
by centrifugation at 10,000 rpm for 10 minutes at RT. The eluate was then extracted 
twice with phenol/chloroform and the DNA was ethanol precipited as described 
previously. The DNA was resuspended in 50 /xl of TE buffer pH 8.0. The 85 bp 
fragment was approximately 2% of the plasmid DNA. The maximum concentration of 
the fragment expected would be 80 ng//xl.
2.20.2 Labelling DNA for footprinting
2 /xl ( approx. 160 ng) of the Eco RI/Hind III fragment of pCRE2CAT was labelled 
with 5 /xl (50 mCi) [a-32P] dGTP (>3000 mCi/mmol). The reaction mixture (10 /xl) 
also contained 0.5 /xl of 1 mM dATP, dCTP,dTTP and 1 /xl (4U) of Klenow fragment 
in 50 mM Tris HC1 (pH 7.8), 5 mM MgCl2and 10 mM 2-mercaptoethanol. It was 
left for 30 minutes at room temperature then passed through a G-50 spin column. The 
G-50 spin column was prepared in a 1 ml syringe; a small amount of glass wool was 
pushed to the bottom of the syringe and a suspension of G-50 in water was added up 
to the top of the syringe using a pasteur pipette. The G-50 was compacted in the 
column by centrifugation at 1000 rpm for two minutes in a MSE coolspin. The 
process was repeated until the G-50 column reached the 1 ml mark on the syringe. 
1 0 0  /xl of water was added to the top of the syringe and the column was spun again at 
1000 rpm for two minutes. The column was then ready for use. 1 /xl of the probe after
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it had passed through the G-50 column was counted and found to have an activity of 
2 0 , 0 0 0  cpm//xl.
2.20.3 DNase I footprinting
2 /xl of the above probe was digested with various concentrations of DNase I between 
0.8 and 32 /xg/ml. The reaction mixture (100 /xl) also contained 20 /xl of 5 x DNA- 
binding buffer, 4 /xl of dIC (1 mg/ml), 1 /xl of 50 mM CaCl2 and 1 /xl of 100 mM 
MgCl2. The DNase I was the final component to be added to reaction mixture. The 
reaction was allowed to proceed for one minute at 25°C and was stopped with 60 /xl 
of 0.6 M sodium acetate (pH 5.2), 20 mM EDTA. 100 /xl of water was added and the 
solution was extracted once with phenol/chloroform and once with chloroform. DNA 
was precipitated with ethanol at -70°C, centrifuged for 10 minutes at 10000 rpm in the 
cold room, washed in 70% ethanol and resuspended in 5 /xl of loading buffer. The 
samples were run on a 12% polyacrylamide gel at 1500 V for 2-3 hours. The gel was 
fixed in 10% acetic acid for 30 minutes, dried in an oven at 60°C for 2 hours and 
exposed to X-ray film.
From the DNase I titration it was decided that the best cleavage for footprinting was 
obtained using a final concentration of 6  /xg/ml DNase I. The reactions were prepared 
for footprinting in the same way as in the titration experiment except that nuclear 
extract from 5A12 cells (9 mg/ml) was added to all but one of the reactions. The 
nuclear extract was prepared by MDP1 (see following section).
2.20.4 Maxam and Gilbert sequencing reactions
The G-specific Maxam and Gilbert sequencing reactions were performed as described 
by Sambrook et al. (1989). These reactions were run alongside the footprinting 
reactions so that the nucleotides in the footprint could be identified.
2.21 Nuclear extract preparation
Nuclear extracts were prepared by three methods, all of which were modifications of 
that described by Dignam et al. (1983). The methods are termed MDP1, MDP2 and 
MDP3 for modified Dignam procedures 1,2 and 3.
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2.21.1 MDP1
Cells were grown on twenty 90 mm plates. The medium was removed and the cells 
were washed with cold PBS. The cells were harvested in PBS by scraping with a 
'rubber policeman'. The cells were spun down in 50 ml falcon tubes at 2000 rpm in 
an MSE coolspin for five minutes at 4°C, resuspended in 4 ml of cold buffer A (see 
Section 2.9.6) and held on ice for 10 minutes. Finally the cells were disrupted with 
10 strokes with a tight-fitting Dounce homogenizer and nuclei pelleted by centrifugation 
at 16,000 rpm for 20 minutes at 4°C using a Beckman SW50.1 rotor. The pellet was 
resuspended in 4 ml of cold buffer C and nuclei disrupted by 10 strokes of a tight- 
fitting Dounce homogeniser. The nuclear extract was stirred gently on ice for 45 
minutes and chromatin and nuclear membranes were pelleted by centrifugation for 2 0  
minutes at 25,000 rpm at 4°C using the SW50.1 rotor. Ammonium sulphate was used 
to precipitate the proteins present in the supernatant. Solid ammonium sulphate 
(0.33 g per ml of supernatant) was gently stirred into the supernatant which were stirred 
on ice for 30 minutes. The nuclear proteins were pelleted by centrifugation as in the 
previous step. The protein pellet was resuspended in 200 /xl of cold buffer D and 
dialysed against the same buffer overnight at 4°C, unless stated otherwise in the text. 
The following day the nuclear extract was snap frozen in liquid nitrogen in aliquots and 
stored at -70°C.
2.21.2 MDP2
This modification of the Dignam et al. (1983) procedure was described by Andrews 
and Faller (1991), our further modification was to use buffers AM and CM instead of 
A and C (see Section 2.9.6). Using this method nuclear extracts could be prepared 
from a single 90 mm plate of cells. Cells were scraped in 1.5 ml of cold PBS and 
transferred to an Eppendorf tube. Cells were pelleted for 10 seconds and resuspended 
in 400 /xl of cold buffer AM. The cells were left on ice for 10 minutes, vortexed for 
10 seconds and centrifuged. The supernatants were discarded and each pellet was 
resuspended in 20-50 /xl (depending on the starting number of cells) of cold buffer CM 
and left on ice for 20 minutes. Nuclear membranes and chromatin were pelleted by 
a two minute centrifugation at 4°C. The supernatant was snap frozen in liquid nitrogen 
in aliquots and stored at -70PC. All centrifugation steps took place in a bench-top 
microfuge, the 10 second spins took place at RT.
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2.21.3 MDP3
This method was exactly the same as MPD1 except buffers A, C and D were replaced 
by buffers AM, CM and DM (see Section 2.9.6).
2.21.4 Estimations of protein in nuclear extracts
This was performed as described in Section 2.23
2.22 Oligonucleotide end-labelling for gel retardation
CRE1 and kappa were 3’ end-labelled using the Klenow fragment of E.coli DNA 
polymerase I or 5’ end-labelled using T4 polynucleotide kinase. DNA (40 ng) was 
incubated with 4 U of Klenow fragment and 50 /xCi of [a-32P] dGTP (>3000 
mCi/mmol) for 30 minutes at room temperature in 20 /xl final volume, containing 2 /x 1 
of 10 x Klenow labelling buffer, 50 /xM of unlabelled dATP, dCTP and dTTP. 
Alternatively, the same amount of DNA was incubated with T4 polynucleotide kinase 
(20U) and 50 /xCi of [y- 32P] ATP (>  3000 mCi/mmol) at 37°C for 30 minutes in 
20 /xl final volume containing 2 /xl of 10 x kinase buffer. In both cases after 30 
minutes, 10 /d of 50 mM EDTA was added and the mixture was incubated at 65°C for 
10 minutes to inactivate the enzyme. DNA was precipitated by adding 40 /xl of water, 
35 /d of 7.5 M ammonium acetate, 1 /xl of 1% linear polyacrylamide and 350 /xl of 
ethanol for one hour at -70°C and pelleted at 10,000 rpm for 15 minutes at 4°C. The 
pellet was resuspended in 300 /xl of 70% ethanol and centrifuged at 10,000 rpm for 15 
minutes at 4°C dried in vacuo and resuspended in 100 /xl. All centrifugations were 
performed in a bench-top microfuge.
The Spl oligonucleotide was labelled according to the instructions provided by Dr 
S.P.Jackson. 50 ng of one strand was incubated with 20 U of T4 polynucleotide 
kinase, 5 /xl of 10 x kinase buffer, 50 /xCi of [y-32P] ATP (>3000 mCi/mmol), made 
up to 50 /xl with water. After 45 minutes another 10 U of T4 polynucleotide kinase 
was added and the reaction allowed to proceed for a further 45 minutes at 37°C. Then 
250 /xl of 1 M ammonium acetate/0.1%SDS and 250 /xl of phenol/chloroform were 
added. The oligonucleotide was precipitated from the aqueous phase with ethanol for 
15 minutes on dry ice and pelleted by centrifugation for 15 minutes. The ammonium 
acetate/0.1% SDS, phenol/chloroform and ethanol precipitation steps were 
repeated. After a 70% ethanol wash, the pellet was dried. To this 75 ng of the other
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strand in 20 /d of TE was added and the strands were annealed by warming to 9CTC for 
two minutes and then allowed to cool slowly.
2.23 Gel retardation assay
2.23.1 CRE1 and kappa probes
The method employed was based on the procedure originally described by Fried and 
Crothers (1981). Nuclear extracts and labelled oligonucleotide probes were prepared as 
described previously. The binding reactions were carried out in 25 /zl and contained 
10 fig of nuclear extract in 5 /d of buffer C or CM or buffer D or DM, 0.05-0.2 ng 
of end-labelled DNA (approximately 20,000 cpm), 5 /d of 5 x DNA-binding buffer and 
0.25 fxg of poly dl-dC made up to 25 /d with water if the extract was prepared in 
buffers C or CM. However if the extract was prepared in buffer DM, the NaCl 
concentration was adjusted to that of C or CM (80 mM). Extracts prepared in buffer 
D did not have NaCl added to the binding reaction unless otherwise stated on the figure 
legends. Complexes were allowed to form during a twenty minute incubation at RT. 
Complexes were resolved from free probe by electrophoresis in 6 % native 
polyacrylamide gels. The gels were run in 0.5 x TBE, for 90 minutes at 4°C. Gels 
were fixed for 10 minutes in 10% v/v acetic acid, transferred to Whatman 3MM paper, 
dried under vacuum at 80°C for 30 minutes and exposed to X-ray film.
2.23.2 Spl probe
The binding conditions used for this oligonucleotide were as recommended by Dr 
S.P.Jackson. The binding reaction was carried out in 10 /d and contained 1 ng of 
probe, 0.5 fig of sonicated salmon sperm, 10 fig of nuclear extract and 6  fi\ of Spl 
DNA-binding buffer. When competitor DNA was used it was added before the probe. 
The reaction mixture was incubated for 15 minutes at 30°C without the probe and 
incubated for a further 15 minutes at 30°C with the labelled probe. The samples were 
loaded on a 6 % native polyacrylamide gel. The fixing and drying steps were performed 
as described previously.
2.24 DNA-protein crosslinking
The method employed was modified from that of Dorn et al. (1989). A standard gel 
retardation assay was run except the reaction volume was increased three-fold, the 
radio-labelled DNA was increased 40-fold, the poly[dI-dC] and the extract were 
increased three fold. The wet gel was exposed to X-ray film for several hours and the
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developed film was used to locate the DNA-protein complexes which were excised from 
the gel and incubated in 20 ml of formaldehyde solution at 4°C overnight on a rotary 
mixer. Crosslinked complexes were extracted from the gel by electroelution in 400 (A 
of 1 x TAE for three hours at 100 V. The 400 /d of TAE was divided equally between 
2  eppendorfs, to each was added 1 ml of cold acetone and 1 pil of linear polyacrylamide 
(as a carrier). After 1 hour at -70°C, the samples were spun for 15 minutes at 10,000 
rpm at 4°C. The pellets were washed in 70% ethanol and spun for a further 15 minutes 
at 10,000 rpm at 4°C. The pellets were dried and taken up in water, mixed with 
sample buffer and loaded onto a 15% SDS/polyacrylamide gel. [14C] methylated 
molecular weight markers were run alongside the samples.
2.25 Autoradiography
Dried gels were exposed to X-ray film for an appropriate length of time. For the 
detection of 32P a phosphotungstate intensifying screen was used and the autoradiograms 
were left at -70°C. Films were developed using an X-OGRAPH automatic developer.
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Chapter 3
Functional and Molecular Characterization of CRE2
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3.1 Introduction
Adl2-transformed cells have lower levels of MHC class I expression and higher levels 
of CRE2-binding factors (Ackrill and Blair, 1989) than cells transformed by Ad2 or 
Ad5. It has been proposed that CRE2-binding factors repress MHC class I transcription 
in Adl2-transformed cells (Ge et al., 1992), however the role of CRE2-binding factors 
in the control of class I transcription is still unclear. It was therefore decided to 
investigate the role of this sequence in transcriptional control in Ad-transformed cell 
lines by the use of an assay in which the transient expression of the reporter gene CAT 
is monitored. One copy of the oligonucleotide CRE2 (see table 2.1) was cloned into 
the vector pBLCAT2, in which the reporter gene CAT is under the control of the 
herpes simplex virus thymidine kinase basal promoter (Luckow and Schutz, 1987). 
Bacterial colonies containing recombinant plasmids were identified by colony 
hybridization with a CRE2 radio-labelled probe. The orientation of the CRE2 insert 
was determined by DNA sequencing. The recombinant plasmid in which one copy of 
the CRE2 insert was present in the forward orientation in the vector pBLCAT2 was 
termed pCRE2CAT. This plasmid and pBLCAT2 were transfected separately into Ad- 
transformed cell lines and the influence of the CRE2 sequence on transient CAT 
expression was evaluated. A plasmid in which CRE2 was inserted in the reverse 
orientation into pBLCAT2, termed pCRE2CATR, was used in DNase I footprinting in 
an attempt to elucidate the binding site for CRE2. The possible role of phosphorylation 
on CRE2 binding was investigated by the use of sodium fluoride in nuclear extract 
preparation, sodium fluoride being an activator of protein kinase C (PKC) as well as 
an inhibitor of phosphatases (Seifert & Schultz, 1991; Hewitt & Nicholas, 1963).
3.2 Cloning of CRE2 and the use of colony hybridization to detect colonies 
containing recombinant plasmid
The vector pBLCAT2 was digested with Bam HI and the CRE2 oligonucleotide was 
ligated into the vector. The ligation mixture was used to transform competent E.coli 
strain DH5a. The transformed bacteria were plated onto a LB plate containing 
ampicillin (100 ^g/ml). A nitrocellulose filter was placed on the transformation plate 
to make a mirror image of the pattern of colonies present on the plate. The filter was 
then used in colony hybridization with a CRE2 probe radio-labelled by T4 
polynucleotide kinase (Fig 3. la) and many of the colonies gave a strong signal. Twenty 
of the colonies which gave the strongest signal were picked and spotted onto both a 
second nitrocellulose filter and a master LB agar plate containing ampicillin (100 /ig/ml)
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Fig 3.1 Colony hybridization using the a radiolabelled CRE2 probe
The vector pBLCAT2 was digested with Bam HI and the CRE2 oligonucleotide was 
ligated into the vector. E.coli strain DH5a was transformed with the ligation mixture. 
Fig 3.1a: the transformed bacteria were plated onto a LB agar plate containing 
ampicillin (100 /xg/ml). A nitrocellulose filter was placed over the plate, the filter was 
then used in colony hybridization with the radio-labelled CRE2 probe. Fig 3. lb: twenty 
of the colonies which gave the strongest signal were picked and spotted onto a second 
filter and a master LB agar plate containing ampicillin (100 /xg/ml). The second filter 
was also hybridized to the radio-labelled CRE2 probe.
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(Fig 3.1b). The six colonies which gave the strongest signal were grown up in 10 ml 
of LB containing ampicillin (100 /d/ml) overnight and mini-preparations were made of 
the DNA.
3.3 Sequencing of the CRE2 insert in the vector dBLCAT2
DNA from the six mini-preparations chosen from the results of the colony hybridization 
were sequenced according to the method of Sanger et al. (1977) using a Pharmacia 
sequencing kit. One clone was obtained in which the CRE2 oligonucleotide was 
inserted in the forward orientation into the Bam HI site of the vector pBLCAT2. The 
plasmid was referred to as pCRE2CAT (Fig 3.2). This plasmid was used in CAT 
assays. Another of the six clones appeared to have the CRE2 sequence present in the 
reverse orientation (data not shown). The orientation of CRE2 in the vector was 
confirmed by sequencing reactions as described by Maxam and Gilbert (1980) The 
plasmid was referred to as pCRE2CATR; this plasmid was used for DNase I 
footprinting and Maxam and Gilbert G-specific sequencing reactions which were run 
alongside the DNase I footprint (Fig 3.3, lane 8 ).
3.4 Investigation of the functional role of the CRE2 region bv CAT assays
The CAT assay is a transient expression assay used to investigate the functional role of 
specific DNA sequences. The CAT gene is a bacterial gene and there is no endogenous 
CAT activity present in eukaryotic cells. The CAT enzyme can be monitored by a 
sensitive assay which can be used to demonstrate the properties of sequences which act 
as enhancers, repressors or promoters. The latter require different vectors from those 
required for enhancers or repressors. Vectors to test promoters have no promoter 
region placed upstream of the CAT reporter gene, whereas in vectors designed to test 
enhancers or repressors a weak promoter is present. This was the case for the vector 
used in this study, pBLCAT2, which has the basal promoter of the herpes simplex virus 
thymidine kinase gene present (Luckow and Schutz, 1987).
In this study the plasmids pBLCAT2 and pCRE2CAT were transfected separately into 
Ad-transformed cell lines by calcium phosphate-mediated transfection. Cellular extracts 
were prepared approximately 40 hours after transfection. Depending on the rate of 
transcription from the CAT gene, these extracts would contain varying amounts of the 
bacterial enzyme CAT. This enzyme can convert [14C] chloramphenicol to its 
acetylated forms. In order to determine the amount of CAT enzyme activity present in
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Fig 3.2 Sequencing of the CRE2 insert in the plasmid pCRE2CAT
The CRE2 oligonucleotide is shown to be inserted in the forward orientation in the 
Bam HI site of pBLCAT2, creating the vector pCRE2CAT. The sequence in bold is 
that of the CRE2 insert, the pBLCAT2 sequence surrounding the Bam HI site is in 
italics.
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Fig 3.3 DNase I footprint of the CRE2 binding in 5A12 nuclear extracts
Lane 1: no protein, lane 2-6: 9, 18, 45, 90, 180 g of nuclear extract, lane 7: 180 fig 
of nuclear extract and a 100-fold excess of unlabelled CRE2, lane 8 : G-specific 
sequencing reactions. The CRE2 oligonucleotide sequence is shown to the right of 
lane 8  in bold, the pBLCAT2 sequence surrounding the Bam HI insert is shown in 
italics. The region of protection is shown to the left of lane 1.
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individual cellular extracts from the transfected cells, a fixed amount of cellular extract 
was incubated with a fixed amount of [14C] chloramphenicol and acetyl CoA (as a 
source of acetyl groups). After the incubation period the acetylated and unacetylated 
forms of [14C] chloramphenicol were extracted and spotted onto thin layer 
chromatography (TLC) plates. The acetylated forms were separated from the 
unacetylated form by thin layer chromatography as the acetylated forms migrate further 
(compare the positions of c and d with that of b in Fig 3.4). The radioactivity 
associated with the acetylated and unacetylated forms was counted and used to calculate 
the % conversion as a measure of CAT activity. Although % conversion gives a more 
accurate measure of CAT activity, an indication of this activity can be obtained from 
observing the intensity of the spots corresponding to the acetylated forms. The more 
CAT enzyme present, the more [14C] chloramphenicol would be converted and so the 
spots corresponding to the acetylated forms would be more intense. Conversely, the 
presence of less CAT enzyme would be associated with less intense spots corresponding 
to the acetylated forms. Since enhancers increase CAT gene transcription which in turn 
has been shown to correlate with CAT enzyme activity (Latchman, 1993), the CAT 
assay gives a measure of enhancer activity. Repressors reduce CAT gene expression 
and, because of the direct correlation to CAT enzyme activity, CAT assays can also be 
used to detect repressor function.
Fig 3.4 shows a typical CAT assay result comparing the CAT activity in extracts from 
5A12 cells transfected either with pBLCAT2 or pCRE2CAT. Extracts from cells 
transfected by pCRE2CAT did not show significantly altered CAT activity compared 
to those from cells transfected by the vector pBLCAT2. Fig 3.5 summarizes the CAT 
assay results obtained in four cell lines: 5A12, RFC-1, BMK and Ad5Xho. The 
presence of the CRE2 sequence was not associated with strong enhancer or repressor 
activity in any of the cell lines tested. However in RFC-1 and Ad5Xho, it did appear 
to repress CAT activity to some degree.
3.5 DNase I footprinting of the binding site for CRE2-specific DNA-binding 
factor(s)
DNase I footprinting is based on the cleavage of DNA molecules by this enzyme. The 
DNA of interest is radioactively labelled at one end of one of the two strands. It is 
necessary to establish conditions which produce limited cleavage for fragments to be 
present over the full range of sizes from full-length to a few bps. If too much cleavage
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Fig 3.4 The CAT activity present in extracts from 5A12 cells transfected with either 
PCRE2CAT or pBLCAT2
Extracts were prepared from 5 A12 cells transfected with either 15 jug of pBLCAT2 or 
15 ng of pCRE2CAT. An aliquot of cell extract corresponding to 150 jLtg was mixed 
with 8  (200 /xCi) of [14C] chloramphenicol and 40 of acetyl CoA (5 mg/ml) and
incubated overnight. The acetylated and unacetylated forms of [14C] chloramphenicol 
were extracted and spotted onto a TLC plate at position a, b represents the position of 
the unacetylated and c/d represent the positions of the acetylated forms.
Lane 1: extract from cells transfected with pBLCAT2, lane 2: extract from cells 
transfected with pCRE2CAT.
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Fig 3.5 Expression of the pCRE2CAT and pBLCAT2 plasmids in Ad-transformed 
cells
The CAT activity of extracts from cells transfected by the vector pBLCAT2 is 
presented as 100 and that of extracts from cells transfected by pCRE2CAT is presented 
relative to it. Results are shown for four cell lines: 5A12, RFC-1, BMK and Ad5Xho. 
Each column represents the average of at least 3 separate experiments. The^  runo  ^of
Volue.  ^ <aro_ shown.
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occurs all the fragments will be small and if too little, the smaller fragments will not 
be properly represented. These fragments can be separated by gel electrophoresis to 
form a ladder of bands with each band in the ladder differing from the next by one 
nucleotide. Maxam and Gilbert sequencing reactions can be performed on the same 
radio-labelled DNA fragment. These reactions cut the DNA into a series of fragments 
each terminating in a specific nucleotide or nucleotides, for example, G or G+A. 
When Maxam and Gilbert sequencing reactions are run alongside DNase I cleavage 
products, the identity of the terminal nucleotide of the cleavage product can be 
ascertained. If the DNA is complexed to protein(s), for example from a nuclear 
extract, prior to being treated with the cleavage agent, DNase I, the nucleotides to 
which the protein is bound will be protected from cleavage. Fragments of a particular 
length will not be formed, resulting in a gap in the DNA ladder; this region is called 
a footprint and represents the region of DNA protected from cleavage by bound protein. 
If the protein does not completely hinder DNase I cleavage of a particular region, a site 
of partial protection will be created in which the radioactive bands have not completely 
disappeared but are of reduced intensity.
The non-coding strand of the Eco RI-Hind III fragment of pCRE2CATR was radio­
labelled using the Klenow fragment for DNase I footprinting and Maxam and Gilbert 
sequencing reactions. A titration was performed to ascertain the correct conditions to 
obtain a full range of cleavage product sizes. DNase I was used at a final concentration 
of 0.8-32 fig!ml; 6 fig/m\ was found to give the best cleavage pattern (data not shown). 
The non-coding vector sequence in this fragment contains the coding strand of CRE2 
as shown by the G-specific sequencing reactions shown in lane 8 of Fig 3.3. Lanes 1 
to 7 show DNase I footprinting of this fragment in the absence of nuclear extracts and 
in the presence of increasing amounts of 5A12 nuclear extracts (from 9 to 180 fig). A 
region of protection between -180 and -201 was evident with 180 fig of nuclear extract 
(lane 6). Some degree of protection began with 18 fig of nuclear extract (lane 3) and 
the size of the footprint enlarged with increasing amounts of nuclear extract up to 180 
fig (lane 6). The protection seen with 180 fig was not complete throughout region II. 
The section of best protection covered the sequence AGGTCA between -197 and -192, 
this is the conserved sequence present in the ER/TR subfamily of hormone receptors 
that includes RXR13/H-2RIIBP. The protection was lost in the presence of excess 
unlabelled CRE2 (lane 7) which indicates that the protection observed was due to 
specific binding to CRE2.
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3.6 The effect of sodium fluoride in the preparation of nuclear extracts on
CRE2-binding activity
Sodium fluoride is an inhibitor of phosphatases and an activator of PKC (Seifert and 
Schultz, 1991; Hewitt and Nicholas, 1963). Nuclear extracts prepared in the presence 
of sodium fluoride therefore contain proteins in a more phosphorylated state, so the 
effect of phosphorylation on CRE2-binding can be investigated. 5A12 nuclear extracts 
were prepared by MDPI with and without 10 mM sodium fluoride in buffers A, C and 
D. The use of sodium fluoride in the preparation of extracts caused intensification of 
one binding activity and the appearance of the second of slower mobility (compare lanes 
1 and 3 in Fig 3.6).
3.7 Discussion
The functional properties of CRE2-binding proteins were studied using CAT assays in 
which a single copy of the CRE2 sequence was placed upstream of the CAT reporter 
gene in the plasmid pBLCAT2. The binding site of CRE2-specific binding factors was 
analysed by DNase I footprinting. The influence of phosphorylation on binding was 
investigated by preparation of extracts in the presence and absence of sodium fluoride.
It has been proposed that a region of the class I promoter approximately equivalent to 
CRE2, termed R2, acts as a repressor of MHC class I transcription in 
Adl2-transformed cells but not in Ad5-transformed cells and this difference in repressor 
activity accounts, at least in part, for the higher levels of MHC class I expression found 
in Ad5-transformed cells (Kralli et al., 1992; Ge et al., 1992). The tissue distribution 
of CRE2-binding also suggests a negative role for factors binding to this sequence; 
CRE2-binding factors is higher in Adl2- than Ad5-transformed cell lines (Ackrill and 
Blair, 1989; Ge et al., 1992). Burke et al. (1989) found high levels of CRE2-binding 
activity in the brain and in the early stages of gestation when MHC class I antigens are 
undetectable. In this study the role of CRE2-binding factors was investigated by the 
transient CAT expression assay in cells transformed by Ad2, Ad5, Adl2 or recombinant 
virus. In two cell lines termed 5A12 and 5B12, the transforming agent was Adl2 
E1A/Ad5 E1B and Ad5 E1A/Adl2 E1B respectively. Because of this, the cell lines 
used in this study will be described as Ad2, Ad5 or Ad 12 El A expressing cells. Four 
cell lines were chosen which expressed Ad 12 El A and four were chosen which 
expressed either Ad2 or Ad5 El A. A single copy of CRE2 was placed upstream of the
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Fig 3.6 The effect of sodium fluoride in the preparation of nuclear extracts on 
CRE2-binding activity
5 A12 nuclear extracts were prepared by method MDP1 with (lane 1 and 2) or without 
(lane 3 and 4) 10 mM sodium fluoride. Lane 2 and 4 contained 100-fold excess of 
unlabelled CRE2. A CRE2 radiolabelled probe was used.
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CAT reporter gene in pBLCAT2 creating the construct pCRE2CAT. The CAT assays 
did not show CRE2 to greatly influence CAT activity when pCRE2CAT was compared 
to pBLCAT2. In two of the four cell lines tested, RFC-1 and Ad5Xho, it was 
associated with a small degree of repression. The results of Ge et al. (1992) and Kralli 
et al. (1992) could explain why CRE2 was not found to have a strong repressor function 
in this study. They could only demonstrate a weak repressor function for R2 (the 
sequence of which is virtually identical to CRE2) in Adl2-transformed cells, when a 
tetramer of this sequence was cloned in front of a H-2Kb minimal promoter or the 
thymidine kinase (TK) promoter taken from the vector pBLCAT2. However, the R2 
sequence did appear to repress R1 activation (a sequence virtually identical to CRE1) 
in Adl2- but not Ad5-transformed cells. To demonstrate this effect R1 and MR1 were 
used, the latter being a mutated version of R1 which did not bind transcription factors. 
The cassettes R22R12 and MR22R12 were used, cloned as one, two or four copies 
upstream of the H-2Kb minimal promoter. MR22R12 and R22R12 showed increased 
transcriptional activity as the number of copies increased from one to four in Ad5- 
transformed cells, whereas only the former showed an increase in transcriptional 
activity with increased copy number in Adl2-transformed cells suggesting the sequence 
R2 represses R1 activation in Adl2- but not in Ad5-transformed cells. There was no 
difference in CAT activity associated with a single copy of MR22R 12 or R22R12 in 
either Adl2 or Ad5 cells. If these results are generally valid, the repressor function 
of R2/CRE2 would not be expected to be demonstrated using the experimental design 
adopted in this study, firstly because R1 is required to be present and secondly because 
both R1 and R2 need to be present in multiple copies. R2 appears to need to be 
adjacent to R1 to repress R1 induced activation; Kralli et al. (1992) suggest that factors 
binding to R2 could prevent proteins binding to Rl. In the MHC class I promoter R1 
and R2 do exist as adjacent sequences so transcription factors binding to one sequence 
would have the opportunity to interact with factors binding to the adjacent sequence. 
It is unclear why multiple copies of Rl and R2 should be required as this situation does 
not exist in the MHC class I promoter. R2/CRE2 sequence has been reported to act 
as an enhancer; Kralli et al. (1992) report that retinoic acid treatment causes this 
sequence to no longer act as a repressor. It seems likely that R2/CRE2 can have 
different roles in transcriptional control depending upon the presence or absence of 
agents such as retinoic acid.
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The coding strand of the CRE2 oligonucleotide was footprinted using 5A12 nuclear 
extracts. The region of protection which was visible between -201 and -180, increased 
with increasing amounts of nuclear extract from 9 to 180 ^g. The protection was not 
complete within this region and was best between -197 and -192 which covers the 
sequence AGGTCA, the conserved sequence present at the binding site for 
RXR/3/H-2RIIBP and other members of the ER/TR subfamily of steroid/thyroid 
hormone receptors. Since this is a conserved sequence one would expect binding to 
occur to this sequence. The protection shown is unlikely to be due to non-specific 
binding because in the presence of an excess of the CRE2 oligonucleotide the protection 
disappears. Methylation interference has been performed on the coding strand of CRE2 
(Griffiths, 1992) using 5A12, Hela and rat brain extracts, and on a similar sequence 
referred to as region II (Shirayoshi et al., 1987). Griffiths (1992) found the eight G 
residues between -200 and -188 to be protected. Shirayoshi et al. (1987) used the H- 
2Ld region II sequence and LH8  lymphocyte line and found protection at G residues 
between -200, and -190 (equivalent to between residues -198 and -188 in the H-2Kb 
sequence). The precise sequence protected was different in the various cell types; this 
could reflect the presence of different binding factors found in these cells. Shirayoshi 
et al. (1987) found mutant oligonucleotides with mutations in the G residues at -198, - 
197, -192 and -191 were unable to compete for wildtype binding further demonstrating 
the importance of these G residues. Griffiths (1992) confirmed these results using 
oligonucleotides with mutations to the equivalent G residues in the H-2Kb sequence.
The result shown here with DNase I footprinting suggest a larger area of binding than 
that found by methylation interference with the same extract. This is not unexpected 
as DNase I is a large molecule; because of this it not only is prevented from cutting 
DNA at the site where protein is bound to DNA, but also it is too large to reach the 
bases adjacent to the binding site. For this reason, it tends to overestimate the size of 
the binding site. Another disadvantage of DNase I is that it cuts preferentially at 
certain sites and at sites of poor cutting it is not possible to tell if protection has 
occurred.
Overall, more detailed results about the binding site of transcription factors can be 
obtained by methylation interference, although this method has the disadvantage of only 
giving information about G residues. DNase I footprinting, methylation interference 
and competition analysis with mutant oligonucleotides all suggest the conserved
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sequence AGGTCA to be an important part of the binding site for CRE2-specific 
binding factors.
Sodium fluoride was shown to have a marked effect on the binding pattern obtained by 
gel retardation. It caused intensification of a band already present in the absence of 
sodium fluoride and the appearance of a second fainter band of slower mobility. 
Sodium fluoride acts as a phosphatase inhibitor and it is also an activator of protein 
kinase C (PKC) (Chabre, 1990; Seifert and Schultz, 1991). As a result of these 
properties, certain proteins of extracts prepared in the presence of sodium fluoride are 
more likely to be phosphorylated than those from extracts prepared in the absence of 
sodium fluoride. This suggests that the phosphorylation of certain proteins, possibly 
CRE2-binding proteins themselves, could lead to their enhanced binding to this DNA- 
binding motif. Work by Griffiths (1992) supplied further evidence for the potential role 
of phosphorylation in CRE2-factor binding; it was found that the binding activity 
disappeared when extracts were treated with potato acid phosphatase and binding was 
restored when extracts were treated with protein kinase A.
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4.1 Introduction
As described previously, Adl2-transformed cells have reduced MHC class I expression 
compared to cells transformed by Ad2 or Ad5 (Schrier et al., 1983; Eager et al., 1985). 
Although some researchers have suggested that this difference might be due to 
differences in the levels of CRE2-binding factors (Ackrill and Blair, 1989; Ge et al., 
1992), others have suggested that the lowered level of class I expression is due to 
reduced NF-/cB binding (Nielsch et al., 1991) or reduced NF-kB and H2TF1 binding 
in Adl2-transformed cells (Meijer et al., 1992). Both these factors bind to a region 
called region I (Shirayoshi et al., 1987) or CRE1 (Ackrill and Blair, 1989). It was 
decided to investigate the functional role of this sequence in Ad-transformed cells by 
the use of CAT assays. Two oligonucleotides were used: CRE1 and mCREl, the latter 
had mutations (Table 2.1) which have been shown to prevent transcription factor 
binding (Shirayoshi et al.,1987).
A single copy of the CRE1 or mCREl sequence was cloned into the vector pBLCAT2. 
The orientation of the insert in either case was determined by sequencing. The plasmid 
in which one copy of CRE1 was present in the forward orientation in the vector 
pBLCAT2 was termed pCRElCAT, similarly the plasmid pmCRElCAT contained a 
single copy of mCREl. These plasmids and pBLCAT2 were transfected separately into 
Ad-transformed cell lines and the influence of CRE1 and mCREl sequence on transient 
CAT expression was investigated.
4.2 Cloning the CRE1 and mCREl oligonucleotides into the vector pBLCAT2
These two oligonucleotides were cloned into pBLCAT2 in exactly the same manner as 
CRE2. In cloning the CRE2 oligonucleotide in pBLCAT2 (Chapter 3), a large number 
of bacterial colonies was found by colony hybridization to contain recombinant 
plasmids, therefore it was decided that this step could be omitted. Several colonies of 
transformants were chosen at random and grown up overnight in 10 ml of LB/ampicillin 
(100 f i g / ml) and mini-preparations of DNA were made the following day.
4.3 Sequencing of the CRE1 and mCREl inserts in plasmids pCRElCAT and 
pmCRElCAT
The minipreparations of DNA from colonies of E.coli DH5a transformed by 
CREl/pBLCAT2 ligation mix were sequenced and one was found which had the CRE1 
oligonucleotide present in the forward orientation. Similarly the minipreparations of
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DNA from colonies of E.coli DH5a transformed by mCREl/pBLCAT2 ligation mix 
were sequenced and one was obtained which had the mCRE2 oligonucleotide present 
in the forward orientation. The sequences of the CRE1 and mCREl oligonucleotides 
are shown in table 2.1, these oligonucleotides have Bam HI/Bgl II compatible ends. 
Fig 4.1a shows the CRE1 oligonucleotide inserted in the forward orientation in the 
Bam HI site of the vector pBLCAT2, creating pCRElCAT. Fig 4.1b shows the 
mCREl oligonucleotide inserted in the forward orientation in the Bam HI site of 
pBLCAT2, creating pmCRElCAT.
4.4 Investigation of the functional role of CRE1 using plasmids pCRElCAT. 
pmCREl and pBLCAT2 in CAT assays
Fig 4.2 shows a typical CAT assay result in which transient expression directed by 
plasmids pCRElCAT and pmCRElCAT was compared to that directed by the vector 
pBLCAT2 using 5A12 cell extracts. There was little difference in the CAT activity in 
extracts from cells transfected with pCRElCAT compared to extracts from cells 
transfected with pBLCAT2, whereas extracts from cells transfected with pmCRElCAT 
had significantly reduced CAT activity. Fig 4.3 summarizes the CAT assay results 
obtained in four cell lines: 5A12, RFC-1, BMK and Ad5Xho. The transient expression 
of CAT directed by plasmids pCRElCAT was approximately equivalent to that directed 
by pBLCAT2 in 5A12 and RFC-1 (Fig 4.3a) whereas it was slightly less than that 
directed by pBLCAT2 in BMK and Ad5Xho. The CAT activity driven by 
pmCRElCAT was below 40% of that directed by the vector pBLCAT2 in all the cell 
lines tested (Fig 4.3b).
4.5 Discussion
It is possible that the reduced levels of MHC class I in Adl2-transformed cells 
compared to Ad2- or Ad5-transformed cells could reflect a reduced functioning of an 
enhancer in the former. CRE1 is a likely candidate for such an enhancer, as multiple 
copies of this sequence have been shown to enhance CAT expression (Mauxion and 
Sen, 1989; Kralli et al., 1992). In this study the functional properties of CREl-binding 
factors was investigated by the transient CAT expression assay system in cells 
transformed by Ad2, Ad5, Adl2 or recombinant virus. Four cell lines expressed Ad2 
or Ad5 E1A and four expressed Adl2 E1A. A single copy of the CRE1 sequence was 
placed upstream of the CAT reporter gene in the plasmid pBLCAT2 to create the 
construct pCRElCAT. A mutant CRE1, containing mutations that inhibit CRE1-
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Fig 4.1 Sequencing of pCRElCAT and pmCRElCAT
The sequence of the CRE1 and the mCREl inserts are shown in Fig 4.1a. and 
Fig 4.1b. respectively. In each case the sequence in bold is that of the insert and the 
surrounding sequence which is that of the vector pBLCAT2 around the Bam HI site is 
shown in italics.
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Fig 4.2 The CAT activity in extracts of 5A12 cells transfected with the vector 
pBLCAT2 or one of the constructs pCRElCAT or pmCRElCAT
Extracts were prepared from 5A12 cells transfected with one of the following: 15 fig 
of pBLCAT2, 15 fig of pCRElCAT or 15 fig of pmCRElCAT. An aliquot of cell 
extract corresponding to 150 fig of protein was mixed with 8  fil (200 fiCi) of [14C] 
chloramphenicol and 40 fil of acetyl CoA (5 mg/ml) and incubated overnight. The 
acetylated and unacetylated forms of [14C] chloramphenicol were separated by TLC. 
Lane 1: extracts from cells transfected with pBLCAT2, lane 2: extracts from cells 
transfected with pCRElCAT and lane 3: extracts from cells transfected with 
pmCRElCAT.
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Fig 4.3 Expression of plasmids pBLCAT2. pCRElCAT and pmCRElCAT in 
Ad-transformed cells
The CAT activity detected in extracts from cells transfected with the vector pBLCAT2 
was assigned a value of 1 0 0  and those from extracts of cells transfected with 
pCRElCAT or pmCRElCAT are presented relative to it in Figs 4.3a and 4.3b
respectively. Results are presented for four cell lines: 5A12, RFC-1, BMK and
Ad5Xho. Each column represents the average of at least 3 separate experiments.
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binding was also cloned into the same vector. The CAT activity of the two constructs 
was compared with that of the vector alone.
The CRE1 sequence was not shown to have enhancer activity. It is possible that the 
sequence did not demonstrate enhancer activity because it was present only as a single 
copy and multiple copies are necessary to demonstrate its activity. However, Meijer 
et al. (1992) showed enhancer activity in certain circumstances using a single copy of 
a sequence virtually identical to CRE1 which they called H2TF1. They found a single 
copy of this sequence was associated with enhancer activity in cells transformed by 
Adl2 12S E1A but not by Adl2 13S E1A. In this study cell lines expressing both the 
12S and 13S products of Adl2 or Ad5 were studied. The different cell systems used 
make comparison between this study and that of Meijer et al. (1992) difficult.
mCRElCAT was found to be associated with reduced CAT activity compared to the 
vector alone. Meijer et al (1992) obtained similar results with a mutated form of 
H2TF1; reasons for this effect are not known.
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Chapter 5
Production and characterization of an antibody to the 
C-terminal peptide of the NF-kB p50 subunit
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5.1 Introduction
There are two premises to the theory that CREl-binding proteins are involved in 
causing the down-regulation of MHC class I in Adl2-transformed cells compared to 
cells transformed by Ad2 or Ad5. Firstly, that such proteins act to enhance 
transcription; this was investigated in the previous chapter. Secondly, that such proteins 
are more abundant in the nucleus in Ad2- or Ad5-transformed cell lines than in 
Adl2-transformed cell lines (nuclear localization is required for such proteins to be 
transcriptionally active).
The levels of CREl-binding factors in the nucleus could be investigated by various 
approaches, the most commonly used being that of gel retardation using nuclear 
extracts; this method will be described in a later chapter. Another approach would be 
to use an antibody to a known CREl-binding factor and investigate the presence of this 
factor in nuclear extracts by Western blotting. Dr R. Hay donated three antibodies to 
the p50 subunit of NF-kB; to the C-terminus, the N-terminus and the DNA-binding 
domain. However, because limited amounts were provided, it was decided to produce 
our own antibody. An anti-peptide antibody was chosen as peptide synthesis facilities 
were available. The antibody was made to the C-terminal peptide as it binds more 
specifically to NF-kB as compared to antibody to the N-terminal peptide. The antibody 
produced to the C-terminal domain was used to investigate the levels of p50 in Ad- 
transformed cells. These results will be discussed later in relation to the results 
obtained by gel retardations with the CRE1 probe and with the kappa probe. In this 
chapter the production of an antibody to the C-terminal peptide of NF-kB p50 will be 
described, followed by a section on its characterization by ELISA and Western blotting 
alongside the antibodies to NF-kB provided by Dr R. Hay and the c-rel antibody 
provided by Dr P. Enrietto.
5.2 Coupling of the peptide to a carrier
5.2.1 Removal of DTT from reduced peptide by use of a Sephadex G-10 column 
The peptide/DTT mix was added to a Sephadex G-10 column and the column was 
eluted with 0.1 M sodium phosphate buffer pH 6.0. Fractions (1 ml) were collected 
and the Ellman’s test was performed on 20 fil of each fraction and the absorbance was 
read at 412 nm . As shown in Fig 5.1, most of the peptide was eluted in fractions 4 
to 6  and the DTT eluted later, mainly in fractions 10 to 14. Fractions 4, 5 and 6  were 
retained for mixing with the activated PPD.
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Fig 5.1 Removal of excess DTT from reduced peptide bv use of a Sephadex G-10
column
Fractions (1 ml) were collected from a Sephadex G-10 column, eluted with 0.1 M 
sodium phosphate, pH 6.0. The Ellman’s test was performed on 20 /d of each fraction 
and the absorbance was measured at 412 nm. The results are plotted as fraction 
number versus absorbance reading at 412 nm.
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5.2.2 Removal of SMCC from activated PPD using a Sephadex G-25 column
The activated PPD/SMCC mix was added to a Sephadex G-25 column and eluted with 
50 mM sodium phosphate buffer pH 6.0. Fractions (1 ml) were collected and 
absorbance was read at 280 nm. From the absorbance readings, Fig 5.2, it can be seen 
that the activated PPD (which elutes first) appeared between fractions 13 and 19, mainly 
in fractions 15, 16 and 17. These three fractions were mixed with the reduced peptide. 
The SMCC eluted later in fractions 28 to 38.
5.3 ELISA results
The ELISA was used to detect whether the antisera raised in the two rabbits, termed 
A and B, bound to the peptide to which they were raised when the peptide was itself 
attached to an ELISA plate. Information about the specificity of the reaction was 
obtained when conditions were included in which either the antiserum or the peptide 
were absent. Further information on the specificity of the antibody reaction was 
obtained by use of an unrelated peptide. The ELISA was also used to calculate the 
titres of the antibody response in the two rabbits 1 0  days after the initial injection with 
the PPD-peptide conjugate and 10 days after subsequent boosts.
Figs 5.3 and 5.4 show the ELISA results obtained with rabbits A and B respectively. 
Both figures show that negligible absorbance readings were obtained for the pre-immune 
sera at all the dilutions used. Readings not significantly different from those obtained 
for the pre-immune sera were found for both rabbits for wells incubated with the p50 
peptide but having no contact with serum and for wells which had no contact with either 
serum or peptide (Table 5.1). Negligible readings were obtained when serum taken 10 
days after the second boost from rabbit B was used with wells coated with an unrelated 
peptide (which forms part of the 5/6 loop of the human neurokinin-2 receptor), or when 
such serum was pre-incubated with the p50 peptide (Table 5.1). The same serum did 
produce a strong reaction if not pre-incubated with p50 peptide and used in wells coated 
with the p50 peptide. In the case of rabbit A the highest titre was obtained after the 
third boost (15,000). The titre increased from 2,200 after the initial injection to 10,000 
following the first boost and to 11,500 following the second boost. For rabbit B the 
highest titre appeared after the first boost (29,000). The titre rose from 9,000 following 
the initial injection, peaked with the first boost, reduced to 17,000 after the second 
boost and dropped to 7,000 following the third boost.
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Fig 5.2 Removal of SMCC from activated PPD by use of a Sephadex G-25 column
Fractions (1 ml) were collected from a Sephadex G-25 column, eluted with 50 mM 
sodium phosphate buffer, pH 6.0. The absorbance at 280 nm of each fraction was 
read. The results are plotted as fraction number versus absorbance reading at 280 nm.
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Fig 5.3 Levels of antibody against the C-terminal peptide of p50 in the serum of
rabbit A
The results are presented as -log dilutions verus absorbance readings at 490 nm for: 
pre-immune (O-O),  first injection (□ -□ ) , first boost (a -a ), second boost ( a - a )  and 
third boost (o-o). The titres are calculated from the graph as the dilution (derived from 
-log dilution) which corresponds to 50% of the maximal O.D, as shown by the dotted 
lines.
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Fig 5.4 Levels of antibody against the C-terminal peptide of p50 in the serum of
rabbit B
The results are presented as -log dilutions versus absorbance readings at 490 nm for: 
pre-immune (O-O),  first injection (□ -□ ) , first boost (a -a ), second boost ( a - a )  and 
third boost (o-o). The titres are calculated from the graph as the dilutnDD(derived from 
-log dilution) which corresponds to 50% of the maximal absorbance, as shown by the 
dotted lines.
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Table 5.1 ELISA results for rabbits A and B
Table A shows the ELISA results for rabbit A for pre-immune serum, and for wells 
coated with p50 peptide but no serum or for wells which were neither coated with 
peptide or treated with serum.
Table B shows the ELISA results for rabbit B for all the conditions described in table 
A for rabbit A, also included in table B are the results for wells treated with p50 
peptide and serum taken 1 0  days after the second boost and a repeat of this condition 
with the exception that the serum was pre-incubated with p50 peptide. The final 
condition included in the table consists of wells coated with the neurokinin- 2  receptor 
peptide and serum taken 1 0  days after the second boost.
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5.4 Western Blotting using antisera from rabbits A and B raised to the
C-terminal peptide of p50 as compared to other p 50 and c-rel antisera 
Fig 5.5 shows that for rabbit A a protein of approximately 6 8  kDa reacted weakly with 
the immune serum (lane 2) but not with the pre-immune serum (lane 1). The binding 
of antibody to the 6 8  kDa protein was not blocked when the immune serum was pre- 
incubated with 50 fig of the peptide to which the antiserum was raised (lane 3). The 
immune serum of rabbit A reacted weakly with a second protein at 55 kDa (lane 2) 
which did not react with the pre-immune serum (lane 1). The binding of antibody to 
this 55 kDa protein was partially blocked by pre-incubation of serum with 50 fig of the 
C-terminal peptide (lane 3). A protein of approximately 55 kDa also reacted with the 
immune serum of rabbit B (lane 5) but not with the pre-immune serum (lane 4). The 
reaction appeared much stronger than for rabbit A serum. The binding of antibody to 
the 55 kDa protein was almost completely blocked when the immune serum was pre- 
incubated with 50 fig of peptide (lane 6 ). A protein of apparently the same molecular 
weight also bound to three other antisera raised to p50, these were the antisera donated 
by Dr R. Hay to the C-terminal peptide (lane 7), the N-terminal peptide (lane 8 ) and 
the DNA-binding domain (lane 9). They were all used at 1 in 100 dilution, as 
recommended. At this dilution they all gave high background, in fact only for the 
DNA-binding domain antiserum was the strongest binding reaction with the 55 kDa 
protein. The protein of this size only reacted weakly with the C-terminal peptide 
antiserum. Four proteins clearly reacted with the N-terminal peptide antibody, one of 
which was approximately 100 kDa; a protein of the same size also reacted with the c-rel 
antiserum (lane 1 0 ).
5.5 Discussion
It was decided to generate an antibody to the C-terminal peptide of p50. Two peptides 
of 12 and 13 amino-acids were synthesized (with and without a terminal cysteine used 
to crosslink the peptide to a carrier). In general, it is uncommon for amino-acids of 
these lengths to be immunogenic (Lachmann et al., 1986). Normally peptides of these 
length are considered haptens, incapable of eliciting an immune response alone, they 
need to be linked to a carrier. The carrier elicits a T-cell response which, by some 
poorly understood mechanism, activates a B-cell response and subsequent antibody 
production to the hapten. It was decided to use PPD as the carrier as it is an unusually 
powerful T-cell antigen, it gives a T-cell mediated delayed-type hypersensitivity (DTH) 
in animals which have previously encountered the tubercle bacillus, for example, as a
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Fig 5.5 Western blotting of rabbit A and rabbit B antisera raised to C-terminal peptide
of p50 as compared with antiserum to c-rel and three p50 antisera
Adl2#l nuclear extracts prepared by method MDP3 were used for Western blotting. 
Antisera from rabbit A were used in lanes 1-3, antisera from rabbit B were used in 
lanes 4-6. Lanes 1 and 4 were with pre-immune antisera. Lanes 2, 3, 5 and 6  were 
with antisera taken 10 days after the second boost. The antisera used in lanes 3 and 6  
were pre-incubated for 1 hour with 50 fig of peptide to the C-terminal of p50. Lanes 
7-9 were with p50 antibodies provided by Dr R Hay; lane 7 was with antiserum to the 
C-terminal peptide of p50, lane 8  was with antiserum to the N-terminal of p50 and lane 
9 was with antiserum to the DNA-binding domain of p50. Antiserum to c-rel provided 
by Dr P. Enrietto was used in lane 10. Antisera from rabbits A and B were used at 
1 in 1 0 0 0  dilution, where as other antisera were used at 1 in 1 0 0  dilution.
130
result of immunization with Bacillus Calmette-Guerin (BCG) (Lachmann et al., 1986). 
For this reason the rabbits were initially inoculated with BCG before the first injection 
with PPD-peptide conjugate. PPD is prepared from the culture supernatants of 
Mycobacterium tuberculosis by ultrafiltration, heating to 100°C and precipitation of 
protein with trichloroacetic acid (Seibert, 1940). Another advantage of PPD is that it 
is does not cause antibody production to itself (Lachmann et al., 1986).
The stages in the preparation of the peptide-PPD conjugate involved the use of two 
Sephadex columns. The G-10 column was eluted to give two well separated peaks 
when absorbance at 412 nm was plotted against fraction number from the results of the 
Ellman’s test, showing the DTT was effectively removed from the reduced peptide. 
Removal of the DTT was necessary to allow formation of a disulphide bond between 
the reduced peptide and the activated PPD. Elution of the G-25 column also gave two 
well-defined peaks when absorbance at 280 nm was plotted against fraction number, 
demonstrating the clear separation of activated PPD from excess SMCC.
The ELISA results showed that both rabbits did not contain antibody in the pre-immune 
sera which reacted with the p50 C-terminal peptide; readings for the pre-immune serum 
at all dilutions were as low as for wells treated with p50 peptide but having no contact 
with serum, and almost as low as for wells which received neither peptide or serum. 
High titres were obtained with both rabbits with the immune serum and the p50 peptide.
For both, the titres increased from serum taken 10 days after the first injection with 
the peptide/PPD conjugate to serum taken 10 days after the first boost. One month 
before the initial injection with the peptide/PPD conjugate, the rabbits were injected 
with BCG, a potent stimulator of T- and B-cells and macrophages. The BCG enhanced 
the initial response to the peptide/PPD conjugate. In the initial response there would 
have been clonal proliferation of the B-cells which had epitopes for the p50 peptide 
under the influence of T-cells activated by PPD. Memory B-cells specific for the p50 
peptide would have been produced as part of the primary response. Some of these 
memory cells would have been stimulated to proliferate and produce antibody upon each 
subsequent contact with peptide. Memory B-cells are more sensitive to antigenic 
triggering, have higher affinity for antigen and respond more effectively to T-cell help 
(Roitt, 1988). Consequently, the secondary response was greater than the primary 
response. The time course of the response was quite different in the two different 
rabbits; in rabbit B the response peaked after the first boost and then declined, whereas
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in rabbit A the response was still increasing after the third boost. The highest titre 
with rabbit B was greater than that obtained with rabbit A. Evidence that the response 
was specific for the p50 peptide came from the results obtained with peptide to the 5/6 
loop of the human neurokinin 2  receptor; very low readings were obtained, as low as 
for wells untreated with peptide or serum. This shows the antibody did not react with 
an unrelated peptide. Further evidence for the specificity of the reaction came from the 
results with serum taken 1 0  days after the second boost; when this serum was pre- 
incubated with p50 peptide it no longer reacted on ELISA for wells incubated with the 
p50 peptide.
The titres obtained with both rabbits were high; certain peptides do not appear to give 
rise to specific antibody. The reasons for this are not completely understood. It is 
thought that a hydrophobic part of the peptide is necessary for it to attach to the lipid 
bilayer of the antigen presenting cell (APC) and a hydrophilic part is required for it to 
interact with the T cell receptor in an aqueous environment. The C-terminal p50 
peptide contains a small hydrophobic region with the majority of the peptide being 
hydrophilic, it is therefore a likely candidate to give a good antibody response.
A protein of 6 8  kDa reacted on Western blots with rabbit A immune serum but not with 
the pre-immune serum. However the reaction was not blocked by pre-incubation of the 
serum, taken 10 days after the second boost, with 50 fig of the peptide to which the 
antiserum was raised. This suggests the protein does not represent p50 and it might 
represent a protein to which the animal has raised antibodies as a result of infection 
which occurred between the time the pre-immune and immune blood samples were 
taken. The size of the protein, at 6 8  kDa, suggests it is too large to represent p50. 
The immune serum of rabbit A reacted weakly with a second protein of 55 kDa, this 
reaction was partially blocked by pre-incubation of serum with 50 fig of the C-terminal 
peptide which suggests the protein represents p50. The size is slightly larger than the 
50 kDa that would be expected for p50 however, within the accuracy of the markers, 
the protein band could actually represent a protein of 50 kDa. Stronger evidence that 
the protein does represent p50 comes from the fact that a protein of the same mobility 
reacted with Dr Hay’s antisera to p50. The reaction of the 55 kDa protein appeared 
much stronger for rabbit B than for rabbit A. This could be because rabbit B antiserum 
gave a higher titre on ELISA. Also in Western blotting the anti-peptide antibody has 
to recognize the peptide to which it was raised in the context of the whole protein; it
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is possible that the antibodies raised in rabbit B were better suited to use in Western 
blotting. The binding of antibody to the 55 kDa protein was almost completely blocked 
by pre-incubation of the serum with 50 fxg of the peptide to which the antiserum was 
raised. This again suggests the protein represents p50; it is possible that because of the 
high titre of the antibody more peptide would be required to produce complete blocking.
The antisera provided by Dr R. Hay did not react as specifically at the recommended 
dilution of 1 in 1 0 0 , however, all three antisera reacted with a protein of approximately 
55 kDa, with the antibody against the DNA-binding domain showing the highest binding 
activity. The C-terminal peptide antiserum reacted with so many proteins that, used 
alone, it would not provide any useful information. The antiserum to the N-terminal 
peptide would be expected to react with other members of the rel-related family. It 
reacted with a protein of 100 kDa; the anti c-rel antiserum also reacted with a protein 
of 100 kDa, suggesting this protein could represent c-rel.
Two proteins, both smaller than 50 kDa reacted weakly with the immune serum. It is 
possible these proteins represent breakdown products of p50, especially since these 
reactions were completely blocked by pre-incubation of immune serum with 50 pg of 
C-terminal peptide of p50.
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Chapter 6
Characterization of CREl-binding proteins
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6.1 Introduction
This study was directed towards characterizing the nuclear levels of CRE1-specific 
DNA-binding proteins present in Ad-transformed cells. Initially it was necessary to 
determine which method of nuclear extract preparation would be most suitable to 
investigate this question as it was found that different methods for the preparation of 
nuclear extracts produced different patterns of DNA-protein complexes on gel 
retardation. The methods used have been termed MDP1, MDP2 and MDP3. The 
complexes of different mobilities will be described in the section below. This will be 
followed be a section in which various techniques were used to characterize these DNA- 
protein complexes.
6.2 Comparison of the DNA-protein complexes obtained on gel retardation using 
different methods for the preparation of nuclear extracts
The DNA-protein complexes obtained with the different methods have been numbered 
from 1 to 7; complex 1 being that with the slowest mobility and complex 7 being the 
that with the fastest mobility.
6.2.1 DNA/protein complexes obtained on gel retardations using MDP1 extracts 
Nuclear extracts were originally prepared by MDP1. The major differences from the 
Dignam procedure (Dignam et al., 1983) were that the cells were not spun down in 
buffer A before homogenization in this buffer and, unlike the Dignam procedure, this 
modification included an ammonium sulphate precipitation step and overnight dialysis. 
Four complexes were obtained; 1, 3, 4 and 7 as shown in Fig 6.1a lane 1 and Fig 6.1c 
lanes 1, 5-7. Not all cell lines used produced all complexes.
Complex 1
This complex had the slowest mobility and was usually present in extracts prepared by 
this method (Fig 6.1a lane 1, Fig 6.1c lanes 1, 5-7).
Complex 2
This complex was not detected using extracts prepared by the MDP1 method. 
Complex 3
This complex was not always present but when present it usually appeared as a sharp 
complex, running faster than complex 1 (Fig 6.1a lane 1 and Fig 6.1c lanes 1,5-7).
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Fig 6.1 Comparison of the DNA-protein complexes obtained on gel retardations using
the CRE1 probe with different methods for the preparation of nuclear extracts
Fig 6.1a: Lane 1: complexes 1, 3, 4 and 7 were obtained using MDP1 extracts from 
F19 cells. Lane 2: MDP1 extracts from F19 cells containing 100-fold excess of 
unlabelled CRE1 in the binding reaction. Lane 3: complexes 3, 5 and 6  present with 
F19 MDP2 extracts. Fig 6.1b : Lane 1: complexes 3, 5 and 6  obtained using MDP3 
extracts of Hela cells. Lane 2: MDP3 extracts of Hela cells treated with TNFa 
(100 U/ml) for 1 hour showed the same complexes as in lane 1 as well as the inducible 
complex 2. Fig 6.1c: lane 1 to 6  MDP1 F19 extracts, lanes 2, 3 and 4 with 100-fold, 
200-fold and 500-fold excess of unlabelled CRE1 respectively and lanes 5 to 7 with 
100-fold, 200-fold and 500-fold excess of unlabelled mCREl respectively.
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Complex 4
This complex migrated slightly faster than complex 3. It usually appeared as a more 
diffuse complex than complex 3 (Fig 6.1a lane 1 and Fig 6.1c lanes 1, 5-7).
Complexes 5 and 6
These were not detected using nuclear extracts prepared by the MDP1 method. 
Complex 7
This complex had the fastest mobility and was quite a diffuse complex. (Fig 6.1a lane 
1 and Fig 6.1c lanes 1,5-7).
6.2.2 DNA/protein complexes obtained on gel retardations using MDP2 extracts 
This is a modification of the Dignam procedure that is quicker and simpler than MDP1 
and requires fewer cells (Andrews and Faller, 1991). Buffers A and C are the same 
in both procedures, but MDP2 has no ammonium sulphate precipitation step. The 
complexes obtained on gel retardations using this procedure were 2, 3, 5 and 6  
(complex 2  was not always present).
Complexes 2 and 3
Fig 6.1b shows complex 2, running just above complex 3. Complex 1 runs 
considerably more slowly than complex 3, whereas complex 2 runs much more closely 
to complex 3; compare Fig 6.1b lane 2 and Fig 6.1c lane 1.
Complexes 5 and 6
These complexes ran as a doublet between complexes 4 and 7 (Fig 6.1a compare lane 
3 to lane 1). When the resolution of the gel is good as in Fig 6 . la, they can be clearly 
visualized as a doublet. When the resolution of the gel is not as good they tend to 
appear as one complex, as in Fig 6.1b (lanes 1 and 2). These two complexes were not 
always present on gels. The probe labelled with varying levels of specific activity on 
different occasions. These complexes were only present when probes of higher specific 
activity were used.
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6.2.3 DNA/protein complexes obtained on gel retardations using MDP3 extracts
This is a modification of MDP1, in which leupeptin (0.5 mg/ml) and aprotinin (0.24 
TIU/ml) were used as additional protease inhibiters and sodium fluoride was present at 
50 mM. MDP3 produced the same complexes as MDP2 (Fig 6.1b, lanes 1 and 2).
6.2.4 Investigation of factors involved in DNA/protein complex formation 
When different complexes were obtained with MDP2, MDP1 was assessed for steps, 
not present in MDP2, which could potentially cause proteolysis. One such step was the 
overnight dialysis. When MDP1 was performed with 1 hour as opposed to overnight 
dialysis, only complex 3 was present (Fig 6.2). In this case, after overnight dialysis 
complexes 1, 4 and 7 were present.
Binding reactions were set up in 25 pi, containing 5pi of extract. When MDP2 extracts 
were used 5 pi of extract in Dig C were used. Dig C contains 0.42M NaCl, therefore 
the reaction mix (which contained no other source of NaCl) had NaCl present at 84 
mM. When NaCl concentration in the reaction mix was increased to 80 mM with 
MDP1 extracts, complex 5 and 6  were obtained on gel retentions (Fig 6.3).
A TNFa inducible complex was not obtained with MDP1. A TNFa inducible complex 
(complex 2) was produced by MDP2 (see later). MDP1 was modified by the addition 
of extra protease inhibitors; the modification was called MDP3. A TNFa inducible 
complex was obtained with MDP3 as shown with Hela cells in Fig 6 . lb lanes 1 and 2.
6.3 Characterization of the DNA-protein complexes obtained bv gel retardation
After determining which complexes were present with different methods of nuclear 
extract preparation and binding reaction conditions, it was of interest to characterize 
these complexes. Information was obtained as to the nature of these complexes from 
several different procedures: oligonucleotide competition assays, the use of the kappa 
oligonucleotide, the effect of. non-specific competitors on binding, induction 
experiments, and a crosslinking procedure.
6.3.1 Competition assays
If the complexes shown on gel retardations represent proteins that bind specifically to 
NF-/cB and related DNA-binding motifs, then one would expect the binding to be
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Fig 6.2 The effect of 1 hour as compared to overnight dialysis on the DNA/protein 
complexes obtained by gel retardation using the MDP1 method of nuclear extract 
preparation
Lane 1 and 2: extracts which had been dialysed for one hour. Lanes 3 and 4: extracts 
which had been dialysed overnight. Lane 2 and 4: binding reactions contained 100-fold 
excess of unlabelled CRE1. The CRE1 probe was used with F19 extracts.
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Fig 6.3 The effect of sodium chloride on the formation of DNA-protein complexes
Nuclear extracts were prepared by MDP1. Lanes 1-8 MDP1 extracts, binding reaction 
supplemented with 80 mM NaCl. Lane 1: 5B12, lane 2: BMK, lane 3: Ad5Xho and 
lane 4: F19, lane 5: 5A12, lane 6 : C57, lane 7: RFC-1, lane 8 : Adl2#l. Lane 9: Hela 
MDP2 nuclear extracts from cells treated with TNFa (100 U/ml) for 1 hour. The 
CRE1 probe was used.
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competed out by either CRE1 or the kappa oligonucleotide but not by mCREl in which 
residues shown to be essential for the binding of NF-kB and related proteins have been 
mutated (Shirayoshi et al., 1987). The following section will review the information 
obtained from competition assays for the different complexes.
Complex 1
Fig 6 . lc shows that complex 1 was competed out by 100-fold excess of CRE1 (lane 2) 
but not by 100-fold excess of mCREl (lane 5).
Complex 2
Fig 6.4 shows that complex 2 was competed out with the CRE1 (lanes 2-4) or kappa 
(lanes 8 -1 0 ) oligonucleotides with as little as a 1 0 -fold excess of the unlabelled 
oligonucleotide. Complex 2 was not competed with the oligonucleotide mCREl (lanes 
5-7).
Complex 3
Fig 6.1c shows that complex 3 was not completely competed out at a 100-fold excess 
(lane 2) but it was competed out at 200-fold excess (lane 3) of unlabelled CRE1. It was 
not competed out by a 200-fold excess of mCREl (lane 6 ).
Complex 4
Fig 6.1c shows that this binding activity was competed out at a 100-fold excess of 
CRE1 (lane 2), but not with a 100-fold excess of mCREl (lane 5).
Complexes 5 and 6
In Fig 6.4 the probe was not labelled to as high a specific activity as in other 
experiments, probably because of this, complexes 5 and 6  only appeared faintly. 
However competition is not complete with a 100-fold excess of CRE1 (lane 4) but did 
appear to occur with 100-fold excess of the kappa probe (lane 10). In certain 
experiments, efficient competition was not obtained for these DNA-binding proteins.
Complex 7
Fig 6 . lc shows that complex 7 was competed out by a 100-fold excess of CRE1 (lane 
2) but not by a 100-fold excess of mCREl (lane 5).
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Fig 6.4 Specific competition analysis using the CRE1 probe and CRE1. mCREl and 
kappa as competitor oligonucleotides
MBP1 nuclear extracts from 5B12 cells were used. Lane 1: no competitor, Lane 2-4: 
10, 50 and 100-fold excess of unlabelled CRE1, lanes 5-7: 10, 50 and 100-fold excess 
of unlabelled mCRE2 and lanes 8-10: 10, 50 and 100-fold excess of unlabelled kappa 
oligonucleotide.
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6.3.2 Binding to the kappa oligonucleotide
Fig 6.5 shows gel retardations using MDP3 nuclear extracts with labelled kappa (lanes 
1-8) and CRE1 (lanes 9-16) probes. Complexes 2 and 3 had the same mobility with 
either probe. Complex 2 was more intense with the kappa probe. Fig 6 . 6  shows that 
both complexes 2 and 3 produced with the kappa probe can be competed with an excess 
of unlabelled CRE1 (Fig 6 .6 a) or kappa oligonucleotide (Fig 6 .6 b).
6.3.3 The effect of non-specific competitors on binding to CRE1
Fig 6.7 and Fig 6 . 8  show that the proportion of binding activity present as complex 4 
or complex 7 could be altered depending on the non-specific competitor. The same 
batch of frozen aliquots of F19 MDP1 extracts was used in these experiments. Using 
poly (dG-dC) as a non-specific competitor, complex 4 was more intense than complex 
7 (Fig 6.7) whereas the reverse was the case when poly (dl-dC) was used (Fig 6 .8 ).
6.3.4 Induction experiments
One of the most interesting features of NF-kB is its inducibility. A number of agents 
can be used to treat cells which are thought to cause the dissociation of NF-/cB from 
I-kB in the cytoplasm and allow the nuclear translocation of NF-kB.  On gel retardation, 
these events are seen as the appearance or increased intensity of a particular complex 
using nuclear extracts prepared from cells treated with an inducing agent as compared 
to nuclear extracts made from untreated cells.
If in this study a particular complex could be shown to be inducible by several agents 
that are known to induce NF-kB, then it would be indicative that the complex represents 
NF-kB; that was indeed found to be the case as complex 2 was shown to be inducible 
by TNFa, cycloheximide, LPS and H20 2. These are all agents that have been shown 
to induce NF-kB. Schreck et al. (1991) have proposed that these agents (in common 
with all others that induce NF-kB) act through a mechanism that involves ROI; this will 
be discussed further in chapter 8 .
TNFa
TNFa has been shown to be a strong inducer of NF-kB in a number of cell lines (Duh 
et al., 1989). Duh et al. (1989) produced induction by TNFa present at 100 U/ml. 
Fig 6 .6 a shows that complex 2 is demonstrable in Hela cells nuclear extracts after the 
exposure of the cells to TNFa (100 U/ml) for just 5 minutes (lane 3), although greater
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Fig 6.5 Levels of CRE1- and kappa-binding factors in nuclear extracts prepared from 
Ad-transformed cell lines bv the MDP3 method
Lane 1-8 were with the kappa probe and lanes 9-16 were with the CRE1 probe. The 
following Ad2 or Ad5 cells ElA-expressing cells were analyzed: 5B12 (lanes 1 and 9), 
BMK (lanes 2 and 10), Ad5Xho (lanes 3 and 11), F19 (lanes 4 and 12), along with the 
following Adl2 ElA-expressing cells: 5A12 (lanes 5 and 13), C57 (lanes 6  and 14), 
RFC-1 (lanes 7 and 15) and Adl2#l (lanes 8  and 16).
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Fig 6 . 6  Induction of complex 2 by TNFa detected with the kappa probe and either 
CRE1 or kappa oligonucleotides as competitors
All extracts were prepared by MDP2. A, In lanes 1-2 extracts were prepared from 
untreated Hela cells. In lanes 3-8, extracts were from cells treated with TNFo? (100 
U/ml) for 5 (lanes 3 and 4), 10 (lanes 5 and 6 ) and 15 minutes (lanes 7 and 8 ). In 
lanes 2, 4, 6  and 8  the binding reactions contained a 100-fold excess of unlabelled 
CRE1 oligonucleotide.
B, In lanes 1 and 2 Hela MDP2 nuclear extracts prepared from cells treated with TNFa 
(100 U/ml) for 15 minutes. Lane 2: the binding reaction contained a 100-fold excess 
of the unlabelled kappa oligonucleotide.
151
152
Fig 6.7 Competition analysis using the CRE1 probe with CRE1 and kappa as
competitor oligonucleotides and dG-dC as non-specific competitor
The competitor present in lanes 2-6 was unlabelled CRE1 and in lanes 8-12 was 
unlabelled kappa. Competitor was present at 20-fold excess in lanes 2 and 8 , 40-fold 
excess in lanes 3 and 9, 80-fold excess in lanes 4 and 10, 160-fold excess in lanes 5 
and 11 and 320-fold excess in lanes 6  and 12.
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Fig 6.8 Competition analysis using the CRE1 probe with CRE1 and kappa as
competitor oligonucleotides and polv dl-dC as non specific competitor
The competitor present in lanes 2-6 was unlabelled CRE1 and in lanes 8-12 was 
unlabelled kappa. Competitor was present at 20-fold excess in lanes 2 and 8 , 40-fold 
excess in lanes 3 and 9, 80-fold excess in lanes 4 and 10, 160-fold excess in lanes 5 
and 11 and 320-fold excess in lanes 6  and 12.
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induction was obtained with 10 or 15 minutes exposure to TNFa (lanes 5 and 7). 
Complex 2 has been demonstrated to be inducible in several Ad-transformed cell lines 
for 15 minutes to 18 hours treatment with TNFa (see chapter 8 ).
Cvcloheximide
Cycloheximide interferes with translation by binding to the 60S subunit of ribosomes 
(Todorov, 1990). Cycloheximide also induces NF-kB as was first shown by Sen and 
Baltimore (1986); they treated cells for 4 hours with cycloheximide (10 fig/ml). A 
strong induction of complex 2 was obtained by treating cells with cycloheximide (30 
fig/ml) for 9 hours as shown with BMK cells in Fig 6.9 (lane 17).
Lipopolvsaccharide
LPS is a constituent of the membrane of gram-negative bacteria (Male et al., 1992). 
LPS is a B-cell mitogen. Sen and Baltimore (1986) were the first to demonstrate the 
induction of NF-kB by LPS. They found induction of NF-kB binding activity with LPS 
treatment (10 fig/ml) of between 30 minutes and 8  hours. Complex 2 was induced 
following a 1 hour treatment with LPS (20 fig/ml) of Hela cells (Fig 6.10, lane 3).
Hydrogen Peroxide
Hydrogen peroxide (H20 2) is a powerful oxidizing agent which is broken down within 
the cell to water, although it can cause the production of some hydroxyl radicals 
(Halliwell, 1992). Schreck et al. (1991) found that treatment of cells with 100 fiM 
H20 2 for 1 hour resulted in the induction of NF-kB. Treatment of 5B12 cells with 
H20 2 (100 fiM) for 1 hour was sufficient to induce complex 2 (Fig 6.11, lane 3).
6.3.5 Formaldehyde crosslinking
The DNA and protein of complexes 1, 4, 5, 6  and 7 were crosslinked using 
formaldehyde. Unfortunately the technique did not work for complexes 2 and 3. In 
this procedure the complexes are excised from a gel retardation, crosslinked with 
formaldehyde, eluted and acetone precipitated, then separated by SDS/polyacrylamide 
gel electrophoresis, with molecular weight markers used to estimate the size of the 
protein/oligonucleotide complexes. Fig 6.12a shows that complex 1 from a gel 
retardation did not enter a SDS/polyacrylamide gel; its size can be estimated to be 
greater than 200 kDa. Fig 6.12b shows the cross-linked products of complex 4, when 
analysed by SDS/polyacrylamide gel electrophoresis, gave two DNA/protein complexes
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Fig 6.9 The effect of TNFa and/or cycloheximide on the levels of CRE1-binding 
factors in MDP2 nuclear extracts of BMK cells
Lanes 2, 4, 6 , 8 , 10, 12, 14, 16 and 18 all had a 100-fold excess of unlabelled CRE1 
in the reaction mixes. The nuclear extracts used in lanes 1 and 2 were prepared from 
untreated cells. Lanes 3 to 16 used nuclear extracts from cells treated with TNFa 
(100 U/ml) for 15 minutes (lanes 3 and 4), 30 minutes (lanes 5 and 6 ), 1 hour (lanes 
7 and 8 ), 2 hours (lanes 9 and 10), 6  hours (lanes 11 and 12) and 8  hours (lanes 13 to 
16). The nuclear extracts used in lanes 15 and 16 were from cells treated with 
cycloheximide (30 jig/ml) for 9 hours as well as TNFa. The nuclear extracts in lanes 
17 and 18 were prepared from cells treated for 9 hours with cycloheximide (30 jig/ml) 
alone.
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Fig 6.10 Induction of complex 2 in Hela cells treated with LPS
The CRE1 probe was used with Hela MBP2 nuclear extracts. Lanes 2 and 4 had a 
100-fold excess of unlabelled CRE1 in the reaction mixes. The nuclear extracts used 
in lanes 1 and 2 were prepared from untreated cells. The nuclear extracts in lanes 3 
and 4 were prepared from cells treated with LPS (20 pig/ml) for 1 hour.
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Fi^ 6.11 Induction of complex 2 in 5B12 cells treated with HoQ»
The CRE1 probe was used with 5B12 MBP2 nuclear extracts. Lane 2 had 100-fold 
excess of unlabelled CRE1 in the reaction mix (competition results not shown for cells 
treated with H20 2). The nuclear extracts used in lanes 1 and 2 were prepared from 
untreated cells. The nuclear extracts in lanes 3 were prepared from cells treated with 
H20 2 (100 f i M )  for 1 hour
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Fig 6.12 Estimation of the size of DNA-protein complexes stabilized by formaldehyde
crosslinking
The CRE1 probe was used in all the crosslinking experiments.
Fig 6.12a: Lane 1, complex 1 was excised from a native polyacrylamide gel used to 
separate retarded complexes in F19 nuclear extracts, the DNA:protein complexes were 
crosslinked with formaldehyde, eluted, acetone precipitated and separated by 
SDS/polyacrylamide gel electrophoresis along with 14C molecular weight markers in 
lane 2 .
Fig 6 .12b: Lane 1 ,14C molecular weight markers. Complexes 4 (lane 2) and 7 (lane 3) 
from BMK nuclear extracts were excised from a native polyacrylamide gel and treated 
as described in Fig 6 .12a and run on a SDS/polyacrylamide gel.
Fig 6.12c: Lane 1, complexes 5 and 6  from C57 extracts were excised from a native 
polyacrylamide gel and treated as described in Fig 6.12a and separated by SDS 
polyacrylamide gel electrophoresis along with 14C molecular weight markers in lane 2.
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of approximately 65 kDa and 93 kDa, whereas complex 7 gave a single complex of 
approximately 50 kDa. Fig 6 .12c shows that complexes 5 and 6  generated a complex 
of approximately 65 kDa.
6.4 Discussion
A rapid method for the preparation of nuclear extracts was recently published (Andrews 
and Faller, 1991) and is referred to as MDP2. When MDP2 was compared to a 
modification of the Dignam procedure (Dignam et al., 1983), referred to as MDP1, it 
was found that different complexes were present on gel retardations using the CRE1 
probe. MDP1 gave complexes referred to as 1,3,4 and 7 whereas MDP2 gave 
complexes 2,3,5 and 6 . Because MDP2 extracts were prepared in buffer C, the 
binding reactions for MDP2 extracts had NaCl present unlike MDP1 extracts which 
were in buffer D which contains no NaCl. When NaCl was added to binding reactions 
with MDP1 extracts to approximately the same concentrations as that found in binding 
reactions with MDP2 extracts, complexes 5 and 6 , previously only associated with 
MDP2, were found with extracts prepared by either method. This shows that the 
proteins that produce complexes 5 and 6  when bound to the CRE1 probe are present 
in MDP1 extracts but require NaCl to be present at approximately 80 mM in order to 
bind to the CRE1 probe. Using MDP1, complexes 1, 4 and 7 were present with 
overnight dialysis, whereas only complex 3 was present with 1 hour dialysis. This 
suggests complexes 1, 4 and 7 could represent proteolytic breakdown products; this will 
be discussed further in relation to the results obtained by formaldehyde crosslinking. 
Since MDP2 is a quicker process there may be less opportunity for proteolysis to occur. 
Also the proteins might be more stable in the high salt concentration present in Dig C 
but not Dig D. Either reason could cause the absence of these complexes in MDP2. 
Since a TNFa-inducible complex was not obtained with MDP1 but was obtained with 
MDP2, it seemed likely that such a binding activity was being lost due to proteolysis. 
Therefore MDP1 was modified by the addition of extra protease inhibitors, aprotinin 
and leupeptin, also sodium fluoride was increased to 50 mM; the modification was 
called MDP3. As MDP3 extracts gave complex 2 on gel retardation, it seems likely 
that complex 2 was indeed subject to proteolytic attack in MDP1.
Information was obtained as to the nature of the different complexes from several 
different procedures including competition assays, the use of the kappa oligonucleotide
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as a probe, the effect of different non-specific competitors, induction experiments and 
crosslinking procedures.
If the complexes shown on gel retardations represent proteins that bind specifically to 
NF-KB-like DNA-binding motifs, then one would expect the complexes to be competed 
out by either CRE1 or the kappa oligonucleotides but not at all or only slightly by 
mCREl in which G residues shown to be essential for binding of NF-/cB-like proteins 
have been mutated (Shirayoshi et al., 1987). From these criteria complex 1, 2, 3, 4 
and 7 were all shown to bind specifically to the CRE1 probe. Complexes 5 and 6  
appeared to be competed out with an excess of the kappa oligonucleotide, but not 
always with an excess of the CRE1 oligonucleotide. The reason for this variation was 
not known, although it could possibly be due to variations in the specific activity of the 
probe. The kappa oligonucleotide was made to the same length as the CRE1 
oligonucleotide, so that if complexes appeared with the same mobility with either probe 
it would be indicative that they represent the same protein and that the protein is a 
NF-kB-like DNA-binding protein. Complexes 2, 3, 5 and 6  were present with either 
probe and were competed out by an excess of either of the unlabelled oligonucleotide 
sequences; this is evidence that they all represent NF-/cB-like DNA-binding proteins 
(although competition for complexes 5 and 6  by CRE1 was not always obtained).
The same batch of aliquots of MDP1 nuclear extracts gave a more intense complex 4  
than complex 7 when poly(dG-dC) was used as a non-specific competitor, whereas the 
reverse was the case when poly(dl-dC) was used. This suggests poly(dl-dC) and 
poly(dG-dC) do more than act as non-specific competitors. It appears they can both 
compete to some extent with the formation of specific binding; complex 4  is partially 
competed out by poly(dl-dC) whereas complex 7 is to some extent competed out by 
poly(dG-dC). p50 and p65 homodimers are strongly inhibited by poly(dl-dC) more so 
than N F - kB  (Baeuerle et al., 1991). This suggests that complex 4  could represent a p50 
or a p65 homodimer or their breakdown products. Since p65 homodimers tend to be 
only represented on gel retardations when special binding conditions are used (Hiscott 
and Cohen, 1992), complex 4  is more likely to represent p50 homodimers or their 
breakdown products. Poly(dG-dC) competes for binding of N F - kB  more efficiently 
than poly(dl-dC) (Baeuerle, 1991). Poly(dG-dC) inhibits the binding of complex 7 more 
than poly(dl-dC), suggesting it might represent N F - kB , or one of its breakdown 
products.
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A major feature of NF-kB is its inducibility. It was considered that if in this study, a 
particular complex shown by gel retardation was induced by several of the agents 
known to induce NF-kB, then this would be strongly indicative that the complex 
represented NF-kB. The results obtained indicated that complex 2 could represent 
NF-kB as it was shown to be inducible by TNFa, cycloheximide, LPS and H20 2; all 
are agents that have been shown to induce NF-kB. Furthermore, complex 2 induction 
occurred after cells were treated with the agents for periods of time and with dosages 
known to induce NF-kB.
Formaldehyde crosslinking is a means of obtaining information on the size of the 
protein component of complexes detected by gel retardation. This information was 
obtained for complexes 1, 4, 5, 6  and 7. Unfortunately this technique did not work for 
complexes 2 and 3 . Complex 1 was greater than 200 kDa. It could represent one of 
the large PRDII-BFl-like proteins, alternatively it could represent a tetramer of NF-kB; 
Baeuerle (1991) suggests NF-kB can bind to DNA in this way. When the crosslinked 
products of complex 4 were analysed on an SDS/polyacrylamide gel, two species were 
present of approximately 65 and 93 kDa. Because of the relatively small length of the 
probe and the relatively large size of DNase I it was not considered necessary to 
DNase I treat the formaldehyde crosslinked products. However, the probe would have 
caused a certain degree of overestimation of the sizes; it can be said that the complexes 
on the SDS/polyacrylamide gels should represent proteins no larger than the estimated 
size. Since the free probe runs faster than the smallest marker, it is not thought that 
the overestimation problem was too great. Given the potential overestimation, the 65 
kDa complex associated with complex 4 could represent p50 and the 93 kDa complex 
associated with complex 4 could represent c-rel. Similarly because of overestimation, 
the 65 kDa complex associated with complexes 5 and 6  could also represent p50; 
perhaps it has a slightly different conformation and so runs differently on gel 
retardations. Again with overestimation, the 50 kDa protein of complex 7 could 
represent the p42 proteolytic breakdown product of p50 described by Baueurle (1991). 
Complex 7 appeared only after overnight as opposed to 1 hour dialysis of MDP1 
extracts, which provides further evidence that complex 7 could represent a proteolytic 
breakdown product.
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Chapter 7
Nuclear levels of CRE1/kappa binding factors 
in Ad-transformed cells
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7.1 Introduction
It has been claimed that the differences in levels of MHC class I expression found in 
oncogenic and non-oncogenic Ad-transformed cells is due to differences in the levels 
of CREl/kappa binding factors in these cells (Nielsch et al., 1991; Meijer et al., 1992). 
In this chapter the levels of these binding factors in the nucleus of Ad-transformed cells 
was investigated by two different approaches; gel retardation using CRE1 and kappa 
oligonucleotides and Western blotting using the rabbit B antiserum raised to the C- 
terminal of p50.
7.2 The use of gel retardation to investigate the nuclear levels of CRE1/kappa- 
binding factors in Ad-transformed cell lines
The levels of CREl/kappa binding factors were investigated in eight adenovirus cell 
lines; four expressing Ad2 or Ad5 E1A and four expressing Adl2 E1A. The results 
obtained appeared to depend upon the method by which the extracts were prepared.
7.2.1 Levels of CREl-binding factors in nuclear extracts prepared from 
Ad-transformed cells bv the MDP1 method
Fig 7.1, shows the levels of CREl-binding factors in nuclear extracts prepared by 
MDP1. Complex 1 appeared to be present in three of the four Ad 12 El A expressing 
cell lines and not present with any cell line expressing Ad2 or Ad5 E1A. Complex 4 
was present in 3 of the 4 Ad2 or Ad5 El A expressing cell lines and was not present in 
any cell line expressing Ad 12 El A. Complex 7 appeared as an intense band in BMK, 
F19 and Ad5Xho cells but it was also present, although fainter, in 5B12 as well as 
5A12, C57 and Adl2#l( the three latter cell lines express Adl2 E1A).
7.2.2 Levels of CREl-binding factors in nuclear extracts prepared from 
Ad-transformed cells by the MDP1 method with 10 mM sodium fluoride
Fig 7.2 shows the levels of CREl-binding factors found when nuclear extracts were 
prepared by MDP1 with the modification that all buffers contained 10 mM sodium 
fluoride. The intensity of complex 1 varied between different cell lines, but there 
seemed to be no relation to the serotype of El A expressed by a particular cell line. 
Complexes 4 and 7 were present in all cell lines which expressed Ad2 or Ad5 El A and 
absent in all Adl2 E1A expressing cell lines.
170
Fig 7.1 Levels of CREl-binding factors in nuclear extracts prepared from
Ad-transformed cell lines by the MDP1 method
MDP1 nuclear extracts of the following Ad2 or Ad5 ElA-expressing cells were 
analysed: 5B12 (lane 1), BMK (lane 2), Ad5Xho (lane 3) and F19 (lane 4) along with 
the following Adl2 ElA-expressing cells: 5A12 (lane 5), C57 (lane 6), RFC-1 (lane 7) 
and Adl2#l (lane 8). The CRE1 probe was used.
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Fig 7.2 Levels of CRE1-binding factors in nuclear extracts prepared from
Ad-transformed cell lines by the MDP1 method in the presence of sodium fluoride
MDP1 nuclear extracts prepared in the presence of lOmM sodium fluoride were 
analysed from the following Ad2 or Ad5 ElA-expressing cells: 5B12 (lane 1), BMK 
(lane 2), Ad5Xho (lane 3) and F19 (lane 4) along with the following Adl2 ElA- 
expressing cells: 5A12 (lane 5), C57 (lane 6), RFC-1 (lane 7) and Adl2#l (lane 8). 
The CRE1 probe was used.
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7.2.3 Levels of CREl-binding factors in nuclear extracts prepared from 
Ad-transformed cells by the MDP2 method
When extracts were prepared by MDP2, there was no difference between cell lines 
expressing Adl2 E1A compared to those expressing Ad2 or Ad5 E1A, in any of the 
complexes present; 2, 3, 5 and 6 (Fig 7.3). Complex 2 was clearly present in extracts 
from BMK and Adl2#l cells, and faintly present in F19 cells. Complexes 3, 5 and 6 
were present in all the cell lines.
7.2.4 Levels of kappa-binding factors in nuclear extracts prepared from 
Ad-transformed cells by the MDP2 method
When MDP2 nuclear extracts were used with the kappa probe a slightly different 
binding pattern was found than with the CRE1 probe (compare Fig 7.3 with Fig 7.4). 
Complex 2, although sometimes faint, was visible in the extracts of more cell lines and 
complexes 5 and 6 were barely visible. Complex 3 was present in all cell lines except 
C57. As with the CRE1 probe, there did not appear to be any differences in binding 
between cell lines which expressed Ad 12 El A and those which expressed Ad2 or Ad5 
E1A.
7.2.5 Levels of CRE1- and kappa-binding factors in nuclear extracts prepared from 
Ad-transformed cells bv the MDP3 method
Fig 6.5 shows that complex 2 was found in all the cell lines tested with either probe, 
but was more intense in cells expressing Ad2 or Ad5 El A than in those expressing 
Adl2 E1A. Complex 3 binding more clearly demonstrated with the CRE1 probe and, 
although it was present with all cell lines, it appeared to be more intense in cell lines 
which express Ad2 or Ad5 El A, with the exception of C57 which also showed an 
intense complex 3. Complex 5 and 6 appeared very faintly with the kappa probe.
7.3 The use of Western blotting to investigate the steadv-state levels of p50 in 
nuclear extracts of Ad-transformed cell lines
The steady-state levels of p50 were investigated using MDP3 nuclear extracts from the 
eight different Ad-transformed cell lines and rabbit B antiserum taken 10 days after the 
second boost. Western blotting of these nuclear extracts revealed three polypeptides of 
approximately 55K, 54K and 50K (Fig 7.5). All the polypeptides appeared to be 
present in all the cell lines. The intensity of the polypeptides varied between cell lines,
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Fig 7.3 Levels of CRE1-binding factors in nuclear extracts prepared from
Ad-transformed cell lines by the MDP2
MDP2 nuclear extracts of the following Ad2 or Ad5 ElA-expressing cells were 
analysed: 5B12 (lane 1), BMK (lane 2), Ad5Xho (lane 3) and F19 (lane 4) along with 
the following Ad 12 ElA-expressing cells: 5A12 (lane 5), C57 (lane 6), RFC-1 (lane 
7) and Adl2#l (lane 8). The CRE1 probe was used.
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Fig 7.4 Levels o f kappa-binding factors in nuclear extracts prepared from
Ad-transformed cell lines by MDP2 method
MDP2 nuclear extracts of the following Ad2 or Ad5 ElA-expressing cells were 
analysed: 5B12 (lane 1), BMK (lane 2), Ad5Xho (lane 3) and F19 (lane 4) along with 
the following Adl2 ElA-expressing cells: 5A12 (lane 5), C57 (lane 6), RFC-1 (lane 
7) and Adl2#l (lane 8). The kappa probe was used.
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Fig 7.5 The steady-state levels of p50 in nuclear extracts of Ad-transformed cells
The levels of p50 in nuclear extracts prepared by the MDP3 method were investigated 
by Western Blotting of the following Ad2 or Ad5 ElA-expressing cells: 5B12 (lane 1), 
BMK (lane 2), Ad5Xho (lane 3), F19 (lane 4) along with the following Ad 12 ElA- 
expressing cells: 5A12 (lane 5), C57 (lane 6), RFC-1 (lane 7) and Adl2#l (lane 8). 
Rabbit B antiserum was used, taken 10 days after the second boost. The serum was 
used at 1 in 1000 dilution.
180
50 kDa^
but there was no general difference in the intensity of the polypeptides between cell 
lines which expressed Adl2 E1A compared to those which expressed Ad2 or Ad5 E1A.
7.4 Levels of Spl-binding factors in nuclear extracts prepared from Ad- 
transformed cell lines bv the MDP3 method
It was decided to investigate whether the differences found in CREl/kappa binding 
factors between cells expressing Ad2 or Ad5 E1A compared to those expressing Adl2 
El A were restricted to factors which bind to these two probes or were part of a more 
general phenomenon; for this reason it was decided to investigate the levels of 
Spl-binding factors in these cell lines. Fig 7.6a shows that the Spl-binding activity was 
specific as it was competed out with 100-fold excess of unlabelled competitor. The 
level of Spl-binding activity varied slightly between the eight different cell lines, but 
there was no overall difference between those expressing Ad 12 El A compared to those 
expressing Ad2 or Ad5 El A (Fig 7.6b).
7.5 Discussion
This chapter investigated the levels of CREl/kappa binding factors in eight different cell 
lines, four in which Ad 12 El A was expressed and four in which either Ad2 or Ad5 
E1A was expressed. Two different approaches were used to investigate these levels: 
gel retardation and Western blotting. The detection of differences between the two 
groups of transformed cells by gel retardation depended on the method used for nuclear 
extract preparation; higher levels of CREl/kappa-binding factors were present in Ad2 
or Ad5 El A expressing cell lines when extracts were prepared by the MDP1 and MDP3 
methods but not when the extracts were prepared by the MDP2 method. Hemar et al. 
(1992) found a quick method of extract preparation, different to MDP2, gave nuclear 
NF-kB binding in cells where such binding was absent when extracts were prepared by 
the Dignam method (Dignam et al., 1983). The quick method used by Hemar et al. 
(1992) involved the use of detergent which is not the case for MDP2. They suggest 
that the quick method leads to erroneous results due to the leakage of cytoplasmic 
contents into nuclear extracts. Although this is more likely to be the case with 
methods involving the use of detergent, if this also applied to the MDP2 quick method 
of nuclear extract preparation, the CREl-binding found in cells expressing Ad 12 El A 
with this method could be due to cytoplasmic contamination of the nuclear extract 
preparation.
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Fig 7.6 Levels of Spl-specific binding factors in nuclear extracts prepared from
Ad-transformed cell lines by the MDP3 method
MDP3 nuclear extracts of the following Ad2 or Ad5 ElA-expressing cells were 
analysed: 5B12 (lane 1), BMK (lane 2), Ad5Xho (lane 3) and F19 (lane 4) along with 
the following Adl2 ElA-expressing cells: 5A12 (lane 5), C57 (lane 6), RFC-1 (lane
7) and Adl2#l (lane 8). The Spl probe was used.
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The binding pattern with MDP1 is likely to reflect the levels of proteolytic breakdown 
products. Since this method should provide the same level of separation of cytoplasmic 
and nuclear contents as MDP3, one would expect the difference in CRE1-binding 
between the cells expressing Ad 12 El A compared to those expressing Ad2 or Ad5 to 
be present as well with MDP3, as indeed was found to be the case. This study found 
both the major binding activities detected by this method, complexes 2 and 3, to be 
more intense for cells expressing Ad2 or Ad5 E1A compared to cells expressing Adl2 
El A. It is likely that complexes 2 and 3 represent NF-kB and H2TF1/KBF1 
respectively. Meijer et al. (1992) also found higher levels of these factors in Ad5- 
compared to Adl2-transformed cells. However, since they used whole cell extracts, 
their results do not provide information on the nuclear levels of these factors. Ge et 
al. (1992) did not find any significant difference between Ad5- and Adl2-transformed 
cells in levels of CRE1-binding; the lack of agreement with the results of this study 
could be due to the different method used to prepare nuclear extracts. Nielsch et al. 
(1991) found only NF-kB to be present at higher levels in Ad5- compared to Adl2- 
transformed cells. The cell lines used by Nielsch et al. (1991) were established cell 
lines before adenovirus transformation, whereas the cell lines used in this study were 
derived from primary cells transformed by adenovirus; this could account for the 
differences in the results obtained.
Spl-binding levels varied slightly between cell lines but there was no overall difference 
between the cell lines expressing Adl2 compared to Ad2 or Ad5 E1A. Ge et al. (1992) 
also did not obtain any difference between Ad5- and Adl2-transformed cells in the level 
of Spl-binding factors. This demonstrates that the differences found in the levels of 
CREl-binding factors between these groups is not just part of a general difference in 
the level of transcription factors between these two groups.
The Western blotting results did not appear, at first sight, to agree with the results 
obtained on gel retardations. However, the two systems are capable of investigating 
different questions. Western blotting was used to detect the levels of p50 in nuclear 
extracts in which the proteins were denatured and probably broken down into their 
subunit constituents, therefore this system could not be used to obtain information as 
to whether the p50 present in the nuclear extract was bound to another p50 or a p65 for 
example, whereas on gel retardations p50 homodimers and p50/p65 heterodimers have 
been shown to run with different mobilities as non-denaturing conditions are used
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(Cohen and Hiscott, 1992; Baeuerle, 1992). It is reasonable to assume that complexes 
2 and 3 are likely to represent NF-kB (p50/p65 heterodimer) and H2TF1/KBF1 (p50 
dimer) respectively. Combining the results of gel retardations with those of Western 
blotting suggests that the levels of p50 do not differ between the cell lines expressing 
Adl2 E1A compared to those expressing Ad2 or Ad5 E1A but the conformation of 
some of the p50 must be different between these groups since it is capable of binding 
DNA either as a homodimer or a heterodimer with p65 more readily in cell lines 
expressing Ad2 or Ad5 E1A. Alternatively, the p50 present in Adl2 ElA-expressing 
cells could be bound to another protein; for example, c-rel and this heterodimer was not 
detectable on gel retardations under the conditions used.
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Chapter 8
Induction of CRE1-binding proteins by TNFce, cycloheximide, 
puromycin and benzoyl peroxide in Ad-transformed cells
187
8.1 Introduction
An understanding of the mechanism of induction of NF-kB would be of great 
importance, particularly because the long terminal repeat (LTR) of HIV-1 contains two 
NF-acB binding sites and NF-kB has been implicated in the activation of transcription 
of HIV genes (Osborn et al.,1989). In this chapter several aspects of NF-kB induction 
in Ad-transformed cells were investigated. Induction by TNFa and cycloheximide in 
different adenovirus cell lines was studied. It was hoped that this information might be 
relevant to the different properties of cell lines expressing Adl2 E l A compared to those 
expressing Ad2 or Ad5 E1A. Schreck et al. (1991) proposed that NF-/cB induction 
involves ROI. The results with puromycin and benzoyl peroxide were hoped to provide 
further information about the process of induction in general, and in the case of benzoyl 
peroxide help provide further evidence for the role of ROI. Induction by benzoyl 
peroxide was investigated in Ad-transformed cell lines as it was hoped this information 
might be relevant to the different properties of these cell lines.
8.2 The induction of CREl-binding factor(s) bv TNFar and/or cycloheximide
When cells transformed by Ad2 or Ad5 E1A are introduced into syngeneic newborn 
rodents they are not oncogenic, whereas cells transformed by Adl2 E1A are highly 
oncogenic. It is known that members of the former group have higher levels of MHC 
class I antigens than members of the latter group. It could be argued that a more 
relevant parameter of oncogenicity is the level of surface MHC class I when these cells 
are introduced into living animals. In such an environment the cells would be under 
the influence of many cytokines including TNFa which is known to up-regulate the 
levels of MHC class I and cause the nuclear translocation of NF-kB (Duh et al., 1989; 
Osborn et al., 1989). It could be envisaged that members of these two groups respond 
differently to TNFa in terms of the type of response, degree of response and the 
kinetics of the response. For this reason the response to TNFa in cells expressing 
Adl2 E1A compared to Ad2 or Ad5 E1A was investigated over an eight hour time- 
course.
The nature of the response to TNFa was investigated by use of the protein synthesis 
inhibitor cycloheximide (Todorov, 1990); if the response to TNFa required protein 
synthesis it should be inhibited by pretreatment with cycloheximide. The effect of 
cycloheximide alone was also investigated in these cells as it is another agent known
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to induce NF-acB; as will be described later, free radicals may be involved in its method 
of activation.
The induction of complex 2 by TNFa occurred in all the cell lines tested except for F19 
and 5A12. The induction of complex 2 by cycloheximide was evident in all the cell 
lines. The four cell lines expressing Ad2 or Ad5 E1A will be discussed first.
In 5B12, TNFa induction appeared by 15 minutes (lane 3) and seemed strongest for the 
first hour and gradually decreased towards 8 hours (Fig 8.1). Cycloheximide and 
TNFa appeared to act synergistically, the induction being greater with both agents than 
with either one alone (compare lane 15 to lanes 13 and 17).
Complex 3, although present before treatment with TNFa or cycloheximide, was 
stronger after treatment, appearing most intense at 1 hour of TNFa treatment (lane 7) 
and after 8 hours of TNFa treatment in association with 9 hours of cycloheximide 
treatment (lane 15).
In BMK cells complex 2 was also induced after only 15 minutes of TNFa treatment 
(Fig 6.9). Its induction pattern was different from that of 5B12. Induction appeared 
to increase up to 6 hours and was maintained until 8 hours. The induction of complex 
2 by cycloheximide alone was greater than the induction by TNFa alone. Complex 3 
did not appear to be induced by cycloheximide or TNFa, in fact there was the 
disappearance of complex 3 when cells were treated with both TNFa and 
cycloheximide.
In Ad5Xho cells complex 2 was again shown to be induced by just 15 minutes treatment 
with TNFa (lane 3, Fig 8.2). The level of induction increased in the first hour of 
treatment, was reduced at 2 hours (lane 9) and peaked again at 6 hours (lane 11). 
Relatively strong induction of complex 2 was achieved by cycloheximide (lane 17), 
while induction with TNFa and cycloheximide (lane 15) did not appear to be greater 
than that of cycloheximide alone. Complex 3 appeared to show a similar pattern of 
induction to complex 2.
In F19 cells complex 2 was not induced by TNFa (Fig 8.3). Although TNFa did not 
induce complex 2, complex 3 was intensified by 15 minutes treatment (lane 3).
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Fig 8.1 The effect of TNFa and/or cycloheximide on the levels of CRE1-binding
factors in MBP2 nuclear extracts of 5B12 cells
Lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18 all had a 100-fold excess of unlabelled CRE1 
in the binding reaction. The nuclear extracts used in lanes 1 and 2 were prepared from 
untreated cells. Lanes 3 to 16 used nuclear extracts from cells treated with TNFa 
(100 U/ml) for 15 minutes (lanes 3 and 4), 30 minutes (lanes 5 and 6), 1 hour (lanes 
7 and 8), 2 hours (lanes 9 and 10), 6 hours (lanes 11 and 12) and 8 hours (lanes 13 to 
16). The nuclear extracts used in lanes 15 and 16 were from cells treated with 
cycloheximide (30 /tg/ml) for 9 hours as well as TNFa. The nuclear extracts in lanes 
17 and 18 were prepared from cells treated for 9 hours with cycloheximide (30 /xg/ml) 
alone.
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Fig 8.2 The effect of TNFa and/or cycloheximide on the levels o f CREl-binding
factors in MDP2 nuclear extracts of Ad5Xho cells
Lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18 all had a 100-fold excess of unlabelled CRE1 
in the binding reaction. The nuclear extracts used in lanes 1 and 2 were prepared from 
untreated cells. Lanes 3 to 16 used nuclear extracts from cells treated with TNFa 
(100 U/ml) for 15 minutes (lanes 3 and 4), 30 minutes (lanes 5 and 6), 1 hour (lanes 
7 and 8), 2 hours (lanes 9 and 10), 6 hours (lanes 11 and 12) and 8 hours (lanes 13 to 
16). The nuclear extracts used in lanes 15 and 16 were from cells treated with 
cycloheximide (30 jug/ml) for 9 hours as well as TNFa. The nuclear extracts in lanes 
17 and 18 were prepared from cells treated for 9 hours with cycloheximide (30 jug/ml) 
alone.
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Fig 8.3 The effect of TNFa and/or cycloheximide on the levels of CREl-binding
factors in MDP2 nuclear extracts of F19 cells
Lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18 all had a 100-fold excess of unlabelled CRE1 
in the binding reaction. The nuclear extracts used in lanes 1 and 2 were prepared from 
untreated cells. Lanes 3 to 16 used nuclear extracts from cells treated with TNFa (100 
U/ml) for 15 minutes (lanes 3 and 4), 30 minutes (lanes 5 and 6), 1 hour (lanes 7 and
8), 2 hours (lanes 9 and 10), 6 hours (lanes 11 and 12) and 8 hours (lanes 13 to 16). 
The nuclear extracts used in lanes 15 and 16 were from cells treated with cycloheximide 
(30 /jg/ml) for 9 hours as well as TNFa. The nuclear extracts in lanes 17 and 18 were 
prepared from cells treated for 9 hours with cycloheximide (30 ^tg/ml) alone.
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Cycloheximide did induce complex 2 and intensify complex 3 (lane 17). In 5A12 cells 
complex 2 was not induced by TNFa (Fig 8.4). However cycloheximide did induce 
complex 2 (lane 17) and treatment with TNFa and cycloheximide (lane 15) caused a 
greater induction of complex 2 than TNFa alone (lane 13). Complex 3 was intensified 
by 1 hour of treatment with TNFa (lane 7).
In C57 cells, complex 2 did not appear to be induced by 15 minutes of treatment with 
TNFa (lane 3, Fig 8.5). Complex 2 was induced by 30 minutes of treatment with 
TNFa (lane 5) and the level of induction remains approximately constant with up to 8 
hours of TNFa treatment. The induction with cycloheximide and TNFa (lane 15) 
appeared to be much greater than that of either agent alone (lanes 13 and 17). Complex 
3 did not appear to be induced in this cell line.
In RFC-1 cells complex 2 was induced by 15 minutes of treatment with TNFa (lane 3). 
The level of induction decreased after 2 hours of treatment (lane 9) and it was not 
evident at 8 hours (lane 13, Fig 8.6). The induction produced by cycloheximide alone 
was barely apparent (lane 17). By far the strongest induction of complex 2 took place 
by the joint treatment with cycloheximide and TNFa. Complex 3 binding was 
particularly strong, however, it appeared to be induced by TNFa, particularly after 15 
minutes of treatment (lane 3). Cycloheximide also induced complex 3 (lane 17), but 
the greatest induction was found with the treatment condition of TNFa (100 U/ml) for 
eight hours and cycloheximide (30 jiglml) for nine hours (lane 15). The induction by 
TNFa (100 U/ml) for 30 minutes was partially, but not completely, inhibited by 
treatment of the cells with 0.1 mM PDTC or 30 mM NAC for 1 hour prior to the 
addition of TNFa (Fig 8.7). PDTC and NAC are both scavengers of free radicals 
(Schreck et al., 1991). Fig 8.8 shows that induction of complex 2 by TNFa (100 
U/ml) was still present with 18 hours. Treatment with interferon 7(1000 U/ml) for 12 
hours was insufficient to induce complex 2 (lane 3), however, in combination with 18 
hours of TNFa treatment, interferon y  caused greater induction of complex 2 than 
TNFa alone (compare lane 7 to lane 9).
In Adl2#l cells there was no induction of complex 2 by 15 minutes of exposure to 
TNFa (lane 3, Fig 8.9). Thirty minutes treatment with TNFa was sufficient to cause 
an induction of complex 2. This time period gave the strongest induction by TNFa 
alone, thereafter the level of induction remained approximately constant between 1 and
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Fig 8.4 The effect of TNFa and/or cycloheximide on the levels of CREl-binding
factors in MDP2 nuclear extracts of 5 A 12 cells
Lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18 all had a 100-fold excess of unlabelled CRE1 
in the binding reaction. The nuclear extracts used in lanes 1 and 2 were prepared from 
untreated cells. Lanes 3 to 16 used nuclear extracts from cells treated with TNFa 
(100 U/ml) for 15 minutes (lanes 3 and 4), 30 minutes (lanes 5 and 6), 1 hour (lanes 
7 and 8), 2 hours (lanes 9 and 10), 6 hours (lanes 11 and 12) and 8 hours (lanes 13 to 
16). The nuclear extracts used in lanes 15 and 16 were from cells treated with 
cycloheximide (30 jig/ml) for 9 hours as well as TNFa. The nuclear extracts in lanes 
17 and 18 were prepared from cells treated for 9 hours with cycloheximide (30 /xg/ml) 
alone.
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Fig 8.5 The effect of TNFa and/or cycloheximide on the levels of CREl-binding
factors in MDP2 nuclear extracts of C57 cells
Lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18 all had a 100-fold excess of unlabelled CRE1 
in the binding reaction. The nuclear extracts used in lanes 1 and 2 were prepared from 
untreated cells. Lanes 3 to 16 used nuclear extracts from cells treated with TNFa 
(100 U/ml) for 15 minutes (lanes 3 and 4), 30 minutes (lanes 5 and 6), 1 hour (lanes 
7 and 8), 2 hours (lanes 9 and 10), 6 hours (lanes 11 and 12) and 8 hours (lanes 13 to 
16). The nuclear extracts used in lanes 15 and 16 were from cells treated with 
cycloheximide (30 /zg/ml) for 9 hours as well as TNFa. The nuclear extracts in lanes 
17 and 18 were prepared from cells treated for 9 hours with cycloheximide (30 \i%Jml) 
alone.
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Fig 8.6 The effect o f TNFa and/or cycloheximide on the levels of CREl-binding
factors in MDP2 nuclear extracts of RFC-1 cells
Lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18 all had a 100-fold excess of unlabelled CRE1 
in the binding reaction. The nuclear extracts used in lanes 1 and 2 were prepared from 
untreated cells. Lanes 3 to 16 used nuclear extracts from cells treated with TNFa 
(100 U/ml) for 15 minutes (lanes 3 and 4), 30 minutes (lanes 5 and 6), 1 hour (lanes 
7 and 8), 2 hours (lanes 9 and 10), 6 hours (lanes 11 and 12) and 8 hours (lanes 13 to 
16). The nuclear extracts used in lanes 15 and 16 were from cells treated with 
cycloheximide (30 /xg/ml) for 9 hours as well as TNFa. The nuclear extracts in lanes 
17 and 18 were prepared from cells treated for 9 hours with cycloheximide (30 ^g/ml) 
alone.
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Fig 8.7 The partial inhibition of TNFa induction of complex 2 bv NAC and PDTC
The CRE1 probe was used with 5 /zg of nuclear MDP2 extracts from RFC-1 cells, the 
cells were treated as follows: lane 1: untreated cells, lane 2-4 TNFa treated cell for 30 
minutes (100 U/ml), lane 3: cells treated with PDTC (0.1 mM) for 1 hour prior to 
addition of TNFa, lane 4: cells treated with NAC (30 mM) for 1 hour prior to addition 
of TNFa.
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Fig 8.8 The effect of TNFce and TNFa with interferon 7 on levels of CREl-binding
factors
RFC-1 MDP2 nuclear extracts were used. Lane 1 and 2: untreated cells, lanes 3 and 
4: cells treated for 12 hours with interferon 7 ( 1 0 0 0  U/ml), lanes 5 and 6 : cells treated 
with interferon 7  (1000 U/ml) for 12 hours and cycloheximide (30 /zg/ml) for 13 hours, 
lanes 7 and 8 : TNFa (100 U/ml) for 18 hours, lanes 9 and 10: TNFa (100 U/ml) for 
18 hours and interferon 7  (1000 U/ml) for 12 hours. Lane 2, 4, 6 , 8  and 10 had 100- 
fold excess of unlabelled CRE1 in the binding reactions.
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Fig 8.9 The effect of TNFa and/or cycloheximide on the levels of CREl-binding
factors in MDP2 nuclear extracts of A dl2#l cells
Lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18 all had a 100-fold excess of unlabelled CRE1 
in the binding reactions. The nuclear extracts used in lanes 1 and 2 were prepared 
from untreated cells. Lanes 3 to 16 used nuclear extracts from cells treated with TNFa 
(100 U/ml) for 15 minutes (lanes 3 and 4), 30 minutes (lanes 5 and 6), 1 hour (lanes 
7 and 8), 2 hours (lanes 9 and 10), 6 hours (lanes 11 and 12) and 8 hours (lanes 13 to
16). The nuclear extracts used in lanes 15 and 16 were from cells treated with 
cycloheximide (30 /xg/ml) for 9 hours as well as TNFa. The nuclear extracts in lanes 
17 and 18 were prepared from cells treated for 9 hours with cycloheximide (30 /zg/ml) 
alone.
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8 hours. The induction found with 8 hours of TNFa and 9 hours of cycloheximide 
(lane 15) was greater than that achieved by either treatment individually (lanes 13 and
17). There is a slight induction of complex 3 by 30 minutes treatment with TNFa (lane 
5) and by a combined TNFa/cycloheximide treatment (lane 15).
8.3 The induction of complexes 2 and 3 bv puromvcin
Puromycin is a protein synthesis inhibitor which has a unique action; the drug itself 
reacts with the C-terminus of the growing peptide chain on the ribosome forming a 
peptidyl-puromycin compound which rapidly dissociates from the ribosome, thus 
causing premature termination of protein synthesis (Franklin and Snow, 1991). The 
action of puromycin is equally effectively on 70S and 80S ribosomes. Treatment of 
C57 cells with puromycin (30 ^g/ml, lane 3) or cycloheximide (30 /zg/ml, lane 5) 
caused the induction of complex 2, however, puromycin caused a greater induction (Fig 
8.10). Cycloheximide did not induce complex 3 in this cell line, whereas puromycin 
did appear to induce complex 3.
8.4 The induction of complex 2 bv benzoyl peroxide
Schreck et al.(1991) have shown that NF-/cB can be induced by H20 2. It was proposed 
that this phenomenon was due to the production of ROI by H20 2, since scavengers of 
ROI prevented the induction of NF-kB by H20 2 and by several other agents. It was 
decided to investigate whether a chemical, other than H20 2, which produces free 
radicals could also induce NF-kB.
Benzoyl peroxide is a well known chemical used as a topical treatment for acne and to 
treat cutaneous ulcers. It is used in several industrial processes because it is a source 
of free radicals (Hogan, 1991) This chemical is known to act as a tumour promoter in 
mice (Iverson, 1986).
Benzoyl peroxide is only slightly soluble in water but readily soluble in DMF, DMSO 
and acetone. Fig 8.11 shows the effect of benzoyl peroxide when dissolved in DMF; 
10 (lane 3) but not 1 fiM (lane 2) benzoyl peroxide caused the induction of 
complex 2 in 5B12 cells. This effect was not due to DMF alone (lanes 4 and 5). 10 
IjlM  benzoyl peroxide in DMF did not induce complex 2 when cells were pretreated for 
1 hour with NAC (30 mM) (lane 7).
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Fig 8.10 The effect of cvcloheximide or puromvcin on CREl-binding factors in C57
cells
The CRE1 probe was used with C57 MBP2 nuclear extracts. Lanes 1 and 2: untreated 
cells, lane 3 and 4: cycloheximide treated cells (30 (ig/ml for 1 hour), lanes 5 and 6 
puromycin treated cells (30 /xg/ml for 1 hour). Lanes 2, 4 and 6 contained 100-fold 
excess of unlabelled CRE1 in the binding reactions.
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Fig 8.11 The effect of benzoyl peroxide dissolved in DMF on CREl-binding factors
in 5B12 cells
The CRE1 probe was used with 5B12 MBP2 nuclear extracts. Lane 1: untreated cells, 
lane 2 and 6 cells treated with 1 /xM benzoyl peroxide dissolved in DMF. The benzoyl 
peroxide was added to each plate in a volume of 7 /xl (0.1 % final concentration). Lanes
3 and 7: cells treated with 10 /xM benzoyl peroxide dissolved in DMF. The benzoyl 
peroxide was added to each plate in a volume of 70 /txl (1 % final concentration). Lanes
4 and 5: cells treated with 7 /xl and 70 /lxI of DMF respectively (equivalent to 0.1 and 
1% final concentration). All treatments with DMF or benzoyl peroxide were for 1 
hour. Lanes 6 and 7 were also treated with NAC (30 mM) for 2 hours.
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Fig 8.12 shows the effect of benzoyl peroxide on levels of nuclear complex 2 and 
complex 3 in 5B12 cells when DMSO or acetone is used as the solvent. Both these 
solvents appeared to cause a slight increase in the level of complex 2 binding (compare 
lane 1 with lanes 2 and 9). When benzoyl peroxide was dissolved in acetone, low 
dosages, 1.25 /zM and 2.5 /zM (lanes 3 and 4), appeared to reduce complex 2 binding 
levels from those obtained by acetone alone to the levels found in untreated cells. The 
levels of complex 2 binding increased consistently with increased dosage from 2.5 /zM 
(lane 4) to 20 /zM (lane 7). At 10 jzM and 20 fiM of benzoyl peroxide dissolved in 
acetone, the intensity of complex 2 was clearly greater than that found with the 
treatment of acetone alone (lane 2 compared to lanes 6 and 7). When cells were 
pretreated with 0.1 mM PDTC 1 hour before treatment with 20 fiM benzoyl peroxide 
in acetone, both complex 2 and complex 3 binding disappeared (lane 8). When benzoyl 
peroxide was dissolved in DMSO, 1.25 /zM (lane 10) appeared to slightly reduce the 
binding as compared to DMSO alone (lane 9). Levels of complex 2 binding increased 
with increasing amounts of benzoyl peroxide from 1.25 fxM (lane 10) to 5 jzM (lane
12), thereafter for 10 /zM (lane 13) and 20 /zM (lane 14) levels where reduced to that 
of untreated cells (lane 1). When cells were pretreated with 0.1 mM PDTC 1 hour 
before treatment with 20 /zM benzoyl peroxide in DMSO (lane 15) complex 2 binding 
was slightly reduced as compared to the 20 /zM benzoyl peroxide in DMSO treatment 
(lane 14). Complex 3 did not produce as intense a complex as complex 2, despite this, 
some induction of complex 3 is demonstrable with treatments of 10 /zM and 20 /zM 
benzoyl peroxide in acetone (lanes 6 and 7) and 5 /zM benzoyl peroxide in DMSO (lane
13)
Fig 8.13 compares the effect of benzoyl peroxide dissolved in acetone with acetone 
treatment alone on CREl-binding levels in MDP2 nuclear extracts from cells expressing 
Adl2 E1A compared to cells expressing Ad2 or Ad5 E1A. Each cell line was treated 
with either 7 ytzl (0.1%) of acetone or an equivalent volume of benzoyl peroxide 
dissolved in acetone which gave a final media concentration of 20 /zM. Binding levels 
were in general quite low in the presence of acetone, with BMK having the highest 
levels of complex 2 and complex 3 binding. In the presence of benzoyl peroxide 
dissolved in acetone, complex 2 was induced in 5B12, BMK and F I9, most strongly 
in BMK (lanes 9, 10 and 12). Complex 3 was induced to a lesser extent in BMK and 
slightly in 5B12 (lanes 9 and 10).
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Fig 8.12 The dose-dependence of induction of complex 2 by benzoyl peroxide 
dissolved in DMSO or acetone
The CRE1 probe was used with 5B12 MDP2 nuclear extracts: lane 1: untreated cells, 
lane 2: cells treated with 14 /zl (0.2% final concentration) of acetone, lanes 3-8: cells 
treated with benzoyl peroxide dissolved in 14 fil of acetone (0.2% final concentration): 
lane 3: 1.25 juM, lane 4: 2.5 fiM, lane 5: 5 /*M, lane 6: 10 fiM, lane 7 and 8: 20 fiM. 
Lane 9 cells treated with 14 /xl of DMSO. Lane 10-15: cells treated with benzoyl 
peroxide dissolved in 14 /A of DMSO (0.2% final concentration), lane 10: 1.25 fxM, 
lane 11: 2.5 ^M, lane 12: 5 ^M, lane 13: 10 fiM, lane 14 and 15: 20 jiM. All 
treatments with benzoyl peroxide, DMSO or acetone were for 1 hour. Lanes 8 and 15 
were also treated with 0.1 mM PDTC.
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Fig 8.13 The effect of benzoyl peroxide on CRE1-binding factors in Ad-transformed
cells
The CRE1 probe was used to analyse MDP2 extracts from the following Ad2 or Ad5 
ElA-expressing cell lines: 5B12 (lanes 1 and 9), BMK (lanes 2 and 10), Ad5Xho (lanes 
3 and 11) and F19 (lanes 4 and 12) along with the following Ad 12 ElA-expressing cell 
lines: 5A12 (lanes 5 and 13), C57 (lanes 6 and 14), RFC-1 (lanes 7 and 15) and 
Adl2#l (lanes 8 and 16). The nuclear extracts in lanes 1-8 were from cells treated 
with 7 fil of acetone (0.1% final concentration) for 1 hour, lanes 9-15 were from cells 
treated for 1 hour with 20 ijlM benzoyl peroxide dissolved in acetone. The benzoyl 
peroxide was added to each plate in a volume of 7 /zl (0.1% final concentration).
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8.5 Discussion
In this chapter the induction of CRE1-binding proteins in Ad-transformed cells was 
investigated. The agents used were TNFa, cycloheximide, puromycin and benzoyl 
peroxide. It was hypothesized that cell lines which expressed Adl2 El A could be less 
sensitive than those expressing Ad2 or Ad5 E1A to NF-/cB induction by TNFa, an 
enhancer of MHC class I transcription, and this could contribute to the lower levels of 
MHC class I in the former. However, no major difference was found between cell 
lines expressing Adl2 E1A compared to those expressing Ad2 or Ad5 E1A. Two cell 
lines 5A12 and F19, expressing Adl2 and Ad2 E1A respectively, failed to respond to 
TNFa; the reason for this is not known. The 55-60 kDa (TR55) receptor is required 
for TNFa induction of NF-kB (Kruppa et al., 1992), therefore if this receptor is not 
present in 5A12 and F19 cell lines, this could explain their failure to respond to TNFa. 
Only RFC-1 out of three Adl2 ElA-expressing cells which responded to TNFa by the 
induction of complex 2, produced this response after 15 minutes of treatment with 
TNFa, the other cell lines required 30 minutes of treatment. Whereas all the three cell 
lines which expressed Ad2 or Ad5 E1A and for which TNFa treatment caused an 
induction of complex 2, the induced complex was present after only 15 minutes 
treatment with TNFa. Overall the induction of complex 2 by TNFa and the time 
course does not seem to be related by the serotype of El A expressed by these cell lines. 
All the cell lines showed an induction of complex 2 by cycloheximide, the induction 
was usually greatest by a combination of treatments with cycloheximide and TNFa. 
This, as well as the fact that cycloheximide induction was possible when TNFa 
induction was absent, strongly suggests that at least the initial part of the induction 
pathways by these two agents is different. Complex 3 induction was shown to occur 
in certain cell lines by either cycloheximide, TNFa or both agents. Other workers 
who obtain two complexes on gel retardations when using NF-/cB-like motifs as probes, 
have not usually shown induction of the lower complex by various agents; this could 
be a property specific to Ad-transformed cells.
Treatment of C57 cells with puromycin caused an induction of complex 2, since 
cycloheximide has already been shown to induce complex 2, this result suggests that 
protein synthesis inhibitors in general might be involved in the induction of this 
complex.
219
Benzoyl peroxide, an agent which induces the production of free radicals, was shown 
to induce complex 2 in certain cell lines. The effect was not due to the solvent used 
to dissolve this chemical; in the case of DMF, no induction was caused. Acetone and 
DMSO both produced a slight induction of NF-kB, but the induction by benzoyl 
peroxide dissolved in these agents was, at the optimal dosage, greater than that 
produced by the solvent alone. NAC and PDTC both prevented complex 2 induction. 
These agents are scavengers of free radicals and so this result suggests that free radicals 
are involved in the induction of complex 2 by benzoyl peroxide. Optimal induction was 
obtained by different dosages in DMSO and acetone, in DMSO a lower dosage was 
found to be optimal. This could be because the benzoyl peroxide enters the cell more 
efficiently when dissolved in DMSO. Alternatively, acetone could scavenge the free 
radicals produced by benzoyl peroxide to a greater extent than DMSO, therefore more 
benzoyl peroxide might be required when dissolved in acetone to give an equivalent 
number of free radicals available to react with molecules present in the cell.
The level of induction achieved increased with increasing dosage over the whole dose 
range when acetone was used as the solvent and up to 5 ( j lM  with DMSO as the solvent. 
This suggests that the effect was a specific effect and not due to over-stimulation of a 
particular receptor to the point were responses were no longer specific. Induction of 
NF-kB by benzoyl peroxide appeared to occur more readily in cells expressing Ad2 or 
Ad5 E1A. Since TNF induction did not appear to vary between these cell lines, this 
suggests that part of the induction pathway specific for benzoyl peroxide might be 
working at lower efficiency in Ad 12-El A expressing cells compared to those expressing 
Ad2 or Ad5 E1A.
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General Discussion
This study focussed on the oncogenic properties of cells transformed by certain 
serotypes of Adenovirus; Adl2-transformed cells but not Ad2 or Ad5 transformed cells 
are oncogenic when introduced in to syngeneic rodents (Schrier et al., 1983). It has 
been proposed that the oncogenic properties of Ad 12 transformed cells are due to such 
cells producing lower levels of the cell surface proteins, MHC class I antigens (Schrier 
et al., 1983). These proteins are involved in displaying viral and other foreign antigens 
to cytotoxic T-cells; therefore a reduction in the level of surface MHC class I antigens 
would be one way to evade immune detection. This reduction in MHC class I has 
been shown in Adl2-transformed cells to involve down-regulation of transcription 
(Ackrill and Blair, 1988a; Friedman and Riccardi, 1988; Lassam and Jay, 1989); how 
this is brought about was a central interest of this study. A region termed the CRE, 
around 200 bp upstream from the transcription initiation site in MHC class I genes, has 
been shown to play an important role in the control of transcription (Kimura et al., 
1986). This region can be divided into two separate regions called CRE1 and CRE2. 
The functional role of these sequences in Ad-transformed cells was investigated by the 
use of the CAT transient expression assay. The levels of factors which bind to the 
CRE1 region was investigated by gel retardation and by Western blotting using an 
antibody which was prepared to the C-terminal peptide of the p50 subunit of NF-kB, 
a CREl-specific binding factor. The binding site for CRE2-specific transcription 
factors was investigated by the use of DNase I footprinting. NF-kB plays a central role 
in controlling the transcription of several important genes in the immune system, it also 
is involved in the control of transcription from the LTR of HIV. The final section of 
this study investigated the mechanism of NF-kB induction in Ad-transformed cells.
The lower level of MHC class I transcription in Ad 12- compared to Ad2- or Ad5- 
transformed cells could be due to an enhancer function being down-regulated or a 
repressor function being up-regulated in Adl2-transformed cells. In this study cell lines 
expressing Ad 12 El A were compared with those expressing Ad2 or Ad5 El A. The 
sequences CRE1, mCREl and CRE2 were each cloned into the vector pBLCAT2. 
CRE2 has been proposed to act as a repressor (Ackrill and Blair, 1989; Kralli et al., 
1992) and CRE1 has been demonstrated to act as an enhancer in certain circumstances 
(Israel et al, 1989; Mauxion and Sen, 1989); neither sequence was shown to play a role 
in the control of transcription in this study. It is possible that multiple copies of these 
control sequences are required to demonstrate their function. How sequence-specific
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DNA-binding factors influence transcription is unknown. It has been proposed 
(Mitchell and Tjian, 1989) that they may function by interacting with proteins of the 
transcription initiation complex by the looping out of the intervening DNA. The 
presence of several copies of a DNA-binding motif would enable several transcription 
factors to interact with the transcription initiation complex, thus stabilizing this 
interaction. From this one would predict, for example, that the enhancer properties of 
a sequence would increase as the number of copies of that sequence increased; this has 
been shown to be the case for CRE1 (Israel et al., 1989) and CRE1/CRE2 (referred to 
as R1 and R2) (Kralli et al., 1992). However, absence of multiple copies in this study 
does not appear to be the only reason why CRE2 function was not demonstrated, Kralli 
et al. (1992) found evidence to suggest the role of CRE2, as a repressor of the enhancer 
function of CRE1, could only be demonstrated when both sequences were present. The 
presence of CRE2-specific binding proteins could hinder the interaction of CRE1- 
specific binding proteins with the transcription initiation complex. In the case of 
CRE1, Meijer et al. (1992) found that enhancer function can be shown using a single 
copy of this sequence in cells transformed by Adl2 12S E1A but not by Adl2 13S 
E1A. The cells used in this study expressed both the 12S and the 13S products; the 
different cell lines used makes comparison of results found in this study with those of 
Meijer et al. (1992) difficult.
If CRE1-binding factors enhance transcription and are instrumental in the different 
levels of MHC class I found in cells expressing Adl2 compared to Ad2 or Ad5 E1A, 
then the lower levels of transcription in the former could be due to reduced levels of 
these factors. This was investigated by gel retardation analysis and by Western 
blotting using an antibody generated to the C-terminal peptide of the p50 subunit of 
NF-kB. The specificity and the titre of the antibody was investigated by ELISA. High 
titres were obtained for both the rabbits used. Specificity of the antibody was suggested 
by the fact that the immune serum only bound to wells coated with p50 peptide and not 
an unrelated peptide. Also the immune serum did not bind to the wells coated with the 
p50 peptide following pre-incubation with this peptide. Western blotting demonstrated 
that a protein of approximately 55 kDa reacted with serum from both rabbits as well 
as with the three antisera provided by Dr Hay to the C-, N- and DNA-binding domain 
of NF-/cB, providing further evidence that the antiserum generated was indeed 
recognizing NF-kB. This protein was not found to be present at different levels in cells 
expressing Ad 12 El A compared to those expresssing Ad2 or Ad5 El A.
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The technique used to prepare nuclear extracts was found to be critical to the results 
obtained by gel retardation using CRE1 and kappa probes. The initial method 
employed, MDP1, did not appear to be sufficient to protect an inducible CRE1-binding 
factor (thus likely to represent NF-kB) from proteolysis. The second method employed, 
MDP2, could be criticised on the grounds that it involved a greater potential risk of 
cytoplasmic contamination of nuclear extracts. It was decided that the method most 
likely to give a true reflection of the nuclear levels of CRE1-binding factors was 
MDP3; with this method complexes 2 and 3 were found to be present at higher levels 
in Ad2- or Ad5- as opposed to Adl2-transformed cells. Results with competition 
experiments, formaldehyde crosslinking and induction experiments suggested that 
complexes 2 and 3 were likely to represent NF-/cB (p50/p65 heterodimers) and 
KBF1/H2TF1 (p50 homodimers respectively). These results taken together with the 
results from Western blotting suggest that cells expressing Ad 12 El A do not differ from 
those expressing Ad2 or Ad5 El A in terms of the levels of p50 but in the ability of that 
p50 to bind DNA either as a heterodimer or as a homodimer. Nielsch et al. (1991) 
found NF-kB to be higher in Ad5-transformed cells compared to Adl2-transformed cells 
with no difference in the levels of H2TF1/KBF1. These results were obtained with 
established cell lines transformed by adenovirus, unlike the cells used in this study 
which were derived from primary cells transformed by adenovirus. It is possible that 
the different cells used accounts for the variation in the results. Meijer et al. (1992) 
did find differences in the levels of these factors between Ad5- and Adl2-transformed 
cells. However, these results do not give information on the nuclear level of these 
factors as whole cell extracts were used. Ge et al. (1992) did not find any differences 
in the levels of CREl-binding factors in Ad5- and Adl2-transformed cells. They 
prepared their nuclear extracts by a method described by Shapiro et al. (1988); this 
could account for their results differing from those obtained in this study. The levels 
of Spl-binding factors were not found to vary between cells expressing Ad 12 El A 
compared to those expressing Ad2 or Ad5 El A; this suggests that the differences found 
on gel retardations for CREl-binding factors are not just part of a general difference 
in the levels of transcription factors found between Adl2 ElA-expressing cells and 
those expressing Ad2 or Ad5 El A.
mCREl was shown in this study to be associated with reduced CAT activity, this 
confirms the results of Meijer et al. (1992). They found that the mutated sequence did
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not bind transcription factors on gel retardations, so the effect is unlikely to be due to 
the binding of a repressor protein and the reason for this effect is not known.
The functional and the molecular characteristics of CRE2-specific binding factors were 
investigated. The former were studied by the use of the transient expression assay CAT 
and the latter through investigation of the effect of sodium fluoride on the binding of 
CRE2-specific binding factors and DNase I footprinting.
The CRE2 DNase I footprint showed a larger area of protection, suggesting a larger 
binding site for transcription factors than that obtained using methylation interference 
(Griffiths, 1992; Shirayoshi et al., 1987). This is a consequence of the large size of 
the DNase I molecule causing overestimation of the size of the binding site. The 
DNase I footprint covered the sequence AGGTCA, the conserved sequence present in 
the binding sites for RXR/3/H-2RIIBP and other members of the ER/TR subfamily of 
steroid/thyroid hormone receptors. Since this sequence is conserved amongst different 
members of this subfamily, it suggests that it is likely to serve an important function; 
it is therefore not unexpected that this region should be part of the binding site for 
transcription factors.
Sodium fluoride has been shown to be an activator of G proteins in association with 
aluminium (Chabre, 1990) or magnesium (Antonny et al., 1993; Bigay et al., 1987). 
One such G protein is coupled to phospholipase C and it is involved in its breakdown 
to products that ultimately lead to the activation of PKC. Sodium fluoride is also a 
phosphatase inhibitor (Chabre, 1990). Resulting from these properties sodium fluoride 
treatment can lead to higher levels of phosphorylation of certain proteins. CRE2- 
binding activity was greater when extracts were prepared in the presence of sodium 
fluoride; this suggests that the phosphorylation of certain proteins potentiates binding. 
The work of Griffiths (1992) suggests the proteins which are being phosphorylated are 
nuclear in origin; it was found that phosphatase treatment of nuclear extracts caused the 
disappearance of binding which was restored by the use of protein kinase A.
Cell lines expressing Ad 12 El A were not found to differ from those expressing Ad2 
or Ad5 El A in terms of the induction of complex 2 by TNFa or cycloheximide. Two 
cell lines were found not to be inducible by TNFa, one expressing Ad2 and one 
expressing Ad 12; it is possible that these cell lines did not express the receptor TR55
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which has been shown to be required for the induction of NF-/cB by TNFa (Kruppa et 
al., 1992).
Schreck et al. (1991) were the first to propose the involvement of ROI in the induction 
of NF-kB by diverse agents. They found H20 2 induced NF-kB and the induction by 
several agents including H20 2 could be inhibited by reducing agents, metal ion chelators 
and free-radical scavengers. In this study benzoyl peroxide was shown by gel 
retardation to induce a complex likely to represent NF-kB and free-radical scavengers 
were found to inhibit that induction.
Fig 9.1 depicts a proposed model showing the presumed involvement of free-radicals 
in the activation of NF-acB. The model is based on the work of Schreck et al.(1991, 
1992) and information on NADPH oxidase and oxidative stress, incorporating the 
results presented in chapter 8 with benzoyl peroxide. Schreck et al. (1991) proposed 
that the various agents which induce NF-kB all cause an increase in ROI. They suggest 
NADPH oxidase could be involved. NADPH oxidase converts 0 2 to the superoxide ion 
0 2 - according to the reaction:
202 +  NADPH ► 202- +  NADP+ + H+
Many of the agents which induce NF-kB activate NADPH oxidase; for example, TNFa 
(Tsujimoto et al., 1986), PMA (Rider et al., 1988; Reibman et al., 1988), LPS 
(Dahinden et al., 1983) and calcium ionophores (Koenderman et al., 1989). The 
mechanism by which LPS and TNFa activate NADPH oxidase is incompletely 
understood. PMA causes an increase in diacylglycerol (DAG) (Rider et al., 1988), 
which, in association with increased intracellular calcium, activates protein kinase C 
(PKC) which is thought to activate NADPH oxidase (Seifert and Schultz, 1991). PMA 
might also activate NADPH oxidase directly (Seifert and Schultz, 1991). Calcium 
ionophores are thought to activate NADPH oxidase through causing an increase in 
intracellular calcium which together with DAG activates PKC and thus, indirectly, 
NADPH oxidase (Smolen, 1984). Cycloheximide, the protein synthesis inhibitor, has 
an initial effect on cells by causing an increase in respiration (Todorov, 1990). This 
causes ATP production which increases the level of protein ADP ribosylation which in 
turn causes a release of mitochondrial calcium and an increase in intracellular calcium 
(Reed, 1990) and so leads to the same effects as a calcium ionophore. Okadaic acid
226
Fig 9.1 A model depicting the involvement of free radicals and hydrogen abstraction 
in NF-/cB induction
This figure shows a model portraying how the different pathways for the induction of 
NF-acB by various agents could all involve the generation of free-radicals and hydrogen 
abstraction.
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activates NF-kB (Thevenin et al., 1990). It is proposed that this activation is caused 
by its inhibition of certain phosphatases which could enable PKC phosphorylation and 
thus its activation (Cohen, 1989). Okadaic acid could therefore indirectly activate 
NADPH oxidase.
NADPH oxidase causes an increase in the level of superoxide radicals. Superoxide 
radicals are also generated in respiration and by arachidonic acid metabolism (Rice- 
Evans et al., 1991). Cycloheximide, by increasing respiration, causes increased levels 
of superoxide radicals by both this NAPDH oxidase-independent pathway, as well as 
the previously described pathway involving NADPH oxidase. The enzyme superoxide 
dismutase converts superoxide radicals to H20 2.
Ionizing radiation, another inducer of NF-/cB (Brach et al., 1991), is also a producer 
of H20 2 (Rice-Evans et al., 1991). H20 2 is detoxified in the cells mainly by the 
glutathione peroxidase system to water. In peroxisomes catalase plays a minor role and 
converts H20 2 to water and oxygen (Jaescke and Mitchell, 1990).
Whilst H20 2 is reduced to water by glutathione peroxidase, reduced glutathione (GSH) 
is oxidised to its disulphide, GSSG (Reed, 1990). Most of the GSSG formed is 
immediately reduced back to GSH through glutathione reductase with the cofactor 
NADPH. When the system is overstretched glutathione reductase cannot convert 
GSSG back to GSH quickly enough and there is a drop in the GSH/GSSG ratio. 
NADPH is used by glutathione reductase to reduce oxidised glutathione. Tribble and 
Jones (1990) suggest the supply of NADPH is the limiting factor for this reaction. 
NADPH oxidase activity will reduce available NADPH and so reduce the rate of 
reduction of oxidized glutathione. Several inducers of NF-kB cause this drop in the 
GSH/GSSG ratio; for example, such a drop has been shown to be caused by a calcium 
ionophore (Olafsdottir et al., 1988), H20 2 (Perchellet et al., 1986), TNFa and PMA 
(Staal et al., 1990). It is proposed here that this drop in GSH/GSSG plays an essential 
role in NF-kB induction since oxidants such as diamide which reduce this ratio enhance 
N F-kB activity (Staal et al., 1990) and reducing agents such as 2-ME which raise the 
GSH/GSSG ratio inhibit NF-/cB induction (Schreck et al., 1992). The reduction in the 
GSH/GSSG ratio is considered important in NF-kB induction, since as a consequence 
not enough GSH is present to deal with all the remaining H20 2. This allows the 
opportunity for some H20 2 to be converted to hydroxyl radicals by reacting with either
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Fe2+ or Cu+ forming Fe3+ and Cu2+ respectively (Rice-Evans et al., 1991). Schreck 
et al. (1992) showed evidence that these steps are involved in NF-kB induction; they 
found desferal, the iron-chelator and O-phenanthroline, the copper chelator, both 
reduced NF-/cB induction by H20 2. Neither produced complete inhibition, presumably 
because hydroxyl radicals could still be created by the other pathway. It is proposed 
that at least five potential pathways exist for the hydroxyl radical from this point all 
involving hydrogen atom abstraction. Since a particular radical of benzoyl peroxide is 
also capable of causing hydrogen abstraction and creating hydroxyl radicals, the 
generation of this radical will now be discussed. Benzoyl peroxide is thought to react 
within the cell with Cu+ to give Cu2+ and the benzoyloxyl radical (Swauger et al., 
1990). The copper chelator O-phenanthroline can prevent benzoyloxyl radical induced 
DNA damage (Swauger et al., 1991). This radical can react in one of two ways; firstly 
degrade to a phenyl radical and carbon dioxide or secondly abstract a hydrogen atom 
to form benzoic acid. Swauger et al. (1990) present evidence to suggest that it is 
principally the latter process which occurs. The benzoyloxyl radical is a very reactive 
species and will abstract a hydrogen atom from molecules in close proximity to its site 
of generation; in an aqueous environment it is likely to abstract a hydrogen atom from 
water, creating a hydroxyl radical. It is also capable of abstracting hydrogen atoms 
from other molecules.
Since TNFa induction involves the production of hydroxyl radicals requiring either 
Fe2+ or Cu+, whereas benzoyl peroxide involves benzoyloxyl radical production 
requiring just Cu+, then the situation could arise when Cu+ but not Fe2+ is available 
in limiting amounts, then TNFa but not benzoyl peroxide induction could occur in a 
particular cell line. This could explain the results obtained in certain cell lines in 
which TNF but not benzoyl peroxide induction occurred.
It is proposed that both hydroxyl radicals and benzoyloxyl radicals carry out hydrogen 
abstraction to form water and benzoic acid respectively. Fig 9.1 shows five potential 
pathways for hydrogen abstraction. When a free radical scavenger is added to the 
cells, such as NAC or PDTC, it provides the hydrogen atom for the hydroxyl radical 
to form water or for the benzoyloxyl radical to form benzoic acid. In the process it 
becomes a radical. When two such radicals come together a disulphide bridge can 
form between them. When these free radical scavengers are present the induction of 
NF-kB is inhibited; this suggests they divert the hydroxyl radicals from following a
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pathway that would ultimately lead to NF-kB induction. So what other pathways are 
available when free radical scavengers are not present in cells? GSH is a scavenger of 
free radicals as well as reacting with H20 2. There is evidence that benzoyl peroxide 
causes a drop in the GSH/GSSG ratio (Perchellet et al., 1986), presumably because 
GSH participates as a hydrogen atom donor to benzoyloxyl radicals. It is proposed 
that this drop in GSH/GSSG ratio is essential so that from this point on benzoyloxyl 
radicals will no longer be efficiently removed by GSH and some will be available to 
follow other pathways of hydrogen atom abstraction. Swauger et al. (1991) provide 
evidence for this; they found GSH provided complete protection against the DNA 
damage which is mediated by the benzoyloxyl radical.
In the case of hydroxyl radicals, the GSH/GSSG ratio would already be reduced by 
H20 2 so little GSH would be available for hydrogen abstraction. For both benzoyloxyl 
radicals and hydroxyl radicals, once GSH levels are low, other pathways must be used 
for hydrogen atom abstraction. These alternative pathways include hydrogen abstraction 
from DNA; it is difficult to see how DNA damage might cause NF-kB induction which 
occurs in minutes. Another pathway is hydrogen abstraction from lipids causing lipid 
peroxidation. This can cause a change in membrane structure, which could enable the 
more efficient passage of NF-kB into the nucleus, but it could not be responsible for the 
dissociation of I-kB from N F -k B  which is an essential part of NF-kB induction. 
Another pathway is that of protein S thiolation, in which proteins donate the hydrogen 
of their SH groups to form disulphide bridges. Obviously this could change the 
conformation of these proteins, leading to possible functional change. For example, if 
S-thiolation were to occur in I-kB it could lead to conformational change which 
prevented N F -k B  binding, so enabling N F -k B  to translocate to the nucleus.
It is hoped that future work might help to establish the biochemical pathways involved 
in N F - kB  induction. Such work might enable the activity of this very important 
transcription factor to be controlled in situations where it could be having a detrimental 
effect on health such as in HIV-infected individuals.
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